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There is evidence that kinetics of tumour markers (TMs) CEA, CA15-3 and 
CA19-9 provide valuable information about disease state over time in patients 
with advanced breast and colorectal cancer but the literature contains 
differences in methodology so comparing findings is difficult. 
 
By modifying criteria developed by Rustin and colleagues [1-5] in ovarian 
carcinoma we have retrospectively identified a subset of patients (those with 
progressive (P) TMs) where survival is significantly reduced compared with 
those with responsive (R) TMs. This is true for CEA, CA15-3 and CA19-9 at 
the first chemotherapy given in advanced disease (chem1) (Hazard ratios 
(HR) = 9.99, 8.89, 5.75, P ≤ 0.001 in all cases) and CEA and CA19-9 at the 
second chemotherapy (chem2) (HR = 7.95, 9.00, P = 0.001 and 0.002 
respectively) in patients with breast cancer. It is also true for CEA at chem1 in 
patients with colorectal cancer (HR = 2.51, P <0.001). Further studies are 
necessary to see if treatment directed by these criteria can influence survival.  
 
CEA and CA19-9 Rustin category in colorectal patients and CA15-3 Rustin 
category in breast patients correlated significantly with radiological category 
at chem1 and chem2 (CEA rs = 0.45 and 0.43, CA19-9 rs = 0.26 and 0.35, 
CA15-3 rs = 0.28 and 0.44). CA19-9 also correlates with radiological category 
at chem2 (rs = 0.38) in breast patients. This provides valuable information 
because RECIST criteria can delay radiological identification of disease 
progression compared with WHO criteria [6, 7] and new therapies may act to 
stabilise tumour growth rather than reduce it [8].  
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(1) Introduction 
(1.1) Cancer 
 
It is reported that approximately a quarter of people in the UK die from the 
diverse group of diseases collectively known as cancer, these diseases are 
characterised by uncontrolled cell replication. 276,678 new cancer cases were 
registered in the UK in 2003, and the number of cancer deaths in 2004 was 
recorded as just above 153,397 (these figures are excluding non-melanoma 
skin cancer) [10]. The 10 most commonly occurring cancers in the UK are 
shown in Figure 1. 
 
Figure 1   Graph showing the incidence of the 10 most common cancers in the UK in 2003. 
Information from Cancer Research UK [10] 
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Cancer is a multi-step process, a disease caused by an accumulation of 
genetic faults within the genetic material of a cell leading to the disruption of 
normal cellular processes. Proto-oncogenes are genes whose product 
normally drives cell proliferation, for example growth factors, cell surface 
receptors, signal transduction system components, DNA binding nuclear 
proteins or genes involved in cell cycle control. Mutations affecting proto-
oncogenes turn these genes into oncogenes and alter these processes. 
 
The products of Tumour Suppressor genes (gatekeepers) on the other hand 
act to prevent unregulated cell cycle progression e.g. the APC gene on 
chromosome 5 which is mutated in familial adenomatous polyposis FAP a 
hereditary predisposition to colorectal cancer as well as in most sporadic 
colorectal cancers [11].  
 
Mutation in either proto-oncogenes or tumour suppressor genes can result 
in unregulated cell proliferation; however, it is now thought that several 
mutations are required in order for cancer to develop. Some individuals are 
predisposed to cancer as they inherit genetic mutations which directly cause 
cancer or move the individual one step closer to cancer development. 
Genetic changes continue to accumulate even after the development of 
cancer (often at an increased rate) and these mutations further increase the 
complexity of the disease and its treatment. 
 
The genetic faults leading to cancer arise as a result of inherited problems 
passed on to the next generation via germ cell mutations or because of 
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environmental factors which cause somatic cell mutations, or due to a 
combination of both of these things. Inherited genetic predispositions can be 
in the form of faulty DNA repair processes, inappropriate gene expression, 
loss of gene function and many more. Environmental factors which may lead 
to cancer include such things as diet, exposure to industrial carcinogens such 
as asbestos and bacterial or viral infection; for example Helicobacter pylori 
has been linked with gastric cancer [12] and the human papiloma virus (HPV) 
has been linked with Cervical cancer [13] the second most common female 
cancer worldwide. 
 
When they do arise cancers can be classified into six major categories as 
seen in table 1, but can also be of mixed type. 
 
Table 1   The major cancer groups. 
 
Category Arises in… 
Carcinoma Epithelium 
Sarcoma Supportive and connective tissue (e.g. bones) 
Lymphoma Lymph nodes 
Leukaemia White blood cells of the Bone marrow 
Myeloma Specifically Plasma cells of the Bone Marrow 
Germ Cell Tumours Germ Cells 
 
It is known that at least 80% of all cancers are carcinomas (the term 
adenocarcinoma refers to a sub group of carcinomas which arise in glandular 
epithelium) and more than 90% of all cancers are solid tumours i.e. 
carcinomas, sarcomas and lymphomas rather than blood cancers. Solid 
tumours are most commonly categorised using the Tumour, Node, Metastasis 
(or TNM) staging system which is defined in table 2. 
 
 11 
Table 2   The TNM staging system 
Category Definition 
Tumour 
 
Usually staged T0 to T4 attempts to describe the extent of the 
primary tumour where T0 is carcinoma in situ and level of invasion 
increases from there. 
 
Node 
 
Usually classified N0 to N3 where N0 is no lymph node metastases 
and N1-3 are varying degrees of lymph node metastases with 1 
being involvement of the nearest lymph nodes to the primary tumour 
and 3 being the involvement of the most distant. 
 
Only the lymph nodes draining the site of the primary tumour are 
taken into account in this analysis. If distant lymph nodes contain 
metastatic tumour then this is counted as a metastasis. 
 
Metastasis 
 
Usually classified as M0 or (MX) to M1 where M0 indicates no distant 
metastases and M1 indicates that a distant metastasis is present 
 
 
This system is used in combination with the individual disease staging system 
(Table 3) in order to decide on the best treatment in each case.
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Table 3   Individual disease staging systems for breast, colorectal, prostate and ovarian cancers 
 
Stage 
Cancer Type 
Breast Colorectal Prostate Ovarian 
0 (carcinoma 
in situ) 
Can be either ductal (DCIS), which is very 
early breast cancer, or Lobular (LCIS), 
which is not cancer but can be a precursor 
of it. 
Cancer found only in the 
mucous membrane of the 
colon or rectum. 
  
I 
Primary tumour is no larger than 2cm and 
has not spread. 
(Duke‟s A) – Cancer has 
spread beyond the innermost 
lining and involves the inside 
wall of the colon or rectum. 
(A1) – Cancer found in 
the prostate only and 
usually discovered by 
chance. 
A – Cancer in a single ovary 
B – Cancer found in both ovaries 
C – Cancer in one or both ovaries and – 
 cancer found on the outside surface of the ovary / ies 
or 
 cancer has ruptured the ovary wall or 
 cancer cells found in the peritoneal fluid. 
II 
A  -  Primary tumour no larger than 2cm but 
has spread to the axillary lymph nodes, or 
-  Primary tumour is 2-5cm but has not 
spread to the axillary lymph nodes. (Duke‟s B) – Cancer has 
spread to the muscularis 
propria of the colon or rectum 
but not to the lymph nodes. 
(A2, B1 or B2) – Cancer 
again confined to the 
prostate but more 
advanced than stage I. 
A – Cancer found in one/both ovaries and the uterus and/or 
fallopian tubes. 
B – Cancer found in one/both ovaries and other tissue within 
the pelvis. 
B  -  Primary tumour 2-5cm and has spread 
to the axillary lymph nodes, or 
-  Primary tumour is > 5cm but has not 
spread to the axillary lymph nodes. 
C – Cancer found in one/both ovaries and the uterus and/or 
fallopian tubes and/or other tissue in the pelvis and – 
 cancer found on the outside surface of the ovary/ies or 
 cancer has ruptured the ovary wall or 
 cancer cells found in the peritoneal fluid. 
III 
A  -  Primary tumour < 5cm, has spread to 
the axillary lymph nodes and these are 
stuck together or to other structures, or 
-  Primary tumour is > 5cm and has spread 
to the axillary lymph nodes which may be 
attatched together or to other structures. 
(Duke‟s C) – Cancer has 
spread to the nearby lymph 
nodes but there are no 
distant metastases. 
(C) – cancer spread 
outside the prostate to 
proximal tissues. 
A – Cancer confined to the pelvis but cancer cells are at the 
surface of the peritoneum. 
B – Cancer has spread to the peritoneum but is < 2cm. 
B  -  The primary tumour has spread to 
tissues near the breast, or 
-  The primary tumour has spread to lymph 
nodes along the breast bone. 
C – Cancer has spread to the peritoneum but is > 2cm and/or 
has spread to the abdominal lymph nodes. 
IV 
-  Cancer has metastasised to other parts of 
the body, or to the lymph nodes in the neck. 
(Duke‟s D) – Cancer has 
metastasised. 
(D1, D2) – Cancer has 
metastasized. 
Cancer has metastasised outside the abdomen and is found in 
the liver. 
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Disease stage has been found to be an effective predictor of survival in both 
breast and colorectal cancer [14, 15] and treatment is planned on an individual 
patient basis according to these measurements and many other factors such as 
tumour cell type, cancer differentiation and the health and preference of the 
patient. Practice can vary greatly but is becoming increasingly evidence based. 
 
As well as radiological and histological results clinicians increasingly use 
biochemical information to aid in the diagnosis and treatment of some 
malignancies. Serum tumour markers are a diverse group of chemicals present 
in the serum of healthy individuals. Levels of these chemicals can become 
elevated in people with cancer but they can also increase in response to other 
biological or external stimulus. Unlike routine radiological examinations such as 
computed tomography (CT) scans and mammograms tumour marker levels are 
simple to obtain, relatively inexpensive (as they can be detected in a routine 
blood sample) and apart from minor discomfort, cause little inconvenience or risk 
to the patient.  
 
(1.2) Tumour markers  
 
Carcinoembryonic antigen or CEA was one of the first tumour markers to be 
identified and developed by Gold and Freedman in 1965 [16]. As with most 
tumour markers CEA levels can be ascertained form the serum from a simple 
blood test using monoclonal antibodies specific for one particular epitope. The 
use of certain tumour markers can aid clinical follow up, may be the first sign of 
the development of advanced disease and in some cases can provide 
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information about survival. Nicolini et. al. (2003) have shown significantly (p = 
0.0017 at 84 months from mastectomy) increased survival in breast cancer 
patients who were treated in a “tumour marker guided” manner. Treatment was 
based upon an elevated level of one or more tumour markers within the CEA – 
TPA – CA15-3 (carcinoembryonic antigen – tissue polypeptide antigen – cancer 
antigen 15-3) tumour marker panel compared with conventional treatment based 
upon positive radiological or clinical diagnosis [120]. Other research suggests 
that in the setting of advanced disease tumour markers may give an indication of 
the degree to which the cancer is responding to treatment [1]. These findings 
indicate a potentially very important role for tumour markers to play in the setting 
of advanced disease.  
 
In order for a tumour marker to be valuable it should be able to provide 
information which helps to diagnose the malignancy, identify recurrence or 
predict response to treatment or ideally all of these things. In order to be effective 
a tumour marker should be –  
 
  Sensitive (correctly identify all of the individuals with the disease being 
tested for), 
  Specific (does not incorrectly identify an individual without the disease 
as a sufferer),  
  Detectable via a non-intrusive, inexpensive test, and 
  Always representative of tumour volume and disease stage (in order to 
accurately measure fluctuations in disease status), 
 
However, as yet no tumour marker is without limitations. 
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Now in several cases arrays of markers are being used at once to investigate to 
what extent combining the results of the different markers increases sensitivity 
and specificity. Fuzzy logic modelling used by Schneider et. al. in gastro 
intestinal in GI cancers [18] and lung cancer [19] aims to increase sensitivity and 
specificity by combining tumour markers in a panel. This approach is also being 
studied in a current trial using fuzzy logic in the diagnosis of lung cancer. 
 
Potential tumour markers are continuously being identified and tested but as yet 
relatively few are used regularly in clinical practice those which are include 
squamous cell carcinoma antigen (SCC) in cervical cancer, prostate specific 
antigen (PSA) in prostate cancer, cancer antigen 125 (CA125) in ovarian cancer 
and human chorionic gonadotrophin (hCG) in gestational choriocarcinoma. The 
use of PSA and CA125 are described in more detail below. 
 
(1.2.1) PSA and Prostate Cancer 
31,900 men were diagnosed with prostate cancer in the UK in 2003 and in 2005 
10,000 male deaths were attributed to it [10]. This makes prostate cancer the 
most common cancer and the second most common cause of cancer death in 
males in the UK [10]. Like colorectal and breast cancers, the vast majority of 
prostate cancers are carcinomas (epithelial in origin) and their incidence 
increases with age. Few cases of prostate cancer occur in the under 50s and 
Cancer Research UK state that “more than 60% of cases occur in men over 70” 
[10], they estimate the lifetime risk of a man getting prostate cancer to be 
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approximately 1 in 13 although it is found in its highest rates in African American 
populations. 
 
Prostate cancers are staged using the TNM system (Table 2) and as shown in 
Table 3 and are given a Gleason score according to how well differentiated the 
cells within the primary tumour are. If cells are well differentiated (Gleason score 
<4) the tumour is less aggressive and the patient has a better prognosis than 
those with poorly differentiated prostate cancer (Gleason score 8 – 10). 
 
Treatment for prostate cancer can vary greatly according to the many factors 
which must be taken into account in each case. Currently treatment options for 
localised cancer include watchful waiting (particularly in older patients), radical 
prostatectomy or radical radiotherapy. The outcomes of these various treatment 
modalities are currently being investigated as each is associated with negative 
effects for the patient. Bill-Axelson et. al. (2005) compared radical prostatectomy 
with watchful waiting in early prostate cancer and found that radical 
prostatectomy reduces the risk of prostate cancer related death, development of 
metastases and local progression over 10 years. However these results are 
estimated 10 year results and the authors point out that “the absolute reduction in 
the risk of death after 10 years is small” [20]. 
 
Hormone treatment in the form of orchidectomy or treatment with an anti-
androgen or luteinising hormone-releasing hormone agonist can be used in 
conjunction with these treatments. Hormone treatment aims to reduce the level of 
circulating testosterone and can have a dramatic effect upon the tumour. 
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Hormone therapy is also used in advanced disease sometimes alongside 
chemotherapy.  
 
Patients can be treated with chemotherapy when hormone treatment is no longer 
effective. Docetaxel is usually the first line treatment since it has been shown to 
improve survival when compared with mitoxantrone [21]. Research is currently 
being done into many areas of prostate cancer treatment, one example is the 
ProtecT trial (Prostate testing for cancer and Treatment) run by the University of 
Bristol which aims to compare efficacy of the three main modalities of treatment 
currently used, treatment with radiotherapy, radical prostatectomy and active 
monitoring. 
 
Prostate specific antigen (PSA) is a serine protease which is produced in the 
prostate and which acts to “dissolve the gel formed after ejaculation and thereby 
permit sperm movement in the female genital tract” [22] The gene encoding PSA, 
or as it is otherwise known human kallikrein 3 (hK3), is located on 19q. During 
childhood levels of PSA do not differ greatly between the sexes however this all 
changes at about 12 years of age when the prostate develops in males and as a 
result male PSA levels increase dramatically [23].  
 
A small amount of PSA leaks into the body‟s general circulation where it can be 
detected in the serum in all men however the level of PSA in the serum often 
increases as a result of the development of prostate cancer. The most commonly 
quoted cut off level is 4 ng / ml, a PSA level less than this is generally considered 
normal but this level can vary depending upon the assay used. 
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Although PSA can be used to screen patients for prostate cancer it is not specific 
enough to exclude the possibility of prostate cancer in all men who have normal 
PSA levels and not sensitive enough to identify all patients with prostate cancer 
as it is reported that approximately 45% of men with localised prostate cancer 
(cancer within the prostate) have a PSA of <4 ng/ml [22]. Thompson et. al. (2004) 
found that out of 2950 men whose PSA levels were 4 ng/ml 15.2% were 
diagnosed with prostate cancer and 14.9% of the cancers were Gleeson score 
7 [24]. These results mean that in some cases the PSA test is at best 
inaccurate and at worst misleading. 
 
Other limitations of the PSA test are the fact that there is large intra-individual 
variation in PSA levels, with higher levels of PSA often seen in those with larger 
prostates and in older men (which could be attributed to the fact that prostatic 
volume can increase with age). It has also been speculated that race may affect 
PSA levels [25].Other benign prostatic conditions found commonly in the 
population considered to be at risk of prostate cancer such as benign prostatic 
hyperplasia (BPH) and prostatic inflammation can also lead to an increased 
serum PSA.  
 
Another problem with screening for prostate cancer is that there is little evidence, 
as yet, that early detection actually reduces the mortality rate of the disease. It is 
possible that this screening may prove to be ineffective in the long term 
particularly in older men where prostate cancer often progresses very slowly and 
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patients may die of other conditions before they are affected by the prostate 
cancer itself. 
 
It is now known that PSA is present in the plasma as a free molecule or it is 
bound to one of several plasma proteins e.g. alpha-1-antichymotrypsin (ACT). 
The binding of some of these proteins can inhibit the recognition of PSA by the 
various immunoassay antibodies that are used to detect PSA levels thereby 
producing inconsistencies in testing. Stenman et. al. however describe how by 
calculating the proportion of free PSA compared to the total PSA the level of 
false-positive results in early diagnosis can be reduced by 20-40% (this assay is 
based on the fact that more free PSA is seen in men with prostate cancer than in 
those with benign prostatic disease) [26]. 
 
Despite problems surrounding the use of the PSA test in screening and the 
process of screening itself there are proven advantages to the use of the marker 
in patients who have been diagnosed with prostate cancer. PSA levels have 
been shown to increase with increasing tumour stage [27] and PSA response to 
treatment has been shown to correlate with patient response and survival: A fall 
in PSA following treatment with Strontium-89 for bony metastatic disease 
correlated with longer overall survival in a small cohort (30 patients) [28]. 
 
Investigations are now underway to identify novel tumour markers in prostate 
cancer such as macrophage inhibitory cytokine 1 (MIC-1) which has been found 
to predict presence of prostate cancer of Gleason score 7 and which combined 
with PSA improved the specificity of PSA alone [29].  
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(1.2.2) CA125 and Ovarian Cancer  
Ovarian cancer is the fourth most common cancer in UK women, 6,906 cases 
were diagnosed in 2003, It is also the fourth most common cause of cancer 
death with 4,434 deaths recorded in 2004 [10]. The majority of cases are 
diagnosed at a late stage (stage III or IV) resulting in a poor survival rate. 
Ovarian cancers can be divided into carcinomas (approximately 80-90% of 
cases) and non-epithelial cancers [10], subtypes can be seen in Table 4. 
 
Table 4   Ovarian cancer sub-groups. 
 
Ovarian Cancer 
Type 
Subtype Arising from 
Carcinomas 
Serous Epithelium  
Mucinous Epithelium  (resembling mucinous tissue) 
Endometrioid Epithelium  (resembling endometrial tissue) 
Clear cell 
Epithelium  (cells with distinctive 
appearance and clear cytoplasm) 
Undifferentiated Epithelium  (cells are hard to identify) 
Non-Carcinomas 
Germ cell The ova  
Stromal Connective tissue of the ovaries 
 
The Non-epithelial cancers usually arise in younger women than epithelial 
ovarian cancers and, on average, are found at an earlier stage. Because of this, 
when treating non-epithelial ovarian cancer, maintaining fertility is often high on 
the list of priorities when choosing treatment options. As with breast, colorectal 
and prostate cancer, ovarian cancer is staged using the TNM staging system 
shown in Table 2 and the staging criteria in Table 3. 
 
Treatment for epithelial ovarian cancer (ovarian carcinoma) can include surgery 
where appropriate for early stage disease or palliation of symptoms in advanced 
disease. The International Collaborative Ovarian Neoplasm trial 1 or ICON1 
showed that adjuvant platinum based chemotherapy improves both recurrence 
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free and overall survival compared with no chemotherapy so this is now the gold 
standard adjuvant treatment [30]. In 2003 a systematic review and meta-analysis 
(including the above study) also found that there is no significant difference 
between chemotherapy and radiotherapy as adjuvant therapies [31]. In advanced 
ovarian cancer the debate is ongoing as to whether a platinum based 
chemotherapy is as effective alone as it is in combination with paclitaxel [32, 33].   
 
The tumour marker cancer antigen 125 or CA125 is a glycoprotein which is 
identified in serum using the monoclonal antibody OC125 [34]. CA125 is 
expressed during development and is present at low levels in the serum of 
healthy individuals. CA125 level is often raised above the upper limit of normal in 
patients with epithelial ovarian cancer but it can also become raised benign 
conditions such as endometriosis, pelvic inflammatory disease, fibroids, renal 
failure, acute pancreatitis, peritonitis [35] and leiomyomas as well as non-ovarian 
malignancies [36]. In some women CA125 level can fluctuate during the 
menstrual cycle and pregnancy [3], this reduces its diagnostic power in pre-
menopausal women.  
 
Despite these limitations levels of CA125 found in benign conditions and cancers 
which are non-ovarian in nature are often lower than those found in patients with 
ovarian cancer [35, 36]. CA125 remains a powerful prognostic factor and the 
degree of CA125 elevation has been shown to correlate with ovarian cancer 
stage [37]. a rise in CA125 has been shown to predict clinical relapse by 4 
months in about 70% of patients [3]. It has also been shown that nadir levels of 
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CA125 can predict time to disease progression and overall survival in patients 
with ovarian cancer [38, 39]. 
 
The power of CA125 has also been demonstrated in monitoring response to 
treatment and the work of Rustin et. al. has produced some reliable definitions of 
CA125 marker response and progression known as the “Rustin criteria of 
response” [40] which have been shown to correlate significantly with clinical 
response and progression [4, 5] These response criteria are detailed below:- 
 
o CA125 Response 
Or the “50% response criteria” [3, 4] requires that a raised level of CA125 which 
is double the upper limit of normal (ULN) before treatment, falls by at least 50% 
[3] following treatment. This response “must be confirmed and maintained for at 
least 28 days” [41].  
 
In patients with measurable disease the Rustin criteria of response has a 
sensitivity and specificity of 92% and 72% respectively and is also able to predict 
time to progression [40]. 
 
o CA125 Progression 
Has been defined and validated as an increase of CA125 to ≥ twice the nadir 
level confirmed by a second sample which must also be ≥ twice the nadir 
(provided that this value is ≥ twice the ULN) [5].  
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Using this criterion progression can be predicted [1, 2] with a sensitivity of 82% 
[3] or 85.9% [5] and a specificity of 98% [3] or 91.3% [5] depending on which 
paper you read. Rustin et. al. (1996) also report that this definition of progression 
has a positive predictive value (PPV) of 94.8% and a negative predictive value 
(NPV) of 77.8% [5]. 
 
In this study I will principally investigate whether the Rustin criteria of response 
and progression, developed in ovarian cancer and described above, can be 
applied when looking at the tumour markers CEA, CA15-3 and cancer antigen 
19-9 (CA19-9) in breast cancer and CEA and CA19-9 in colorectal cancer. 
 
(1.3) CEA, CA 15-3 and CA 19-9 in Breast and Colorectal cancer  
 
(1.3.1) CEA  
The protein structure of the 180kD oncofoetal glycoprotein Carcinoembryonic 
Antigen (CEA also known as CEACAM5 or CD66e) can be seen in Figure 2 [42]. 
CEA is produced by the foetus and in smaller amounts by normal adult cells [43]. 
The molecular weight of the CEA protein alone is 70kD and the extra 110kD is 
attributable to its extensive pattern of glycosylation [44]. CEA levels are 
established using anti CEA antibody. CEA was one of the earliest tumour 
markers to be used and was originally identified in colorectal cancer in 1965 by 
Gold and Freedman [16] and has since been used as a marker of 
adenocarcinomas generally. CEA is part of the CEA gene family which in turn is 
part of the immunoglobulin superfamily [45].  
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Figure 2   CEA protein structure adapted from Hörig et. al. 2000 [42]. 
 
 
 
 
The CEA gene family are located on chromosome 19 the locus of CEA itself is 
19q13. The CEA family consists of the pregnancy-specific glycoproteins (PSG) 
which are, as the name suggests, expressed in pregnancy, and the CEA 
subgroup [46] also known as the carcinoembryonic antigen gene family (CMG). 
In 1988 Zimmerman et. al. reported that there was a tissue specific variation in 
the transcriptional activity of CEA and non-specific cross-reacting antigen (NCA 
also known as CEACAM6) [47].  
 
It is postulated that CEA acts as an intercellular adhesion molecule and in colon 
cancer it is thought that the cellular localisation of CEA may become dispersed 
from its usual location in the luminal membrane of the colonocytes [44] as a 
result of this it is hypothesised that inappropriate expression or localisation of 
CEA may play a role in tumour growth and the metastatic process. Blumenthal 
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et. al. reported in 2005 that by targeting either CEA or non-specific cross-reacting 
antigen (NCA) with monoclonal antibodies in vitro the processes of cell migration, 
invasion and adhesion are affected. The use of these monoclonal antibodies in 
vivo had an anti-metastatic effect [48] however it is unknown through which 
antigen (CEA or NCA) the antibodies had their effect . 
 
CEA is shed from the surface of the cell and is found in the serum of healthy 
individuals but its level in the serum can increase in many carcinomas for 
example colorectal, breast, gastric and lung. CEA can also become elevated as a 
result of heavy smoking and several benign conditions such as alcoholic 
cirrhosis, liver abscess, obstructive jaundice, pancreatitis, inflammatory bowel 
disease, gastritis, diverticulitis, fibrocystic breast disease, renal failure and 
granulomatous cystitis [43] to name a few! Conditions affecting liver function can 
alter CEA level as this is where the majority of CEA clearance occurs [49]. 
 
In patients with cancer, CEA level is thought to relate to overall tumour burden 
and was recently shown to have the highest accuracy when distinguishing 
between malignant and benign pleural effusions when compared with the tumour 
markers CYFRA 21-1, CA15-3, CA19-9 and CA125 [50], it has also been linked 
with reduced cell mediated immunity [51] 
 
(1.3.2) CA15-3 and CA19-9 
Like CEA the cancer (or carbohydrate) antigens 15-3 and 19-9 (CA15-3 and 
CA19-9 respectively) are oncofoetal antigens. CA15-3 and CA19-9 are antigenic 
areas on large molecules called mucins. These areas are recognised by specific 
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antibodies which enable biochemical tests to establish their level in serum. 
Mucins are complex glycoproteins particularly found in mucinous membrane 
secretions. Mucins are a family of proteins that are synthesized as membrane-
bound proteins and are presented on the luminal surface of the cell where they 
are secreted (e.g. mucin 7 or MUC7), or remain membrane bound (e.g. mucin 1 
or MUC1) [52]. Mucins have a high molecular weight and constitute part of most 
epithelial tissues.  
 
The physiological role of MUC 1 is currently unknown however it is thought to be 
involved in cell adhesion [53] and cell protection [54] and it may be involved with 
lubrication, renewal, differentiation, and cell signalling. Mucins are normal 
constituents of many cell types and are differentially expressed and glycosylated 
in different tissues and disease states. MUC 1 is a product of the MUC 1 gene 
located on 1q21-24 [55], as its name suggests it is membrane bound mucin. 
 
CA15-3 is also known as epithelial membrane antigen (EMA) or episalin. It is an 
epitope present on the MUC 1 protein or polymorphic epithelial mucin (PEM) 
(see Figure 3).  
 
The number of tandem repeats found within the extracellular domain of the MUC 
1 protein varies between individuals (25 to over 125). The repeated sequence is 
20 amino acid residues long, rich in serine (S), threonine (T) and proline (P) 
residues and is extensively O-glycosylated (see Figure 3) [56]. It is this level of 
glcosylation which varies between tissues and increases the rigidity of the 
extracellular domain as well as conferring a negative charge to the structure [53]. 
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Figure 3   PEM / MUC 1 protein structure 
 
 
 
The level of PEM or MUC 1 can be determined in several ways, here are three 
of them:-  
 
o By determining the CA15-3 tumour marker level. This is established 
using a double determinant assay which uses 2 antibodies. The first is 
DF3 (first discovered by Kufe et. al. in 1984 [57]) which recognises an 
epitope within the repeated sequence in the extracellular domain of 
MUC1 (see figure 3). The second antibody II5-D8 (or Mam-6) first 
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discovered by Hilkens et. al. (1984) [58] recognises a carbohydrate 
epitope within the carbohydrate side chains of extracellular domain. 
 
o A more recently developed assay uses the single monoclonal antibody 
B27.29. This recognises the CA27.29 antigen which comprises both an 
amino acid sequence present on the MUC 1 protein which overlaps with 
that recognised by DF3 (see Figure 3) and a carbohydrate epitope [52, 
59]. The B27.29 antibody has been shown to be a “fast and reliable 
immunoassay for measuring PEM in serum” [55]. Results of this assay 
have been shown to be comparable to those of the CA15-3 assay with 
increased sensitivity of CA27.29 in low concentrations of antigen [60]. 
 
o A third assay uses monoclonal antibodies 695 and 552 [61]. 
 
Like CEA it is thought that malignancy results in a loss of cell polarity of MUC1 
presentation which usually occurs on the apical surface of the cell, as a result 
this protein is also implicated in the metastatic process. It is thought that in some 
cancers MUC1 may act to inhibit apoptosis therefore conferring drug resistance 
to the tumour [62]. It has been shown by Reddish et. al. that elevated MUC1 
protein levels (>40U.ml), identified using CA27.29 this time rather than CA15-3, 
correlate with higher CD69+ peripheral blood lymphocytes (PBL) and shorter 
survival following active specific immunotherapy (P = 0.0093) indicating a 
possible link between immunosuppression and an increased level of serum MUC 
1 protein [63]. It is also known that MUC1 is targeted by cytotoxic T lymphocytes 
in the immune reaction to breast cancer cells [64]. 
 29 
 
Abnormal levels of CA15-3 are found in 70 – 80% of patients with metastatic 
breast cancer [35, 65] and it is thought that this is as a result of the over 
expression of MUC1 [56]. As well as being found in breast cancer increased 
levels of MUC1 or CA15-3 have been found in other carcinomas such as 
advanced transitional cell carcinoma of the bladder [66]. CA15-3 may also 
become raised in patients with benign diseases such as fibrocystic disease [67] 
chronic hepatitis, liver cirrhosis, sarcoidosis, tuberculosis, systemic lupus 
erythematosous [68], and approximately 5% of people who are apparently 
healthy [35, 69]. 
 
CA19-9 is mucinous tumour marker of the sialyl Lewisa epitope. This epitope is 
formed by the glycans of several different mucins including MUC1. Unlike CA15-
3 which is recognised by antibodies which bind to the protein core and an 
antibody that binds a carbohydrate epitope of MUC 1, CA19-9 or sialyl Lewisa  is 
recognised by the 1116 NS 19-9 antibody (first derived by Koprowski et. al. in 
1979 [44]) which recognises a purely carbohydrate epitope on the mucins. The 
amount of binding is pH dependant. 
 
Sialyl Lewisa is a variant of the normal Lewis blood group antigens (Lea or Leb) 
which are found on intracellular adhesion molecules and are thought to be 
involved in binding e-selectin. They are thought to be expressed in approximately 
90-95% of the population as roughly 5-10% of people are Lewis-negative and so 
cannot synthesise this antigen [70, 71]. The sialyl Lewisa or CA19-9 epitope is a 
product of the interaction or competition of at least three genes FUT2 – the 
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secretor gene, FUT3 – the Lewis gene (located on 19q and 19p respectively) and 
a sialyltransferase (see Figure 4) [72]. The synthesis and release of CA19-9 is 
thought to be up-regulated by cyclic adenosine-monophosphate (cAMP) [73]. 
 
Figure 4   Flow diagram illustrating the production of the Lewis epitopes Le
a
, Le
b
 and Salyl-Le
a
 
adapted from Vestergaard et. al. [72]. 
 
 
CA19-9 can become raised in patients with cirrhosis of the liver, acute 
pancreatitis, biliary obstruction or cirrhosis, benign obstructive jaundice, 
pulmonary disease [35], cystic fibrosis [74] and, as with CEA, levels can become 
raised as a result of smoking, however, gastro-intestinal and particularly 
pancreatic malignancies [75] usually produce the most grossly elevated levels. 
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At least “80% of patients with exocrine pancreatic adenocarcinoma” [35] are said 
to have a raised level of CA19-9. Baseline levels of CA19-9 in patients receiving 
chemotherapy for pancreatic cancer have been shown to be an independent 
prognostic factor for survival [76] and are known to “correlate with both 
recurrence and survival” [77]. It is also thought that “abnormally high serum 
levels of CA19-9” may correlate with unresectable disease [78] and that a normal 
early CA19-9 level following radical surgery is “a relatively favourable prognostic 
index” [79]. Further to this Ziske et. al. (2003) found that a when treating 
inoperable pancreatic cancer, patients with a decrease in the baseline CA19-9 
level of >20% had significantly better median survival than those where CA19-9 
levels increased or decreased by < 20% [80], results very similar to those 
obtained by Maisey et. al. in 2005 [76]. 
 
CA19-9 has been studied in combination with CA-50 and CEA in the monitoring 
of gastric carcinoma where it is thought its measurement “may help in checking 
the prognosis, determining the efficacy of palliative treatment modalities, and 
recognising recurrences” [81] and in combination with CEA and CA125 in the 
study of advanced bladder cancer where the markers were shown to predict 
disease response to chemotherapy [82].  
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(1.3.3) Breast and Colorectal Cancer  
29% of all cancer diagnoses in 2002 were breast or large bowel (colorectal) 
and in 2004 the same two cancer types made up 19% of all cancer deaths (see 
Figure 2) [10]. There is a reasonable, and improving, chance of cure and 
disease free survival in both of these cancer types as research continues to be 
undertaken into treatment and surveillance methods. 
 
Figure 5   UK incidence and mortality rates in colorectal and breast cancer (information from 
Cancer Research UK [10]) 
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(1.3.3.1) Breast Cancer . 
Breast cancer can begin as either ductal carcinoma in situ (DCIS) which, as its 
name suggests is very localised early breast cancer, or lobular carcinoma in situ 
(LCIS) which is also non-invasive. More advanced cancers can be either invasive 
ductal cancers (which amount to 75% of all breast cancers) or invasive lobular 
cancers (approximately 10% of all breast cancers). Invasive lobular cancers are 
found mainly in women aged 45-55 years whereas the incidence of invasive 
ductal cancers increases with age. It is for this reason, together with the fact that 
DCIS is not always readily palpable, that women aged 50 to 70 are asked to 
attend for a routine mammogram every 3 years. A further form of cancer, 
inflammatory breast cancer, is very uncommon; in this disease the lymph ducts in 
the breast become blocked by cancer cells.  
 
Very few breast cancers arise as a result of genetic predisposition however there 
are two very well known genes, BRCA1 and BRCA2, which when mutated in 
certain recognised ways indicate that the individual will develop breast cancer 
during their life with a high degree of certainty. As well as these extremely well 
known genes which may carry inherited mutations, others, which may be more 
commonly mutated in sporadic breast cancer are now known, for example Cyclin 
D and p53 [11]. 
 
Breast cancer is staged as seen in Tables 2 and 3 and treatment is assigned 
accordingly, however with breast cancer, other factors must also be taken into 
account; The hormonal status of the tumour must be considered (is it positive or 
negative for oestrogen and progesterone receptors, ER and PR status 
 34 
respectively), as must its HER-2/neu (or ErbB-2) status and the menopausal 
status of the female patients which can also have a large impact upon the clinical 
decisions which are made. 
 
When a patient presents with LCIS the usual treatment is surveillance, almost all 
other breast cancer patients are offered surgery in the first instance. Patients with 
DCIS are offered surgery in the form of a wide local excision which may be 
followed by radiotherapy. Other individuals with potentially curable disease 
(Stage I to III) are offered mastectomy or wide local excision depending on, 
amongst the other factors described above, the size and position of the tumour. 
Controversy still exists as to the long term efficacy of wide local excision 
compared with mastectomy particularly in young patients [84]. During surgery the 
axillary lymph nodes are also removed and analysed for local metastases in 
order to correctly stage the tumour. New research suggests that histology from 
the sentinel node could be effective in detecting local metastatic spread and 
therefore reduce the need to remove all of the surrounding lymph nodes in some 
patients [85]. This technique could reduce the number of women who go on to 
develop debilitating lymphadenopathy. 
 
Neo-adjuvant chemotherapy is currently given in order to down size locally 
advanced tumours in order to make surgical resection possible. Recently a 
Cochrane Review has been published which investigated the use of neo-
adjuvant versus adjuvant chemotherapy in women with operable breast cancer. 
This review found no difference in overall or disease free survival between the 2 
groups and recommended the use of neo-adjuvant chemotherapy in order to 
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reduce the level of surgery required and “to evaluate chemosensitivity and to 
facilitate translational research” [86]. 
 
Adjuvant radiotherapy is offered to patients if there is a high chance of local 
recurrence and chemotherapy in the form of epirubicin (an anthracyclin) with 
cyclophosphamide, methotrexate and 5-flourouracil (ECMF) is the current 
standard treatment given in the adjuvant setting, and was shown to confer 
statistically significant advantages in terms of relapse free and overall survival 
(p= <0.001 in both cases) over CMF alone [87]. ECMF is offered to patients who 
are ER negative and to some pre-menopausal patients who have a high risk of 
recurrence.  
 
Hormone therapy is offered to all but ER negative patients. This is in the form of 
Tamoxifen or an aromatase inhibitor in postmenopausal patients and ovarian 
suppression or removal in pre-menopausal patients. It is thought by the Early 
Breast Cancer Trialists‟ Collaborative Group that “some years of adjuvant 
tamoxifen treatment substantially improves the 10-year survival of women with 
ER-positive tumours and of women whose tumours are of unknown ER status” 
[88] however tamoxifen can cause increased risk of thromboembolic disorders 
and endometrial changes. Because of this the aromatase inhibitor anastrozole 
was compared with tamoxifen in a randomised trial called the Arimidex, 
Tamoxifen Alone or in Combination trial (the ATAC trial). Results of the ATAC 
trial showed that Anastrozole treatment significantly reduced the occurrence of 
endometrial cancer, vaginal bleeding and thromboembolic events amongst 
others (p=0.02, p<0.0001 and p=0.0006 respectively), whereas treatment with 
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tamoxifen “was significantly better tolerated with respect to musculoskeletal 
disorders and fractures (p<0.0001 for both)” [89]. Recent evidence suggests that 
third generation aromatase inhibitors (anastrozole, letrozole and exemestane) 
have a more favourable toxicity profile than tamoxifen [90, 91]. 
 
Roughly 20 to 30% of patients with breast cancer are found to be HER-2 positive, 
this has been linked with aggressive tumour biology [92]. In these patients the 
monoclonal antibody trastuzmab can now be used. Previously trastuzmab (or 
Herceptin ®) treatment was only approved in the palliative setting however recent 
studies have shown that just one year of treatment with this drug significantly 
(p<0.001) improves disease free survival [93] and overall survival in HER-2 
positive women in the adjuvant setting [94]. 
 
Breast cancer develops into advanced disease with the presence of distant 
metastases in approximately 40 to 50% of cases within the first five years 
following primary treatment [83]. The most common sites of metastatic disease 
are the bones liver, lungs and brain. The development of advanced disease 
usually means that the disease is no longer „curable‟ and treatment becomes 
palliative rather than adjuvant, however, with the development of increasingly 
sophisticated surgical techniques isolated metastases can occasionally be 
resected with curative intent. 
 
In the palliative setting aims of treatment are mainly to improve or maintain the 
patient‟s quality of life to alleviate disease symptoms and to prolong survival. 
Treatment options again depend upon many factors such as patient preference, 
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existing co-morbidities, the sites of metastatic disease, hormone receptor and 
HER-2 status and the treatments previously received by the patient.  
 
Treatment options again include hormonal therapy for those eligible. The same 
considerations that apply to hormone treatment in the adjuvant setting also apply 
in the setting of advanced disease i.e. patients must have hormone sensitive 
disease. This form of treatment is often the first treatment option in advanced 
breast cancer in postmenopausal patients as treatment can be initiated rapidly. If 
hormonal therapy with one of these drugs ceases to be effective treatment can 
be changed to another of them as a second line hormonal therapy. In pre-
menopausal patients ovarian suppression or removal is the usual method of 
hormone therapy. 
 
Chemotherapy is another treatment option and several different individual 
chemotherapy drugs and combinations of drugs are used in the palliative setting. 
First line treatment is usually in the form of anthracycline (e.g. doxorubicin) and / 
or taxane (e.g. taxol) regimens. In anthracycline resistant disease taxane based 
treatment is often used (alone or combined with gemcitabine or capecitabine) 
[91]. Monoclonal antibody treatment in the form of traztuzumab can be given to 
patients eligible for treatment (HER-2 positive) as a single agent or in 
combination with non-anthracycline based chemotherapy. In metastatic breast 
cancer traztuzumab in combination with chemotherapy has been shown to confer 
a significant survival advantage to treatment with chemotherapy alone [92]. 
Radiotherapy can also be given if necessary for palliation of symptoms and 
localised disease control.  
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Bone is the most common site for metastatic disease in patients with breast 
cancer; bisphosphonates are another class of drugs which are commonly given 
to patients with metastatic bone involvement or tumour-induced hypercalcaemia 
(as well as patients without breast cancer who have osteoporosis). 
Bisphosphonates are usually given as regular infusions and they work by 
reducing the rate of bone growth and dissolution [95]. In patients with advanced 
breast cancer the use of bisphosphonates has been shown to significantly 
reduce skeletal events such as fractures and may reduce bone pain [96]. Some 
side effects of bisphosphonates have recently come to light for example an 
increased incidence of osteonecrosis of the jaw [92].  
 
(1.3.3.2) CEA, CA15-3 and CA19-9 in Breast Cancer  
CEA and CA15-3 are the most established and studied tumour markers in breast 
cancer; other markers such as Tissue Polypeptide Specific Antigen (TPA) are 
used but less frequently. Studies into the sensitivity and specificity of these 
markers are often difficult to compare due to differences in assay technique, 
tumour marker source used (e.g. serum/tumour tissue), time of sampling, therapy 
investigated and disease stage. Comparison can also be hindered as tumour 
markers are often combined together in tumour marker panels and studies 
sometimes do not report the results for each marker individually. 
 
The use of CA19-9 in patients with breast cancer is not yet well documented as it 
is though that its main clinical utility lies in patients with Gastro intestinal 
malignancies. 
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Localised Disease 
It is now widely accepted that neither CEA nor CA15-3 is of real value in 
screening for breast cancer, In 1998 Molina et. al. reported that the sensitivity of 
CEA and CA15-3 was 18% and 16% respectively in detecting loco-regional 
disease [97]. In 2003 Molina et. al. quoted similar sensitivities of 13.0% and 
18.8% respectively they also reported that when the markers CEA and CA15-3 
were combined sensitivity increased but remained low at 22.8% [98]. Due to the 
lack of both sensitivity and specificity of both CEA and CA15-3 it is thought that 
neither tumour marker is of value in the detection of early breast cancer [69, 83, 
99]. Despite this it is thought that increased pre-operative levels of both markers 
in patients with loco-regional disease are thought to correlate with adverse 
patient outcome in the long term [69, 100]. It has been speculated that raised 
markers at this early stage may indicate the presence of unidentified metastatic 
disease [83]. 
 
CEA and CA15-3 levels have been shown to correlate with tumour size and 
lymph node status [98] and Sherring et. al. (1998) report that increasing CA15-3 
levels were associated with greater tumour size and involvement of axillary 
lymph nodes but not oestrogen receptor status [101] similar findings to those of 
Cañizares et. al. (2001)[102]. However Duffy et. al. (2000) use multivariate 
analysis to show that CA15-3 is actually a prognostic marker independent of 
these two factors [53]. 
 
Kumpulainen et. al. (2002) found that survival varies significantly (p <0.001) 
between patients with normal and abnormal (ULN = 29 U/ml) CA15-3 levels 
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(Hazard ratio = 3.36) and that raised CA15-3 is an independent prognostic factor 
for reduced disease specific survival [14]. This may result in part from the fact 
that they substituted postoperative CA15-3 levels when no preoperative levels 
were available, however, their findings do agree with those of Duffy et. al. (2004) 
[103]. Shering et. al. (1998) using multivariate analysis also report preoperative 
CA15-3 to be independently and significantly predictive of disease free and 
overall survival at 5 years (p < 0.01 in both cases and relative risk (RR) = 1.84 
and 2.4 respectively) using 30.38 U/ml as the cut-off level [101]. 
 
Ebeling et. al. (2002) used univariate analysis to demonstrate that raised 
preoperative CA15-3 but not CEA correlates with early relapse (p = 0.0003) 
however both CEA and CA15-3 correlate with death from the disease (p = 0.0001 
in both cases) [100], this confirmed their earlier results [104]. Other studies, 
again using univariate analysis, also found that both CEA and CA15-3 
significantly correlate with overall survival but unlike Ebeling et. al. (2002) [100] 
found that increased levels of both markers correlated significantly with disease 
free survival [98, 102]. In fact Molina et. al. (2003) found that CEA and not CA15-
3 was an independent prognostic factor for both DFS and overall survival [98] 
and Canizares et. al. (2000) [102] found that neither of the markers were 
predictive. 
 
Ebeling et al (1999) found that “single postoperative tumour marker values alone 
were without prognostic value concerning relapse or death” [104] however their 
multivariate analyses have also found a significant link between a post-surgery 
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decline in pre-surgery CEA values with an increased risk of recurrence and 
death, the same was not found with CA15-3 [100, 104].  
 
Despite the fact that groups such as ASCO do not recommend the use of tumour 
markers in routine follow up of patients after potentially curative treatment both 
CEA and CA15-3 are routinely used in the follow up of patients with breast 
cancer and in monitoring the efficacy of treatment in advanced disease but as 
yet, there is no clear framework for their use. 
 
Detecting Advanced Disease 
Several studies now demonstrate that increases in the levels of CEA and CA15-3 
sometimes pre-date clinical and radiological evidence of advanced disease 
development; this is often called the tumour marker lead time.  
 
Table 5 shows lead times as quoted by several different papers. Lauro et. al. 
(1999) quoted a mean lead time of 3 months for both CA15-3 and CA27-29 
(range 2-7months) [99] which is to be expected as both of these tests are 
identifying the same molecule. Blijlevens et. al. quote the lead time for CA15-3 as 
double this (6 months) however this is based upon data from only 3 patients 
[105].  
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Table 5   Sensitivity of tumour markers at the time of advanced breast cancer and tumour marker 
lead times. 
 
 
Sensitivity % of tumour 
marker in advanced 
disease (mean lead time in 
months) 
Date  Author 
N
o
 of patients / 
N
o
 with 
advanced 
disease 
CEA CA15-3 
1991 Nicolini et. al. [106] 285 / 40 45 52 (2.7)  
1993 Sölétormos, G et. al. [107] 90 / 21 10 48 (2.1
‡
 ) 
1995 Blijlevens et. al. [105] 121 / 91 (2)** (6)** 
1996 Molina et. al. [108]  200 / 89 30 (4.9) 47 (4.8) 
1996 Pectasides et.al. [109] 209 / 68 34.1 68.2 
1998 Molina et. al. [97] 521 / 185 61 70 
1999 Lauro et. al. [99] 220 / 70 35 (2)  79 (3) 
1999 Robertson et. al. [110] 67 / 67
$
 42 54 
2001 D‟Alessandro et. al. [67] 1365 / 111 - 65.7 
2002 De La Lande et. al. [111] 119 / 119 - (5.3*) 
2003 Kurebayashi et. al. [112] 528 / 528 30.5 44.0 
2003 Nishimura et. al.[113] 220 / 220 41.4 50.9 
 
$ 
All patients had distant metastases (not simply advanced disease) 
‡ Calculated from a lead time quoted as 64 days 
* Calculated from a lead time of 162 days, range 31-765 (however these results excluded patients 
with a lead time of less than 30 days and those who initially developed a local recurrence).  
** Calculated with data from one patient (CEA) and three patients (CA15-3) 
 
As can be seen from the sensitivities listed in Table 5, CA15-3 is considered to 
be more effective than CEA as and indicator of recurrence or metastatic disease. 
It is also thought that a tumour markers sensitivity in detecting advanced disease 
is reduced when the advanced disease takes the form of local recurrence as 
opposed to metastatic disease, Molina et. al. (1996) illustrated this when they 
reported that 30% of patients had a raised CEA level before diagnosis of 
advanced disease compared with 47% with raised CA15-3 and that these figures 
increased to 33% and 56% respectively when patients with local recurrence were 
excluded [108]. Martoni et. al. (1995) report that during metastatic disease 45% 
of patients have raised levels of CEA and 71% have raised  CA15-3 (77% 
sensitivity when CEA and CA15-3 were combined) [65]. I have not included these 
 43 
figures in table 5 as the marker levels were not necessarily recorded at the time 
of diagnosis of advanced disease.   
 
Kurebayashi et. al. (2003) report 55.2% of patients with advanced breast cancer 
have raised CEA, CA15-3 or both [112] (n=348, as only 66% of the 528 patients 
in table 5 had both CEA and CA15-3 measured), this is compared with 75% as 
quoted by both Nicolini et. al. (1991) [106] and Robertson et. al. (1999) [110]. 
The results of Robertson et. al. (1999) refer to a group of patients with distant 
metastatic disease and not simply advanced disease, it is therefore worth nothing 
that this may give falsely high sensitivity as it is known that the sensitivity of CEA 
and CA15-3 to detect advanced disease are thought to be related to the site of 
disease development and as previously stated levels are thought to be higher in 
patients with metastatic disease than in those with local recurrence [105, 108].  
 
The highest levels of CEA and CA15-3 have been associated with liver and bone 
metastases [97, 99, 105, 108, 113, 114] and Nishimura et. al. (2003) found that 
both CEA and CA15-3 were at their lowest in patients with brain metastases 
[113]. Tampellini et. al. (1997) found higher CA15-3 levels in patients with pleural 
effusions as well as the viscera [115]. Markers appear to lack the sensitivity to 
detect lung metastases however De La Lande et. al. (2002) found that a CA15-3 
lead time was most commonly found in patients who developed lung metastases 
[111]. 
 
Like CA15-3, elevation of CA27.29 the alternative MUC1 antigen (identified by 
the B27.29 antibody described in section 1.3.2) has also been found to correlate 
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with the development of advanced disease with a sensitivity comparable to that 
of CA15-3. In a group of 166 patients where 26 patients went on to develop 
recurrence Chan et. al. (1997) found that the CA27.29 assay had a sensitivity of 
57.7%, specificity of 97.9%, a PPV of 83.3 and a NPV of 92.6% and also that the 
average lead time before disease recurrence was 5.3 months which is 
comparable with the result for CA15-3 [116]. 
 
Colomer et. al. (1989) showed that in relapsing patients elevated CA15-3 (> 
40U/ml) was the first sign of recurrence significantly more frequently than CEA 
(45% vs 25% respectively, p <0.001). this paper also claims that the addition of 
CEA does not add any more information to that provided by the CA15-3 assay 
alone, conversely it actually increases the number of false positive results seen 
[68]. It is worth noting here that although tumour marker lead times are 
sometimes seen they are not seen in all cases for example Nicolini et. al. (1991) 
found that of 285 breast cancer patients, 40 patients who relapsed were 
evaluated and of these only 21 patients (53%) had a tumour marker lead time 
from one or more of the markers CEA, CA15-3 or TPA [106].  
 
The marker TPA is often measured in conjunction with CA15-3 and CEA. It has 
been demonstrated that by combining CA15-3 and TPA the sensitivity and 
specificity of CA15-3 to disease recurrence is further increased [67, 106, 109, 
117]. Sonoo et. al. (1996) used TPA, CA15-3 and CEA in a tumour marker panel 
and found that the changes in the levels of the markers correlated significantly 
with response to therapy (see Table 6) however the power of this study was low 
(n = 45) [118] 
 45 
The value of early detection and earlier treatment of advanced breast cancer is 
widely debated, although theoretically treatment at an earlier stage would reduce 
tumour burden to a greater degree than later treatment this approach has not 
been advocated. Joseph et. al. (1998) report that in a group of 1898 patients 
followed up for recurrence, 129 patients developed recurrent disease. In a 
retrospective review of how these recurrences were detected they found no 
significant difference in survival (p=0.18) between patients where recurrence was 
detected by intensive follow up (n=27, 21%) (including LTF, CEA and CA15-3 
analysis, Chest radiograph, CT and bone scan) and those where recurrence was 
detected by minimal follow up (n=99, 79%) with history, physical examination and 
mammography. In contrast to these findings in 1997 Nicolini et. al. [17] reported 
that early treatment based upon the detection of advanced disease by the CEA-
TPA-CA15-3 tumour marker panel (as used above by Sonoo et. al. [118]) 
increased survival “from mastectomy to 72 months and from salvage treatment to 
30 months” significantly (p = 0.031 and 0.004 respectively) [119]. In 2003 Nicolini 
et. al. again demonstrated that early treatment of metastatic breast cancer based 
upon the same tumour marker panel again resulted in a significant increase in 
survival from salvage treatment or mastectomy (p = 0.015 and 0.007 
respectively) [120].  
 
It may be that the inclusion of TPA by Nicolini et. al. in the above studies 
increases tumour marker sensitivity for recurrence or that the tumour marker 
assays done by Joseph et. al. (performed at intervals of 3 months for the first 2 
years and then at 6 month intervals for the following 2 years) at were not 
performed frequently enough to identify the tumour marker lead times quoted in 
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Table 5 which precede clinical of radiological evidence of advanced disease. The 
power all three studies was relatively low and as a result further research into 
these important questions is needed.  
 
During Advanced Disease 
Molina et al (1998) found elevated levels of CEA in 61% of patients with 
advanced breast cancer (n = 413) compared with elevated CA15-3 in 70% of 
patients and Nishimura et al (2003) found similar results (67.3% for CEA and 
76.8% for CA15-3) [113]. Lauro et al (1999) quote these figures as 79% for 
CA15-3, 70% for CA27-29 and a low 35% for CEA, however, the greatest 
sensitivity (82%) was achieved by combining all 3 markers [99]. The level of 
positivity is now thought to be between 70% and 80% for CA15-3 [35].  
 
CA15-3 is thought to be more sensitive and specific than CEA in the monitoring 
of advanced breast cancer [65, 112] however increased sensitivity is thought to 
be gained by combining the 2 markers [83, 112], Molina et. al. state that “most 
reports indicate that by using CEA as well as CA15-3 it is possible to increase 
sensitivity by 7% to 20% compared to that obtained with CA15-3 alone” which 
they report as having a sensitivity of 55-70% in advanced breast cancer [83].  
 
As with the development of loco-regional disease overall survival is thought to be 
shorter in CEA and CA15-3 positive patients who have advanced breast cancer 
[109], Kurebayashi et. al. (2003) found that time to progression (TTP) was 
significantly shorter in patients who had positive pre-treatment levels of CEA and 
CA15-3 but also that patients who had a fall of >20% in either marker level during 
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therapy had a significantly longer TTP. They also found that negative pre 
treatment CA15-3 levels but not CEA levels were an independent predictor of 
increased time to progression in patients with advanced disease [112]. Loprinzi 
et. al also found that CEA levels were not predictive of survival [114]. The results 
of Nishimura et. al. (2003) concur with these findings in terms of CEA however 
contradict them entirely in terms of CA15-3 stating that patients with negative 
CA15-3 levels after recurrence had significantly poorer survival rates (p = 0.003) 
[113].  
 
Some studies only look at CA15-3 and again the same contradicting results are 
reported; Berruti et. al. (1994) report that raised CA15-3 level (>30 U/ml) at the 
time of disease recurrence is an independent prognostic factor for shorter overall 
survival (n = 115) [121]. Tampellini et. al. (1997) found this not to be the case and 
instead related CA15-3 level to disease extent which itself was found to be an 
independent variable in determining survival [115]. It has also been speculated 
that raised CA15-3 levels are linked with Oestrogen Receptor (ER) positivity 
[111] and Loprinzi et al (1986) also link elevated pre-treatment CEA levels with 
oestrogen receptor (ER) positivity [114]. 
 
Many studies aiming to compare tumour marker response and response to 
treatment in advanced breast cancer look at single tumour marker levels 
however some studies use a more dynamic approach to tumour markers by 
looking at marker changes over time and in relation to treatment a summary of 
13 such studies can be seen in Table 6. In 1995 Martoni et. al. did this (see 
Table 6) and investigated change in CEA and CA15-3 (and MCA and CA549) 
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levels during hormone therapy and chemotherapy for metastatic disease. They 
defined 3 categories of tumour marker response in patients with abnormal 
tumour marker values at the start of treatment;  25% increase = progressive 
disease,  25% decrease = partial response, > 25% decrease and normalising of 
tumour marker values = complete response. This system showed that CA15-3 
had a sensitivity of 67% in monitoring the clinical course of the disease in 
patients with an abnormal baseline level which also identified progressive 
disease with a sensitivity of 87% and a positive predictive value (PPV) of 100%. 
This was better than CEA which had a sensitivity of 53% [65].  
 
Blijlevens et. al. (1995) also defined response as a 25% increase or decrease 
from the baseline; they found that in 38% of patients CEA marker response 
correlated with lack of progression and this figure was higher at 49% for CA15-3. 
The levels of false positives were recorded as 22% (CEA) and 11% (CA15-3) 
respectively [105].  
 
Robertson et. al. (1991) when looking at the CEA-ESR-CA15-3 index of 
response and progression (see Table 6) found that combined marker changes 
within this index correlated with UICC response (classified as non-progression or 
progression) with a maximum sensitivity of 92% and specificity of 82% at 4 
months after treatment start. They also found that the maximum sensitivity and 
specificity for CEA and CA15-3 combined (without ESR) was also at 4 months 
and was 85% and 82% respectively. Correlation with UICC response was found 
irrespective of whether 10% or 20% marker change was used to define that 
response [122]. Dixon et. al. (1993) examined the same index (CEA-ESR-CA15-
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3) but in patients undergoing systemic chemotherapy rather than hormone 
therapy, they found significant correlation between the index score at 6-8 weeks 
after initiation of therapy and the UICC response at 3-4 months after initiation of 
therapy (again classified as non-progression or progression). Their results 
showed the response index to have a sensitivity of 89% and a specificity of 96% 
at this time. These results indicate that marker kinetics can reflect response to 
treatment [123].  
 
Dixon et.al. (1993) also take these results one step further by treating people 
based upon their tumour marker movements, although their study was 
underpowered they found that there was a significantly clinical remission period 
in patients who were treated with continuous chemotherapy in a tumour marker 
dependant way compared with those who stopped cytotoxics after 6 months [123].
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Table 6   Research into tumour marker kinetics and response to treatment in advanced breast cancer 
 
Breast Cancer  
Author Date 
Markers & Cut-
off values 
P/R* Patients Aims Treatment Results / Conclusion 
Loprinzi et. al. 
[114] 
1986 CEA: > 5ng/mL P 97 women with 
metastatic 
breast cancer 
To evaluate “the use of 
pre-treatment and serial 
CEA levels “ 
DAVTH Vs 
DAVTH 
alternating 
with CMFP 
Elevated pre-treatment CEA correlated 
significantly with ER positivity, prolonged 
disease-free intervals, hepatic and bone 
metastases and multiple sites of metastatic 
disease but not response rate, time to 
treatment failure or survival.  
 
In the first 4 months of Serial CEA 
measurements CEA levels declined 
progressively from elevated levels or “initially 
rose significantly (mean, 243% of pre-
treatment value) and then declined” [114]. 
Kiang et. al. 
[124] 
1990 CEA: > 5 ng/ml 
CA15-3: >25 U/ml 
P 30 women with 
elevated CEA  
(n=24) and / or 
CA15-3 (n=12) 
To examine the 
kinetics of CEA and 
CA15-3 “in terms of 
plasma doubling time 
and half-life and their 
relationship to 
therapeutic response” 
[124] 
Various 
chemotherapy 
regimens 
The authors report finding “four distinct kinetic 
patterns “ of CEA response to chemotherapy: 
 Marker continues to increase 
 Marker level declines 
 Marker surge followed by decline 
 Sharp marker decline followed by 
increase. 
They also found that “changes of CA15-3 
kinetics were similar to that of CEA” [124]. 
Robertson et. 
al. [122] 
1991 CEA: > 6 ng ml 
CA15-3: > 3 U ml 
(and ESR) 
P 65 patients Assess the correlation 
of the CEA-CA15-3-
ESR tumour markers 
when combined with 
UICC assessed 
response 
Systemic 
endocrine 
therapy 
“changes in the markers at 2, 4 and 6 months 
showed a highly significant correlation with 
UICC assessed response at 6 months” [122]. 
 
They found no significant difference in 
survival between groups assessed 
(radiologically or biochemically) as 
progression or non-progression. 
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Breast Cancer  
Author Date 
Markers & Cut-
off values 
P/R* Patients Aims Treatment Results / Conclusion 
Dixon et. al. 
[123] 
1993 CEA: >6ng ml
-1
 
CA15-3: >33U ml
-
1 
(ESR) 
P 55 (of 67 
patients 
treated with 
chemotherapy) 
To test the “biochemical 
response index 
comprising ESR, CEA 
and CA15-3” [123] to 
direct continuous 
chemotherapy 
treatment. 
Mitozantrone 
+ CMF (n = 
21) or CMF (n 
= 34). 
 
Marker changes at 2 and 4 months correlated 
with the UICC assessed response at 3 and 6 
months (p<0.001), sensitivity = 100%, 
specificity = 87%; PPV = 85%. The survival 
from first treatment and median time to 
biochemical progression were longer (p = 
0.04 and 0.05 respectively) in the responsive 
patients who received continuous 
chemotherapy compared with the control 
group. 
Blijlevens et. 
al. [105] 
1995 CEA: 5μg/l 
CA15-3: 30U/l 
(TPS) 
P 121 (43 = 
NED, 78 = ED) 
Using CEA and CA15-3 
as a reference to 
investigate if TPS can 
determine activity of the 
disease, location of 
metastases and 
response to treatment 
as assessed by UICC 
criteria. 
29 of the ED 
patients 
received 
chemotherapy 
or hormone 
therapy, no 
further details. 
TPS + CA15-3 has a sensitivity = 72% for 
detection of metastatic disease. 
 
Using a 25% increase or decrease in 
baseline tumour marker level as a tumour 
marker progression or response the 
“correlation with clinical deterioration after 6 
months of therapy was 44% for TPS 33% for 
CEA and 28% for CA15-3” [105]. 
Martoni et. al. 
[65] 
1995 CEA: 2.5ng/ml 
CA15-3: 30U/l 
(MCA, CA549) 
P 71 (of 201) 
were monitored 
for relationship 
with response 
to treatment 
To look at the markers 
ability to detect 
advanced disease. 
Study of tumour marker 
changes in response to 
treatment was also 
done on a subset of 
patients (n=71). 
Hormone 
therapy or 
chemotherapy 
(either CMF, 
FEC or MMM) 
 From normal base line levels 
Sensitivity = 42% for CEA and 87% for CA15-
3 (specificity = 100%). Combining markers 
decreased specificity of changes in marker 
levels to monitor clinical course (only 
progression was evaluable in this group). 
 From abnormal baseline levels 
“Overall sensitivity of marker changes was 
between 53% (CEA) and 67% (CA15-3)” [65] 
in monitoring clinical course (As measured by 
WHO criteria). 
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Breast Cancer  
Author Date 
Markers & Cut-
off values 
P/R* Patients Aims Treatment Results / Conclusion 
Sonoo et. al. 
[118] 
1996 CEA: 2.5ng/ml 
CA15-3: 30U/l 
(TPA) 
R 45 (36 with 
recurrent 
breast cancer, 
9 stage IV 
disease) 
To investigate the 
“relationship between 
the initial changes 
and the kinetic 
patterns of the 
markers after therapy 
and the objective 
responses” [118]. 
Hormone, 
chemotherapy 
and 
radiotherapy 
20% increase or decrease in markers was 
taken as significant. Initial changes in all three 
markers significantly correlated with the 
therapeutic responses (P < 0.01)” 
 
Five distinct kinetic patterns were made by the 
tumour markers following the initiation of 
therapy. Kinetic patterns of the tumour 
markers were better at correlating with 
therapeutic response than initial marker 
changes. 
Rubach et. al. 
[9] 
1997 CEA: Unknown 
CA15-3: Unknown 
R 298 patients 
with stage I to 
IV disease 
“to investigate the 
prognostic value of 
CA15-3, CEA and ESR, 
mainly in metastatic 
disease” [9]. 
No details 
given 
Found there to be a significant relationship 
(log-rank P value) between CEA and CA15-3 
marker patterns and both overall survival and 
disease free survival when they categorised 
marker movements as; normal, decreasing, 
fluctuating or increasing. 
Luaro et. al. 
[99] 
1999 CEA: < 5 U/ml 
CA15-3: < 30 
U/ml 
CA27-29: < 35 
U/ml 
(and MCA) 
R 220 patients: 
180 = no 
evidence of 
disease (30 
developed 
advanced 
disease later), 
40 = advanced 
disease at 
diagnosis 
To “define the most 
useful tumour marker 
panel in breast cancer 
patients‟ follow up and 
in monitoring treatment 
response” [99] as 
assessed by UICC 
criteria. 
Various 
regimens of 
endocrine 
therapy, 
radiotherapy 
and 
chemotherapy 
Both CA15-3 and CA27-29 correlated with the 
course of advanced disease 81% of the time 
compared with 40% of the time for CEA. 
 
 
 
 
 
 
 
       
 53 
Breast Cancer  
Author Date 
Markers & Cut-
off values 
P/R* Patients Aims Treatment Results / Conclusion 
Robertson et. 
al. [110] 
1999 CEA: >6 μgl
-1 
CA15-3: > 33 
Kuml
-1 
(and ESR) 
P 83 To investigate if CEA, 
CAI5-3 and ESR can 
measure remission and 
progression in 
Metastatic breast 
cancer 
Hormone or 
chemotherapy  
A marker panel of “CA15-3 and CEA (with and 
without ESR) provide an objective method to 
guide therapy in patients with metastatic 
breast cancer”. 
“Overall changes in the three tumour markers 
reflected UICC-defined disease progression in 
34 out of  39 patients (87%)” and. 
“there was an excellent correlation between 
changes in the three tumour marker s and the 
disease progression by UICC criteria” [110] 
although significance is not quantified here 
De La Lande 
et. al. [111] 
2002 CA15-3: 30 U/mL R 119 patients 
and 140 
matched 
controls 
To analyse “the 
prognostic implications 
of CA15-3 kinetics …. 
before and at first 
metastasis” [111]. 
Standard 
treatment 
Significantly better survival in:- 
 - Patients with a CA15-3 lead time >30 days 
compared with those who do not. 
 - Patients who have a longer interval (>770 
compared with ≤ 770 days) between 
diagnosis and first elevation of CA15-3 
Kurebayashi  
et. al.[112] 
2003 CEA: 5 ng/ml 
CA15-3: 30 U/ml 
R 348 To clarify the 
significance of CEA and 
CA15-3 in monitoring 
advanced breast 
cancer 
Systemic 
therapy with 
endocrine 
therapy, 
chemotherapy 
or both. 
CEA and CA15-3 correlate with response to 
therapy but only in patients with raised marker 
levels.  
 
There was a significant (p < 0.01) correlation 
between a 20% reduction in raised CEA and 
CA15-3 marker levels during therapy and a 
longer time to progression. 
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Author Date 
Markers & Cut-
off values 
P/R* Patients Aims Treatment Results / Conclusion 
Nicolini et. 
al. [120] 
2003 CEA:  
(1981-95) >7ng 
ml
-1
 
(1995-99) 5 ng ml
-
1
 
CA15-3:  
(1981-95) 32mU 
ml
-1
 
(1995-99) 32U ml
-
1
 
(and TPA) 
P 109 the results 
of which only 
68 were 
evaluated 
To see if treatment 
based upon the CEA-
TPA-CA15-3 tumour 
marker panel can 
prolong survival 
Various 
systemic 
treatments 
88% sensitivity of the tumour marker panel for 
detecting distant metastases. 
 
Patients treated early in a tumour marker 
guided way had significantly longer survival 
from mastectomy and from salvage therapy (p 
< 0.01 in both cases) at 7 years and 3 years 
respectively. 
 
This is the final report of the study by Nicolini 
into the effect of treatment based upon the 
CEA-CA15-3-TPA tumour marker panel 
following publication of their preliminary 
findings in 1997 [17]. They found that “tumour 
marker guided” salvage treatment 
significantly prolongs disease-free and overall 
survivals” [120].  
 
 
CA27.29  Cancer antigen 27.29 
CA549  Cancer Antigen 549 
CMF Chemotherapy regimen comprising cyclophosphamide, flourouracil and methotrexate 
CMFP  Cyclophosphamide, methotrexate, 5-flourouracil and prednisone 
DAVTH  Dibromodulcitol, doxorubicin, vinchristine, tamoxifen and fluoxymesterone 
ER   Oestrogen receptor 
ESR  Erythrocyte sedementation rate 
FEC  Chemotherapy regimen comprising cyclophosphamide, flourouracil and epirubicin 
MCA Mucin like Carcinoma Associated Antigen 
MMM  Chemotherapy regimen comprising methotrexate, mitomycin C and mitoxantrone 
NED/ED  Evidence of disease / No evidence of disease 
P/R*  Study type – prospective or retrospective 
TPS/TPA  Tissue polypeptide specific antigen 
UICC  International Union Against Cancer 
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CA15-3 level is considered to be an effective predictor of outcome and is thought 
to correlate with both disease free survival (DFS) and overall survival (OS). 
Kumpulainen et. al. (2002) found that CA15-3 level correlated with OS with a 
greater degree of significance than tumour stage [14] . Kurebarashi et al (2003) 
demonstrated that a decrease in raised levels of CEA and CA15-3 correlate well 
with disease “response to therapy” [112] and increased levels are shown to 
correlate with shorter survival times [98]. Rubach et. al. (1997) have already 
shown that patient survival (both relapse free and overall) and tumour marker 
kinetics (CEA and CA15-3) during post-surgical follow up and/or therapy are 
significantly linked (p < 0.05 in all cases), see table 6. A summary of their results 
from 298 patients can be seen in table 7 below 
 
Table 7   Results of Rubach et. al. (1997) [9]. 
 
 Ten Year Overall / relapse-
free survival rates (%) 
CEA CA15-3 
Within normal range 63.0 / 13.9 71.9 / 20.7 
Decreased 56.9 / 12.7 57.5 / 12.9 
Fluctuating 40.2 / 11.7 24.7 / 0.0 
Increasing 31.4 / 6.2 27.9 / 4.8 
 
As only log rank p values are quoted in this paper it is impossible to comment on 
the exact nature of the relationship between marker movement and survival but 
the results indicate that there may be a survival advantage for patients if their 
tumour markers never rise above the upper limit of normal. The results also 
suggest that patients with decreasing markers may have better survival than 
patients whose tumour markers fluctuate or increase; this would seem intuitive if 
tumour marker levels correlate with tumour burden. The difference between 
 56 
patients whose markers fluctuate and those whose markers increase is less clear 
as patients with fluctuating CEA levels appear to have improved survival when 
compared with patients with increasing tumour markers but this is not the case 
with CA15-3.  
 
As well as monitoring response to treatment there is now increasing evidence 
that the use of CEA and CA15-3 can be used to successfully select patients who 
are responsive to treatment, Dixon et al (1993) demonstrated that by using CEA 
and CA15-3 (along with ESR) levels to select patients to be treated with 
continuous rather than conventional chemotherapy regimens overall survival and 
time to biochemical progression significantly increased [123].  
 
Some of the papers on this subject produce interesting results but closer 
inspection of the methodology within some of these papers shows 
inconsistencies which probably greatly influence the accuracy of the results 
obtained. Nicolini et al (2003) [120] is a final report of a study from which data 
was preliminarily published in 1997 [17] and the main findings of Nicolini et al 
(2003) can be seen in table 6. In the preliminary study data was collected 
between 1977 and 1993 [17] and in the later study the dates during which 
patients were recruited is quoted as 1981 to 1999 [120]. No information is 
provided regarding the reasons for the different start dates and the authors do 
not clarify how patients were selected for the study from the available population. 
The long study duration results in the possible influence of other variables upon 
the results because factors such as available treatments and imaging techniques 
will improve over time. 
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In both of these papers the authors describe the way that patients were allocated 
to the two different treatment groups. The groups consisted of “early” treatment 
based upon the findings of the tumour marker panel, or conventional treatment 
based upon the findings of other clinical tests such as radiology.  The patients 
were not allocated randomly to these groups but in some cases patients refused 
early treatment and were therefore allocated to the conventional treatment group. 
Others were included in the conventional treatment group because they did not 
have an increased tumour marker level at the time of relapse, or because they 
had an increase in tumour marker level at the same time as their relapse which 
was also otherwise diagnosed. These patients could not have been included in 
the “early” treatment group as they did not have an increase in tumour marker 
prior to their relapse or because they did not consent to early treatment. This 
failure to randomise results in the comparison of two groups with different 
characteristics and makes it impossible to draw any conclusions from results 
which are obtained when the two groups are compared [17,120]. 
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(1.3.3.3) Colorectal Cancer 
Incidence and mortality of colorectal cancers in the UK can bee seen in Figure 5. 
Colon cancer accounts for 62% and rectal cancer 38% of the 35,006 recorded 
colorectal incidences in 2003. However colon cancer makes up 64% of the 
colorectal deaths in 2005 whereas rectal cancer accounts for 36% of deaths [10]. 
It is possible that this difference due to increased detection of rectal cancers at 
an early stage, this could be due potentially earlier development of symptoms 
from a tumour at this site. 
 
Most colorectal cancers are sporadic adenocarcinomas which arise in an existing 
adenoma (a benign growth with a glandular structure) as a result of an 
accumulation of genetic mutations over time [49], for example, imbalanced DNA 
methylation is thought to be an early stage in colorectal cancer formation as is a 
deletion in 18q affecting the genes DPC4 (also known as SMAD4) and DCC, and 
17q losses. It is thought that both copies of the adenomatous polyposis coli 
(APC) gene are inactivated in up to 80% of cases of sporadic colorectal cancer 
[10]. 
 
It is thought that only approximately 3-6% of colorectal cancers are hereditary of 
which there are two main forms, both are autosomal dominant disorders.  
 
1. Familial Adenomatous Polyposis (FAP) is the least common of the two 
predispositions. It is a disease characterised by the development of 
benign polyps throughout the large bowel. One or more of these polyps 
will almost certainly become malignant over time. FAP is caused by 
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loss of function of one copy of the APC (adenomatous polyposis coli) 
gene of 5q21. The APC gene product is involved in the degradation of 
β-catenin which in turn is part of the protein complex which activates 
proto-oncogenes e.g. c-myc [10]. 
 
2. Hereditary non-polyposis colorectal cancer (HNPCC) as the name 
suggests has no preceding polyps. It is nearly always caused by a 
mutation in MSH1 or MSH2 (and less commonly the PMS2 gene); this 
affects the process of DNA mismatch repair rendering the cell more 
vulnerable to DNA damage. 
 
Both of these predispositions are associated with early onset of colorectal 
cancers and HNPCC is also associated with increased incidence of other 
malignancies.  
 
The colorectal cancer staging system is defined in Tables 2 and 3. The most 
important aspect of early treatment for Dukes A, B and C colorectal cancers is 
surgery to resect the tumour; this may be undertaken in Dukes D colorectal 
cancer in order to palliate symptoms. Despite surgery half of patients who have 
undergone resection of colorectal cancer will go on to relapse and die of the 
disease within 5 years, decline in survival is not as steep after this point and 42% 
of patients survive to ten years post surgery [125]. 
 
The current National Institute for Clinical Excellence (NICE) guidelines state that 
chemotherapy should be offered post surgery to patients with Dukes C colorectal 
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cancer as this confers a proven survival advantage. For these patients the 
current recommended adjuvant treatment is 5-Flourouracil (5-FU) and Folinic 
acid (FA) with oxaliplatin, or capecitabine alone [126] and guidelines concerning 
the use or irinotecan in this setting are currently in development. There is little 
evidence to support or reject the use of chemotherapy in patients with Dukes B 
colon cancer at present however the QUASAR trial aims to answer this question 
[127].  
 
In the case of rectal cancer the advantage of surgery followed by chemotherapy 
over surgery alone is not known, however some detail can be found concerning 
the impact of radiotherapy with cancer at this site. It is known that the addition of 
radiotherapy to a chemotherapy regimen does not increase survival significantly 
but does reduce the incidence of loco-regional recurrence at the 5 year point 
[128], and also that chemotherapy with early radiotherapy confers a significant 
disease free but not overall survival advantage over patients who receive 
chemotherapy with late radiotherapy [129]. 
 
Following curative resection of localised colorectal disease (Duke‟s A, B and C) 
approximately 50% of patients will go on to develop disease recurrence [49], 
most recurrences will occur within the first 3 years, and nearly all will have 
occurred within the first 5 years following the original diagnosis and resection. 
Although a great deal of treatment for patients who present with, or develop, 
metastatic disease is palliative, re-resection of local recurrence or metastatic 
disease is becoming more available and effective as surgical techniques and 
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diagnostic techniques such as imaging technologies and biochemical tests 
become more sophisticated. 
 
Where resection of metastatic disease is not possible palliative chemotherapy 
has been shown to confer a 35% (95% confidence interval of 24%-44%) 
reduction in the risk of death and an “improvement in median survival of 3.7 
months” [130]. NICE guidelines recommend the use of irinotecan or oxaliplatin 
combined with 5-FU/FA as first line chemotherapy followed by Oxaliplatin – 5-
FU/FA or irinotecan alone in subsequent cycles if appropriate [131]. 
 
(1.3.3.4) CEA and CA19-9 in Colorectal Cancer  
A great deal of work has been done on the use of CEA and CA19-9 in colorectal 
cancer in the adjuvant setting and in predicting relapse. CEA and CA 19-9 are 
the most commonly used tumour markers in this setting.  
 
Localised disease 
CEA is thought to be elevated in more cases of localised colorectal cancer than 
CA19-9 and no correlation between raised levels of one of these tumour markers 
and raised levels of the other has been found [70]. Serum levels of the markers 
have been observed to increase significantly along with increased Duke‟s stage 
as has their sensitivity [132].  
 
In patients with localised rather than advanced colorectal cancer the percentage 
of patients who have raised CEA can be seen in the Table 8. It is thought that 
“CA19-9 contributes little to the early diagnosis of colorectal cancer” as elevated 
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CA19-9 levels are only found in 20-30% of newly diagnosed colorectal cancer 
patients [35] as can also be seen from Table 8.  
 
Table 8   Sensitivity of tumour markers to detect localised colorectal cancer. 
 
 
% of Patients with 
raised tumour marker at 
detection of localised 
colorectal cancer 
Date Author 
N
o
 of Patients 
analysed 
CEA CA19-9 
1997 Nakayama et. al. [70] 121 39.5 20.6 
1998 Andicoechea et. al. [133] 214 31.3 - 
2000 Díez et. al. [134] 174 34.4 - 
2001 Zheng et. al. [135] 97 30.9 25.8 
2004 Morita et. al. [136] 114 45.3 29.8 
2005 Chen et. al. [137] 574 42.3 16.9 
 
As with CEA and CA15-3 in breast cancer increased levels of both CEA [133, 
138] and CA19-9 [70] prior to curative surgery for colorectal cancer have been 
linked with reduced survival [15, 135, 139, 140]. Zheng et. al. (2001) found the 
same results but their analysis also included some individuals with Dukes stage 
D disease [135]. These findings are disputed by other studies [137, 141]. Morita 
et. al. (2004) found that raised preoperative CEA and CA19-9 looked as though 
they correlated with decreased overall survival but this decrease only reached 
significance with CEA [136] and Gebauer et al (2001) found that increased CEA 
and CA19-9 correlated significantly with reduced overall survival but only 
increased CEA correlated with reduced disease free survival [139]. Chen et. al. 
(2005) studied 574 colorectal cancer patients who had undergone a potentially 
curable resection, they found significantly poorer prognosis in stage II colorectal 
cancer patients who had increased preoperative levels of both CEA and CA19-9 
compared to patients who had normal levels of both [137]. 
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CA19-9 is thought to be less sensitive than CEA but despite the lack of sensitivity 
of CA19-9 Reiter et. al. (2000) found that when they evaluated “the prognostic 
value of preoperative serum levels of CEA and/or CA 19-9“ in a retrospective 
study they found that Only Dukes‟ classification and CA 19-9 level corelated 
significantly with prognosis [142]. When looking at risk of recurrence rather than 
prognosis the findings of Zheng et. al. (2001) were similar to this. They found that 
elevated pre-operative CA19-9 was associated with higher Dukes‟ stage as well 
as number of positive lymph nodes and increased risk of recurrence [135] this 
study found that CEA did not correlate well with increased rate of recurrence. In 
contrast to these studies Weissenberger et al (2005) found that rased 
preoperative CA19-9 at this time was not prognostic of shorter survival at all 
[143]. 
 
Several studies have found that increased levels of CEA correlate with greater 
tumour stage [133, 135, 144, 145] and higher rate of recurrence, Díez et al 
(2000) found that this relationship changed over time with raised CEA only 
correlating with increased risk of recurrence in the first two years of follow up, 
after this time no significant correlation was seen [134]. Wiratkapun et. al. saw 
correlation between raised CEA and the later appearance of distant metastases 
but not local recurrence [138]. It is postulated that poor prognosis, higher rate of 
recurrence and high levels of CEA itself may all be due to increased tumour 
stage therefore there appears to be a relationship between high CEA and poor 
prognosis when actually both of these factors occur as a result of a third 
prognostic indicator. Chapman et. al. (1998) showed that if tumour stage has not 
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been controlled for raised preoperative CEA level correlates significantly (p = 
0.001) with survival, however, if tumour stage is controlled for this correlation is 
no longer significant [146].  
 
Although our study will look at the tumour markers in the serum many studies 
have been done which look at the expression levels of these markers in the 
tissues themselves [139, 147, 148].These studies also associate increased levels 
of CEA and CA19-9 [149, 150] within the primary tumour with reduced survival. 
Nakayama et al (1997) also showed that both pre-operative and post-operative 
CA19-9 levels correlate significantly with expressed CA19-9 levels [70]. Nakagoe 
et. al. (2001) found that increased preoperative CEA is not an independent 
predictor for survival but that high CEA within the tumour tissue itself was an 
independent predictor of shorter survival [144]. In contrast to this Gebauer et al 
(2001) looked at CEA and CA19-9 levels in tumour tissue (at the time of 
resection with curative intent) and found that raised levels of either marker did 
not have a significant effect on survival [139], however, this was a small study (n 
= 41, 20 of whom had tumour recurrence in comparison to Nakagoe et. al. where 
n = 79 [144]) which may account for the different findings. Gebauer et. al. (2001) 
did find that a raised CEA (but not CA19-9) levels in the supposedly normal 
mucosa adjacent to the resected tumour did correlate significantly with reduced 
survival (p = 0.0385) [139]. 
 
Elevated pre-operative levels of CEA have also been linked with poor tumour 
differentiation [146] and metastasis to the liver, it is postulated that this could be 
due to the uptake of CEA by the liver facilitating the metastatic process. 
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Most studies refer to preoperative levels of CEA and CA19-9 being related to 
poor prognosis in colorectal cancer however Weissenberger et. al. (2005) relate 
pre-radiotherapy values (in rectal cancer alone) to poor outcome. It may be that 
raised levels at any point indicate poor prognosis. This study also showed 
significant correlation (p < 0.001) between CEA levels increasing or decreasing 
during radiotherapy and overall survival [143], an indication that tumour marker 
response to treatment may correlate with prognosis. This study included 203 
rectal cancer patients with stage II and III disease and excluded smokers of >40 
cigarettes per day increasing the accuracy of the results but this obviously does 
not help to determine the impact of raised CEA levels in patients who are heavy 
smokers. 
 
Post-operative raised levels of CEA have been shown to correlate significantly 
disease free and overall survival [139] and with adjusted survival [151] as have 
post-operatively raised levels of CA19-9 [70]. 
 
Detecting Advanced Disease 
Increasing CEA and CA19-9 levels are often detected prior to clinical or 
radiological detection of advanced disease. Examples of some of the tumour 
marker lead times quoted can be seen in table 9:- 
 
As can be seen from this table, CEA is thought to be more sensitive at detecting 
disease recurrence or the development of distant metastases during follow-up 
than CA 19-9. CEA is also thought to become raised earlier than CA19-9 during 
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the development of advanced disease. Nicolini et. al. (1995) found that sensitivity 
of CEA in detecting early recurrence was 43% and its specificity was 96%, the 
lead time of CEA was found to be 5  3.2 (mean  standard deviation) [152]. 
McCall et. al. (1994) quote similar figures for CEA sensitivity and specificity in 
detecting recurrence - 58% and 93% respectively [153]. 
 
Table 9   Sensitivity of tumour markers at the time of advanced colorectal cancer and tumour 
marker lead times. 
 
 
Sensitivity % of tumour 
marker at recurrence / ADD / 
first palliative chemotherapy 
(and mean lead time (LT) in 
months) 
Date Author 
N
o
 of patients / 
N
o
 evaluated 
CEA CA19-9 
1990 Quentmeier et. al. [154] 179 / 179, 70 
(LT)
 82.1(4.7) - 
1991 Chu et. al. [151] 425 / 132 79 - 
1993 Kouri et. al. [155] 
105 / 102 
(CEA)  
94 
(CA19-9)
 
71 46 
1994 McCall et. al. [153] 311 / 98 58 (6*)  - 
1994 Fiella et. al. [156] 370 / 96 84 48 (3.7 / 3*) 
1995 Nicolini et. al. [152] 90 / 18, 14
‡(LT)
 61 (5) - 
2001 Hanke et. al. [157] 90 / 85 51 39 
2002 Berglund et. al. [158] 87 / 87 87 - 
2004 Morita et. al. [136] 155 / 40 80.0 (3*) 42.5 (2*) 
 
* lead times given as median rather than mean 
‡
 14 patients but 16 relapses analysed 
 
In the postoperative monitoring of CRC patients CEA appears to be better at 
predicting disease recurrence or metastases than CA19-9. Filella et. al. (1994) 
looked at both CEA and CA19-9 in 370 patients with colorectal cancer to 
investigate how effective CA19-9 is at detecting CRC recurrence compared with 
CEA. They found that the “Sensitivity of CA 19-9 in the early diagnosis of 
recurrence was much lower than that obtained for CEA (75%). Only one patient 
had elevated CA 19-9 levels and normal CEA” [156], similar findings have also 
been reported elsewhere [136]. Fiella et al (1994) state that combining CEA and 
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CA19-9 does not usefully improve sensitivity [156]. One more possible 
advantage of combining CA19-9 with CEA in colorectal cancer is that CA19-9 is 
found at increased levels in fewer benign diseases than CEA [35]. 
 
Another interesting point raised by Fiella et. al. is that when progressive rise of 
CA19-9 was taken into account “the concordance between kinetic CA 19-9 
serum levels and disease status (99.65%) was similar to CEA concordance 
(100%)” [156] in patients without clinical evidence of disease. 
 
The main advantage of early detection of advanced disease is the increased 
potential for curative resection of recurrence in patients where 
recurrence/advanced disease is detected by CEA or computed tomography (CT) 
compared with recurrence/advanced disease detected by symptoms. Quentmeier 
et al (1990) found that respectability of recurrence was significantly (p = 0.01) 
related to earlier diagnosis [154] and Chau et. al. (2004) found that 3.1% of pts 
with symptomatic recurrent CRC underwent curative resection (for liver or lung 
metastases) compared with 23.8% of patients where recurrence was detected by 
surveillance CT and/or CEA [159] although this appears to be an impressive 
difference Wolf et. al. (1997) estimated that CEA directed curative re-resection 
would confer a survival advantage of less than 5% [160].  
 
During Advanced Disease 
At the time of development of advanced disease CEA and CA19-9 are often 
raised but the quoted percentage of patients with raised tumour markers at this 
time varies greatly as illustrated by Table 9. Trillet-Lenoir et. al. (2004) found 
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raised levels of CEA and CA19-9 in 85.7% and 67.5% of patients respectively in 
a group of (n=91) patients with metastatic colorectal carcinoma undergoing first 
or second line chemotherapy [161] (this data is not in Table 9 as patients may 
have been undergoing second-line chemotherapy). 
 
As with work done in breast cancer, a lot of studies look at the prognostic 
implications of single marker levels in advanced colorectal cancer [162] [163] 
often producing contradictory results. As well as aiding the diagnosis of 
advanced disease there is evidence that raised pre-treatment levels of both CEA 
[164, 165] and CA19-9 [166] are independent prognostic indicators of poor 
survival. Some studies do not support these findings [158], Mitry et. al. (2004) 
found that although raised CEA was significantly associated with survival in 
univariate analysis it was not in multivariate analysis [167]. 
 
Tomasevic et. al. 2003 looked at single CEA levels determined before the start of 
chemotherapy in advanced disease and found that median survival in 114 
patients decreased significantly (p = 0.006) with increased CEA levels [168] and 
other studies have found similar results [160, 163]. Park et. al. (2005) divided 
patients undergoing curative resection into four groups depending on their 
preoperative CEA levels (<3, 3-6,  6-17, and >17ng/mL), but they only found a 
significant difference in survival between these groups in patients with stage II 
tumours [169].  
 
Webb et. al. (1995) looked at CEA and CA19-9 levels taken prior to 
chemotherapy given in advanced disease and concluded that raised CA19-9 had 
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“no prognostic significance” [170] whereas CEA was found to be an independent 
predictor of poor prognosis (Hazard Ratio (HR) = 1.8, 95% Confidence Interval 
(CI) = 2.8-1.2). Again other studies dispute this, finding CA19-9 the better 
predictor of survival [166, 171] for example Wang et. al .(2002) and Kouri et al 
(1993) used multivariate analysis to show that raised CA19-9 but not CEA was 
predictive of survival in patients with metastatic colorectal cancer (p < 0.001 in 
both cases) [155, 171]. 
 
As in localised disease, in Advanced disease raised CEA has been found to 
correlate significantly with both poor performance status and poorly differentiated 
tumours [170]. Other studies have found that raised CEA levels correlate with the 
presence of liver metastases [145, 153, 166, 172, 173] and Kouri et. al. (1993) 
found that both raised CA19-9 and CEA levels occur significantly more frequently 
in patients with liver metastases [155]. In patients with liver metastases raised 
levels of CEA and CA19-9 correlate with the number of metastases, and raised 
CEA but not CA19-9 correlates with the size of the liver metastases [174]. Again 
there is a link with reduced survival in these individuals because in patients with 
liver metastases raised CEA has been associated with depressed cell-mediated 
immunity which in turn is associated with shorter survival [51]. In contrast to this 
Sasaki et. al. (2005) used multivariate analysis to show that raised CA19-9 and 
not CEA correlated with shorter extra-hepatic disease free time in patients with 
liver metastases [175].  
 
In patients undergoing hepatic resection for colorectal metastases Aldrighetti et. 
al. (2005) found pre-operative CEA levels (> 5ng/ml) were one of the 
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independent prognostic factors for poor survival [176]. In contrast Hohenberger 
et. al. (1994) reported raised post-operative CEA but not pre-operative CEA 
correlated significantly with prognosis (both disease free and overall survival). 
Hohenberger et. al. also found that a reduction in an abnormal pre-operative 
CEA level to a normal post-operative level confers significantly better survival 
than a persistently elevated CEA marker level [177].  
 
This finding, as in breast cancer, raises the possibility that a change in marker 
level over time (marker kinetics) may confer important prognostic information 
about disease state and survival as absolute tumour marker levels have been 
shown to do but with the added possibility that tumour marker kinetics may 
provide more detailed information about fluctuations in disease status and 
treatment efficacy. Several studies have investigated this possibility. Korenaga 
et. al. (1997) found a significant relationship (p = 0.001) between a shorter 
individual CEA doubling time and reduced overall survival [178] however this 
study included both gastric and colorectal carcinoma patients. The major findings 
of 10 more studies who have investigated this possibility can be seen in Table 
10. 
 71 
Table 10   Research into tumour marker kinetics and response to treatment in advanced colorectal cancer 
 
Colorectal Cancer 
Author Date 
Markers & 
Cut-off 
values 
P/R* Patients Aims Treatment  Results / Conclusion 
Lawton et. al.  
[179] 
 
1980 CEA: 
>30ng/ml 
P 43 patients 
following palliative 
resection of 
colonic cancer 
To see if changes in 
CEA levels relate “to 
the clinical status of 
the patient and 
coincident 
therapy”[179] 
27 received 
chemotherapy 
treatment with 
5-FU and 
MCCN 
Showed “CEA level increase with the 
expected progression of the residual tumour 
but that the rise is slower in patients receiving 
chemotherapy” [179] and that irrespective of 
treatment, in patients where CEA rose 
quickly, prognosis was worse.  
Aabo et. al.  
[173] 
1986 CEA: 
>8ng/ml 
R 175 patients with 
progressive 
colorectal cancer 
“To elucidate the 
relationship between 
the level of plasma 
CEA and survival of 
the patients” [173] in 
progressive disease. 
1* Rise in CEA from the ULN “indicates with a 
high degree of certainty relapse or disease 
progression in colorectal patients” [173]. 
But that CEA does not reliably predict clinical 
response to chemotherapy and “an increase 
of CEA is little prognostic value concerning 
survival” [173] 
Allen-Mersh 
et. al. [180] 
1987 Any 
decrease in 
CEA to 
below the 
pre-
treatment 
level. 
R 329 patients To assess 
correlation between 
a fall in CEA 
following treatment 
and prolonged 
survival 
Chemotherapy 
(various 
regimens) 
A fall in CEA following treatment correlated 
significantly with increased survival (p < 
0.001). 
In radiological non-responders there was a 
significant improvement (p = 0.04) in survival 
in those whose CEA level fell following 
treatment. 
Quentmeier 
et. al. [181] 
1989 Individual 
reference 
level of CEA 
developed 
for each 
patient 
R 35 patients who 
had hepatic 
metastases only 
to find out if serial 
CEA 
measurements“ 
yield  reliable data 
on the therapeutic 
progress and the 
individual prognosis” 
[181] of the patients 
Intra-hepatic 
chemotherapy. 
5-FU first line 
(n=35), 
Mitomycin C 
second line 
(n=8) 
Individual reference level of CEA was set in 
the 3-month reference period at the beginning 
of chemotherapy.  
Survival of patients whose CEA level never 
decreased below the reference level following 
the reference period was significantly 
(p<0.001) shorter than the other patients. 
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Colorectal Cancer 
Author Date 
Markers & 
Cut-off 
values 
P/R* Patients Aims Treatment  Results / Conclusion 
Kouri et. al. 
[166] 
1992 CEA: >5 g/l 
CA19-9: 
>37U/ml 
R 85 patients from a 
phase II 
chemotherapy 
trial. 
“to analyse the value 
of CEA and CA19-9 
determinations in 
predicting  the 
tumour response” 
[166] compared to 
the UICC criteria. 
Epirubicin, 
sequential 
methotrexate 
and 5-
flourouracil. 
Response (R) and progression (P) defined as  
35% decrease or increase respectively in a 
raised marker level.  
CEA (R): sensitivity 84%, specificity 77%, PPV 
67% 
CA19-9 (R): sensitivity 88%, specificity 67%, 
PPV 50% 
CEA (P): 75% correlated with clinical 
progression 
CA19-9 (P): 60% correlated with clinical 
progression 
Hamm et. al.  
[182] 
1998 CEA: change 
in level of  
36% in 
patient with 
at least on 
elevated 
level (3.5 
ng/mL) 
R 81 patients, all the 
patients from 1 
centre seen in a 
year who had 
CEA (above ULN) 
measured.  
“to determine the 
reliability of CEA 
level in determining 
tumour response to 
chemotherapy in the 
metastatic setting” 
[182] 
Chemotherapy 
(various 
regimens) 
Sensitivity of CEA = 54% (95% CI  0.37-0.75) 
Specificity of CEA = 53% (95% CI  0.42-0.63) 
Power was very low for this part of the analysis. 
 
There was no significant difference in survival 
between patients who had a “significant drop in 
the CEA level in the first 6 months of treatment” 
[182] and those who did not (this part of the 
study was correctly powered). 
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Colorectal Cancer 
Author Date 
Markers & 
Cut-off 
values 
P/R* Patients Aims Treatment  Results / Conclusion 
Hanke et. al.  
[157] 
2001 CEA: ≥10 
ng/ml 
CA19-9: ≥ 50 
IE/ml 
P 85 patients on 1st 
line treatment 
(primary tumour 
resected). 
“to examine the 
diagnostic accuracy 
of monitoring of 
palliative 
chemotherapy by 
means of CEA and 
CA19-9“ [157] 
compared this the 
WHO criteria. 
First line 
chemotherapy 
consisting of 
high dose 5-
FU and FA 
CEA rise of  > 50% differentiated between PD 
and NC/PR/CR with sensitivity = 76% and 
Specificity = 90%. 
A CEA decrease of ≥ 30% excluded progression 
in 99% of cases  
 
They concluded - “A CEA or CA19-9 rise is only 
conditionally apropreate for recording 
progressions. A progression however, can be 
excluded with falling levels with high diagnostic 
accuracy, in which CEA offers a greater degree 
of certainty than CA19-9“ [157] 
Berglund et. 
al. [158] 
2002 CEA: < 3.1 
μg/l 
(TPS,VEGF, 
bFGF) 
R 87 patients “To evaluate the 
reliability and 
valididty of serum 
...CEA......in 
monitoring palliative 
chemotherapy in 
advanced colorectal 
cancer“ [158]. 
First line 5-FU 
and leucovorin 
A decrease in >25% of CEA level form a 
raised baseline level had sensitivity of 45% for 
an objective response and 46% for a 
subjective response, specificity was 88%. 
 
CEA decrease of >25% was found 
significantly more in patients with response 
than patients with no response  
BUT they conclude that “Repeated 
measurements of CEA .......are of limited 
value in monitoring chemotherapy in ACRC“ 
[158].  
Ito et. al. [183] 2002 CEA: 5 
ng/ml 
P 22 To investigate if the 
doubling time and 
half-life of CEA 
could predict 
progression or 
prognosis 
Surgery and 
no other 
details given 
Of 14 patients assessed for CEA half life the 
group who developed metastases after 
curative surgery (n=9) had a significantly 
longer (p < 0.001) CEA half life of 8.01  2.07 
days [median  SD] compared to those (n=5) 
who did not develop metastases (half life 4.33 
 1.11 days). 
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Colorectal Cancer 
Author Date 
Markers & 
Cut-off 
values 
P/R* Patients Aims Treatment  Results / Conclusion 
Trillet-Lenoir 
et. al. [161] 
2004 CEA: > 5μg/l 
CA19-9: > 30 
kU/l 
P 91 patients 
(Karnofsky index 
≥50% and 
presence of ≥1 
measurable 
hepatic/pulmonary 
metastasis) 
To evaluate the 
usefulness of CEA 
and CA19-9 in 
evaluating response 
to chemotherapy in 
metastatic CRC. 
Chemotherapy 
(regimen at 
discression of 
the 
investegators) 
“Meaningful PPV values (>90%)  for 
progression of an increase of the marker 
levels were only obtained using the 200% 
increase threshold for CEA alone“ or in 
combination with CA19-9 [161]. 
 
To assess the response of metastatic CRC to 
chemotherapy CEA alone or in combination 
with CA19-9 (in adition to CT) “should be 
used with caution in common practice“ [161]. 
 
1*      Adjuvant treatment  = methylcyclohexlchlorethylnitrosourea and –FU Vs no treatment or 
    Palliative treatment = 5-FU Vs furanidyl-5-FU 
5-FU   5-Flourouracil 
ACRC   Advanced colorectal cancer  
bFGF   Basic fibroblast growth factor 
CI    Confidence interval 
CRC   Colorectal cancer   
CT    Computed tomography 
MCCN   Methyl chloethyl cyclohexyl nitrosourea 
P/R*   Study type – prospective or retrospective 
PD / NC / PR / CR  progressive disease / no change / partial remission / complete remission 
PPV   Positive predictive value 
SD    Standard deviation 
TPS   Tissue polypeptide specific antigen 
UICC   International Union Against Cancer  
ULN   Upper limit of normal 
VEGF   Vascular endothelial graowth factor   
WHO   World Health Organisation 
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As can be seen from this table Hamm and Cripps (1998) found no correlation 
between change in CEA after treatment and overall survival [182] wheras 
Allen-Mersh et. al. (1987) found that tumour shrinkage (of > 25% measured 
clinically or radiologically) and fall in CEA level following the start of 
chemotherapy both correlated with increased survival (p < 0.00001 and < 
0.0002 respectively) in disseminated colorectal cancer. However tumour 
shrinkage was found to be the stronger predictor of survival [180]. Wang et. 
al. (2001) found similar results in terms of survival when they classified 
response as a 50% drop in CEA for >4 weeks following chemotherapy for 
metastatic colorectal cancer. They found that patients who had a CEA 
response survived significantly longer that those who did not and that CEA 
marker response had a sensitivity of 72% and 81% and a PPV of 53% and 
85% when detecting true responses and progressive disease respectively 
[184]. 
 
Hanke et. al. (2001) found that CEA was more accurate at demonstrating 
response (compared with WHO criteria) than CA19-9 and that patients who 
had an initial fall of ≥ 50% in CEA level had a significantly higher probability 
(relative risk (RR) = 2.9, p = 0.002) of achieving a (partial or complete) 
response with further treatment [157]. Hanke et. al. (2001) do not link 
response to treatment with increased survival and possibly quality of life 
however it would seem intuitive to do this. Preketes et. al. added further 
evidence to support the theory that marker movement following therapy can 
be predictive of survival when they showed a significant association between 
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the percentage fall in patients (n=33) CEA levels following cryo- and chemo 
therapy for colorectal liver metastases and their survival [185].  
 
CEA, CA15-3 and CA19-9 are frequently used in the diagnosis and treatment 
of both localised and advanced breast and colorectal cancers (CEA and 
CA19-9) as indicators of survival and tumour burden. A great deal is known 
about these biological markers to date however their role in indicating the 
efficacy of treatment in advanced disease is not clear. Several studies have 
investigated the use of sequential tumour marker measurements to track the 
course of advanced disease in response to treatment in both breast and 
colorectal cancer however the findings of these studies are difficult to 
compare and limited in their findings for several reasons: 
 
 Few studies use comparable definitions of tumour marker response 
and progression. 
 Studies are mainly retrospective. 
 Definitions of tumour response and progression vary. 
 
In 1996 the first guidelines regarding the use of tumour markers in breast and 
colorectal cancer were adopted by the American Society of Clinical Oncology 
(ASCO), these guidelines were published in 1997. In patients with breast 
cancer ASCO found insufficient evidence to recommend the routine use of 
either CEA, CA15-3 or CA27.29 in screening, diagnosis, staging or 
surveillance but stated that “in the absence of readily measurable disease, 
CA15-3 and CEA levels can be used to document treatment failure” [186]. 
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The authors also acknowledged that there was evidence to support the ability 
of CA15-3 and CA27.29 to detect the development of advanced disease but 
they found no robust evidence in the literature of this early detection leading 
to clinical benefit for the patient. An update to these recommendations was 
published in 2001 which recommended no change to the previous guidelines 
in terms of the use of any of these three markers [187].  
 
In the ASCO colorectal cancer tumour marker guidelines published in 1997 it 
was recommended that CEA “be measured preoperatively if it would change 
surgical management” [186] and that the levels of CEA are measured 
postoperatively each 2-3 months for ≥2 years in patients with stage II and III 
disease if there was a possibility of liver resection should metastatic disease 
develop. The panel found insufficient evidence in the literature reviewed to 
recommend the routine use of CA19-9 in the screening, diagnosis, staging or 
surveillance of colorectal cancer [186]. Once again these guidelines were not 
changed following the updates published in 2001 [187].  
 
In a more recent update to these colorectal cancer guidelines published in 
2006 no change was made to the guidelines for the use of CA19-9 in 
colorectal cancer but it was recommended that CEA levels be measured 
every 3 months postoperatively for at least 3 years with a confirmed increase 
in level being used to instigate further investigations [188]. It was also 
reported that that adjuvant chemotherapy may produce transient false 
elevations of CEA. The largest change to the recommendations for CEA 
measurement was in monitoring response to therapy in advanced disease 
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where it is now recommended that CEA should be measured at 1 to 3 
monthly intervals throughout treatment with systemic therapy and 
“persistently rising values should prompt restaging but suggest progressive 
disease even in the absence of corroborating radiographs” [188]. The authors 
of these recommendations warn that caution should be taken in interpreting 
results in the first 4-6 weeks of a new therapy as transient and misleading 
rises in CEA may be seen (particularly during treatment with oxaliplatin) [188] 
these findings are similar to those of the recent report of the European Group 
on Tumour Markers who conclude the report with their topics for future work 
one of which states that “the clinical use of existing markers should be 
optimised” [189] citing the use of CEA in monitoring treatment for advanced 
disease as an illustration of this [189]. 
 
In patients who have received adjuvant therapy for either breast or colorectal 
cancer in the form of surgery it is standard practice to see the patient for 
follow up visits and to undertake routine radiotherapy and biochemical testing. 
These visits serve to highlight possible areas of concern relating to 
anomalous test results, symptoms or side effects from treatment, and to 
identify potential disease recurrence at the earliest possible stage, however, 
until recently there was little evidence to support the fact that this early 
detection had any effect upon enhanced survival or quality of life in patients 
who developed advanced disease.  
 
In 2002 a large scale systematic review (5 trials and 1342 patients) and meta-
analysis showed significantly earlier detection of recurrence and improved 
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survival in patients followed up intensively after curative intent colorectal 
cancer resection compared with standard follow up [190], several other 
studies corroborate these findings [191, 192] whereas some do not [193, 194] 
(the results of Secco et. al. (2000) concern rectal cancer alone).  
 
In some cases the advantages of intensive follow up are less straight forward 
for example; Chau et. al. (2004) found that a significantly larger number of 
patients underwent resection for hepatic or pulmonary metastatic disease 
(from a colorectal primary) when relapses were detected by CT or CEA levels 
as opposed to symptoms [159]. In addition to these findings Bonthuis et. al. 
(2004) discovered that although routine follow up (not intense follow up) did 
not correlate significantly with survival, significantly (p = 0.006) longer survival 
was seen in patients who had curative re-resection where recurrence was 
detected in routine follow up compared with other methods of detection [195]. 
Also Rodríguez-Moranta et. al. (2006) found that in stage II and III colorectal 
cancers where curative resection has been carried out intensive follow up 
resulted in significantly higher overall survival in patients with stage II tumours 
and patients with rectal tumours (the reason for this is though to be the 
increased possibility of re-resection if such tumours recur), no difference in 
survival was seen in the group of patients as a whole [196] suggesting that 
intensive follow up may be beneficial only in certain patient groups.  
 
A Cochrane review into follow up strategies for patients with stage I to III 
breast cancer suggested in terms or detection of recurrence, survival and 
quality of live there was that “follow-up programmes based on regular 
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physical examinations and yearly mammography alone are as effective as 
more intensive approaches based on regular performance of laboratory and 
instrumental tests” [197]. Duffy (2006) identifies limitations often found with 
studies which look at survival for example the fact that many of the studies 
are becoming out of date as they use “older and less sensitive biochemical 
tests rather than the newer tumour markers such as CA 15-3” [69] as well as 
the use of older imaging procedures and older treatment regimens [69] and 
this is indeed an issue which is highlighted by the authors of the Cochrane 
review above [197].  
 
Currently advanced disease and disease progression in response to 
treatment is most commonly monitored radiologically. Various criteria of 
response and progression of the disease, based upon the imaging 
techniques, have been proposed and validated over time in order to 
standardise the reporting of disease extent and response to treatment. The 
definitions of response and progression are based upon the premise that 
“overall cancer burden can be characterised by a quantitative evaluation of 
tumour lesions, which are measurable, and a qualitative evaluation of tumour 
lesions, which are not measurable” [198] and also that the change in this 
tumour burden over time is an estimate of the efficacy of treatment, 
unfortunately these assumptions do not always hold true.  
 
Previously the main criteria of response were the UICC (International Union 
Against Cancer) [199] and the WHO (World Health Organisation) criteria 
[200].The UICC criteria were originally proposed in 1977 [199]. They were 
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subsequently integrated into the WHO criteria [198] which was developed “on 
the initiative of the World Health Organisation” [200] and published in 1981, 
the WHO criteria are defined as follows:- 
 
WHO Criteria 
Based upon radiological measurement of lesions two-dimensionally (longest 
diameter (LD) and greatest perpendicular diameter are measured and 
multiplied). The sum of the products of tumour measurement provides a 
baseline measurement and changes from this baseline are measured over 
time (≥ 4 weeks), response is categorised as follows: 
 
 Complete Response – all target lesions disappear 
 Partial Response – ≥ 50% decrease from baseline 
 No Change – Partial response or Progressive disease criteria are not 
met. 
 Progressive Disease - ≥ 25% increase of one or more lesions, or the 
appearance of new lesions [200]. 
 
This system has since been replaced by the RECIST criteria (Response 
Evaluation Criteria in Solid Tumours) proposed by Therasse et. al. (2000) in 
an attempt to standardise tumour measurement following advances in 
imaging technology and particularly for use in clinical trials [201]. RECIST 
criteria of response are subtly different from the WHO criteria despite also 
being based upon the detection and measurement of measurable disease 
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and recording the presence of non-measurable disease. The RECIST criteria 
can be simplistically defined in the following way:- 
 
RECIST Criteria 
RECIST is based upon identification and one-dimensional measurement of at 
least one target lesion (10mm as measured by spiral CT scan). Small 
lesions and other disease for example bone lesions and pleural effusions 
cannot be assessed using these criteria. The longest diameter (LD) of each 
target lesion and the sum of all LDs is recorded and change over time (≥ 4 
weeks) in this figure is assessed. Response of target lesions is classified as 
follows:- 
 
 Complete Response – all target lesions disappear 
 Partial Response –  30% decrease in the sum of all LDs 
 Stable Disease – < 30% decrease or < 20% increase in sum of all LDs 
 Progressive Disease -  20% increase in the sum of all LDs 
 
Although successful in its attempt to standardise and simplify disease 
measurement there are several problems with the RECIST criteria. Although 
it is generally accepted that disease measurement by WHO and RECIST are 
comparable [202] the RECIST criteria can be associated with some problems; 
it can be difficult to apply to all disease sites, anatomical changes in tumours 
may be detected later than they would otherwise be [6], definitions of 
response and progression are arbitrary (change from a baseline) and 
observer variation may affect the consistency of measurement [8]. In addition 
to this Therasse et. al. (2006) conclude that use of RECIST criteria can delay 
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identification of disease progression when compared with WHO criteria. They 
state that a 20% increase in one dimension (the minimum increase required 
by RECIST to define progression) is “approximately equivalent to a 44% 
increase in bidimensional product” [6] when WHO criteria require a minimum 
of 25% increase in bidimensional product to classify the disease status as 
progression, a difference in sensitivity of approximately 19%.  
 
When Mazumdar et. al. (2004) retrospectively tested concordance between 
WHO and RECIST criteria using data from 130 patients they found that 32-
35% of patients who had been classified as having progressive disease by 
WHO criteria were classified differently using RECIST criteria, this is 
compared with the much smaller values of 8-16% and 3-12% for patients 
where disease was classified as partial response and stable disease 
respectively [7].  
 
Another limitation of this approach to response evaluation generally is that 
with the advent of new therapies (such as tyrosine kinase inhibitors in renal 
cancer [203]) which act on cellular processes and often stabilise tumour 
growth initially rather than reduce it [8]) the phrase “overall cancer burden can 
be characterised by a quantitative evaluation of tumour lesions” [198] is 
becoming increasingly inaccurate. 
 
It is because of these limitations that it would be extremely beneficial if tumour 
markers could provide additional, reliable information about response to 
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treatment in advanced disease. This would be especially important in cases 
of disease progression where the limitations of RECIST are most apparent.  
 85 
(1.4) Aims of the Project 
 
We hope to be able to determine within the study populations of breast and 
colorectal cancer patients – 
 
 The sensitivity and specificity of each individual tumour marker in 
detecting the development of advanced disease. 
 The relative levels of each tumour marker at the time of and prior to 
the development of advanced disease and at the time of each 
chemotherapy regimen. 
 Tumour marker lead times prior to the diagnosis of advanced 
disease. 
 
The main aim of this project, however, is to assess the efficacy of our own 
modified tumour marker response criteria (see table 11). This is based upon 
criteria developed by Rustin et. al. using CA125 in ovarian cancer studies 
(see section 1.1.2 CA125 and Ovarian Cancer). We use our modified criteria 
on CEA, CA15-3 and CA19-9 during treatment for advanced breast cancer, 
and CEA and CA19-9 during treatment for advanced colorectal cancer. It is 
vital that we test both the sensitivity and specificity of the modified response 
criteria as the Rustin criteria of response and progressions have been shown 
to have a specificity of >98%. 
 
We aim to establish if the response to chemotherapy, as measured by the 
modified response criteria, correlates with response to chemotherapy as 
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measured radiologically and overall patient survival. This modified response 
criteria should also assess whether tumour marker changes at lower levels, 
within the statistically defined normal range convey potentially valuable 
information about disease response and survival. 
 
If there is time we will also investigate how soon after initiation of 
chemotherapy treatment marker movement can be considered to indicate 
response to treatment. 
 
This will enable us to answer our main study questions 
1. Are tumour markers better than radiology at showing response to 
chemotherapy? 
2. Which is the best marker for each disease site and what do the other 
tumour markers and radiology results add to this? 
3. What is the best way to monitor patients undergoing chemotherapy?  
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(2) Patients and Methods 
 
This retrospective study was given Management approval by the Chair of the 
Airedale Research Ethics Committee.  
 
Data collection was done retrospectively by looking through patients notes 
and where data was missing by looking on the radiology and pathology 
databases of Airedale NHS Trust. 
 
Provisional analysis and results were presented as a poster in 2006 at the 
National Cancer Research Institute Cancer Conference in Birmingham. 
 
(2.1) Patients 
 
Patients were identified from the Oncology Patient Management Audit System 
(OPMAS) of Airedale NHS Trust. The details of all patients who were 
registered onto the hospital chemotherapy prescribing database were 
obtained by Dr M Crawford. For breast cancer patients this was all patients 
who were registered onto this database from June 1992 until June 2003 (12 
patients had no registration date entered so the above dates are the best 
guess excluding these patients) and for colorectal cancer patients this was all 
patients who had been registered onto the database between June 1992 and 
February 2004. 
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Patients were excluded from the analysis if their hospital case notes could not 
be located, if sections (volumes) of the case notes were missing, or if the 
case notes had been destroyed or microfilmed. Patients were also excluded if 
they had no chemotherapy treatment at Airedale General Hospital or 
developed another malignancy which precluded the detailed analysis of their 
tumour markers at the time of advanced disease. 
 
(2.2) Methods 
 
Data was collected retrospectively from patients hospital notes and stored on 
individual data collection sheets (Appendices A and B) which enabled marker 
kinetics to be identified more clearly. Data from each set of case-notes was 
collected to death or to the time of data collection, dates of death were 
updated at the time of analysis to make the survival curves more robust 
however no further information was added to the data collection sheets 
concerning the patients who had subsequently died. 
 
The chemotherapy regimens studied here include cytotoxic chemotherapy 
only (not hormone therapy). Chemotherapy treatment intent (adjuvant or 
palliative) was usually recorded in the hospital notes, if it was not recorded 
explicitly then treatment intent was elucidated from the hospital notes. 
Clinician‟s advice was sought on this if necessary.  
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There was no restriction on the number of chemotherapy cycles within a 
regimen that a patient had to have to be included in the study, if 
chemotherapy treatment had been commenced then they were included. 
 
 
Tumour Marker Measurement  
Only tumour marker levels measured in Airedale General Hospital were used 
in this project as assays and techniques vary between locations and therefore 
results obtained may not have been comparable. 
 
CA15-3 was routinely recorded in breast cancer patients and not in colorectal 
cancer patients as it is not a recognised tumour marker for this disease site 
therefore analysis in the breast patients includes the three tumour markers 
CEA, CA15-3 and CA19-9 whereas analysis in the colorectal patients only 
includes CEA and CA19-9. Apart from this methods of analysis and data 
collection were the same in both groups. 
 
In 1993 the upper limits of normal for CEA and CA19-9 were changed from 10 
ng/ml and 33 U/ml respectively (CA15-3 was not in regular use within the 
hospital until after this point). From this point levels of CEA and CA15-3 were 
assayed using the Abbot AxSYM (Abbot Diagnostics) system. CA19-9 was 
assayed differently initially but then in during April 1995 also started to be 
assayed using this system (this assay change occurred without a change of 
normal ranges for CA19-9). From the change of assay in 1993 the upper 
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limits of normal (ULN) for the markers remained at the following levels until 
April 2004:- 
 CEA = 3 ng/ml  
 CA15-3 = 28 U/ml and 
 CA19-9 = 37 U/ml. 
 
In April 2004 there was a change in laboratory analyser to the TOSOH AIA 
1800 System analyser which used the antibodies ST AIA-PACK CEA, 19-9 
and 27.29 (TOSOH Bioscience inc.). As a result of this the normal ranges or 
the markers were altered to:- 
 CEA = 0-10 ng/ml 
 CA19-9 = 0-30 U/ml (the upper limit of normal for CA19-9 was altered to 
35 U/ml later in 2004).  
  CA 27.29 = 6-23.5 U/ml. It was felt that because CA15-3 and CA27.29 
have overlapping epitopes on the MUC1 glycoprotein (see figure 3 – 
Introduction) and have >0.95 correlation coefficients [63] this change in 
assay was acceptable in the context of this study. 
 
Marker values measured and reported as outside the ranges quoted above 
are regarded as being abnormal. Tumour marker levels of <1 and <2 were 
regarded as 1 and 2 respectively for the purposes of this study, if more than 
one tumour marker level was recorded on one day then the highest value was 
used. 
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If two tumour marker measurements were taken on the same day then the 
highest measurement was used in the analysis. If two tumour marker 
measurements were taken on the same day using different assay techniques 
then the marker level generated using the newer technique was quoted. 
 
For the purposes of this study tumour marker levels which were taken during 
a time period when the ULN was anything other than 3ng/ml for CEA, 28U/ml 
for CA15-3 or 37U/ml for CA19-9 will be indicated in the text. If assessment of 
a Rustin response to a chemotherapy regimen occurred at a time when a 
marker assay change occurred this will be stated in the text. The only 
exception to this concerns patients who have Rustin response measured at 
the time of the CA19-9 assay change in April 1995 because this change in 
assay was not associated with a change in the normal ranges. 
 
(2.2.1) Tumour Marker Levels Leading up to and at the Time of 
Advanced Disease Diagnosis 
Date of advanced disease diagnosis was defined retrospectively as the date 
when metastatic or unresectable locally recurrent disease was first seen 
radiologically, histologically or cytologically, if this date was ambiguous and 
difficult to identify clinician‟s advice was sought. Some patients with colorectal 
cancer went on to have potentially curative surgery for example for liver 
metastases following this date. If this is the case then we also recorded the 
date following this resection when advanced disease re-occurs. 
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Tumour marker levels were included in this analysis if they were recorded 
within 60 days of this date. The nearest tumour marker level to the date of 
advanced disease diagnosis (ADD) was used and if there were two tumour 
marker levels recorded equidistant from the date of ADD then the marker 
prior to ADD was used. 
 
Patients were included in the tumour marker doubling and lead time analysis 
if they had a raised marker at the time of advanced disease diagnosis (within 
60 days of this date) and a previous tumour marker level was recorded which 
was > the upper limit of normal (ULN). Only patients whose tumour markers 
increased prior to advanced disease diagnosis were used in this analysis. 
 
In order to ascertain tumour marker doubling times the following equation was 
used:- 
Doubling Time = d / log2 (y / x) 
Where; 
 x = level of the first raised value > the upper limit of normal (ULN) 
 y = level of the raised value at the time of the clinical advanced 
disease diagnosis 
 d = the time interval between the two marker levels. 
 
Tumour marker lead times were expressed as the number of days between 
the date of the first increase of the tumour marker to a level above the ULN 
(following the final tumour marker level ≤ the ULN) and the date of advanced 
disease diagnosis. 
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(2.2.2) Tumour Marker Levels at the Time of the First and Second 
Chemotherapy Regimens given in Advanced Disease 
Tumour marker levels were included in this analysis if they were recorded 
within 30 days of the chemotherapy start date. The nearest tumour marker 
level to the chemotherapy start date was used and if there were two tumour 
marker levels recorded equidistant from the date of chemotherapy initiation 
then the marker prior to this was used. 
(2.2.3) Tumour Marker Response to Chemotherapy Given in Advanced 
Disease 
The principal aim of this study was to investigate the effect that tumour 
marker kinetics in response to treatment have upon survival, this was 
investigated firstly by survival analysis (using WinSTAT ®). For this analysis 
and throughout all other analyses tumour marker response to treatment was 
defined according to the Rustin Criteria of Response which were developed in 
ovarian cancer and which we have modified for use in this setting (Table 11).  
 
In order to be included in the analysis patients were required to have had at 
least 3 tumour marker levels recorded; the first marker level must have been 
within 30 days of chemotherapy start date and there must have been at least 
two further tumour marker levels taken within the 100 days following the 
chemotherapy start date.  
 
If two tumour marker levels were recorded equidistant from the chemotherapy 
start date then the marker prior to initiation of chemotherapy was used as the 
initial tumour marker level. 
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Table 11   Classification of patients according to marker response to chemotherapy 
based on the Rustin criteria. 
 *Categories not defined by the original Rustin Criteria of Response 
 
Category Inclusion Criteria 
Response (R) 
 
Defined as a decrease of ≥ 50% in a raised first marker level 
within 100 days of the start of chemotherapy for advanced 
disease, which is confirmed by a following sample also ≥ 
50% lower than the first marker level. 
 
Always Normal 
(AN) * 
 
A marker level which remains below the ULN from the first 
marker level, and throughout the 100 day period following 
the first chemotherapy for advanced disease. 
 
Stable (S) 
 
A marker level which is not always within the normal range 
during the time between recording of the first marker level, 
and throughout the 100 day period following the first 
chemotherapy for advanced disease, but which does not 
increase or decrease by ≥ 50% (confirmed by a following 
sample) within this time period. 
 
Progression (P) 
 
A marker level which increases to twice that of the first 
marker level within 100 days following the first chemotherapy 
for advanced disease, providing that this value is ≥ twice the 
ULN e.g. in CA15-3 ≥  56 U/ml. This value must be 
confirmed by a following sample unless the patient dies 
before one is taken. 
 
Progression from 
Within the Normal 
Range (PN)* 
 
A marker level which increases to twice the first marker level 
within 100 days following the first chemotherapy for 
advanced disease, but to a level which is > the ULN but < 
twice that of the ULN. Again this increase must be confirmed 
by a following sample unless the patient dies before one is 
taken. 
 
 
Response was regarded any raised level which fell by ≥ 50%. Patients who 
responded from a level which was raised but not raised to ≥ twice the ULN 
were noted. 
 
Date of response or progression was the date when the marker first reached 
the required level. It was important that this change in marker level was 
confirmed and so this was done by looking at the following tumour marker 
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level. If this did not corroborate the result then this marker movement was not 
considered significant and was not included (the only exception to this rule is 
when tumour marker progression is seen but not confirmed as the patient 
dies before a confirmatory sample is taken, in this case tumour marker 
progression is recorded). The confirmatory marker level did not have to fall 
within the 100 day period after the first chemotherapy was given. 
 
Transient rises in a tumour marker or spiking as it is sometimes known [110] 
is a phenomenon which has been seen in previous studies and it is thought to 
occur as a result of tumour lysis in response to treatment. For the purpose of 
this analysis tumour lysis was defined as a rapid doubling or more of a tumour 
marker concentration (to a level ≥ twice the upper limit of normal) within the 
first 45 days following the initiation of a chemotherapy regimen, followed by 
falling tumour marker levels. On occasions when tumour marker lysis was 
thought to have occurred the original dramatic increase in tumour marker was 
discounted and the trend in the tumour marker following this point was used 
to assess overall tumour marker response.   
 
Survival was recorded in days and if the actual date of death was not 
available then the date of death notification was used instead. If the patient 
was known to have evidence of advanced breast or colorectal cancer then it 
was assumed that the patient died of this disease. Death dates were updated 
before survival analysis was done in order to make the analysis more robust. 
Median Survival data was calculated using the Kaplan-Meier graphs, if the 
survival curve was horizontal at 50% survival then a mean was calculated 
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using the time point when survival fell to 50% and the time point that survival 
fell below 50%. 
 
Further analysis was performed using regression analysis with the kind help 
of Andy Scally Lecturer and Statistician at the University of Bradford. For this 
regression analysis data on the following factors was collected (if available) 
and taken into account using the analysis:- 
 
Sex  
Was graded 0 = Male and 1=Female 
 
Age  
The patient‟s age at the time of the commencement of the cycle of 
chemotherapy under investigation was recorded. 
 
Tumour Differentiation 
Was graded 0 = well differentiated, 1 moderately differentiated, 2 = poorly 
differentiated if two possible differentiations were quoted in the notes e.g. 
„moderately to poorly differentiated‟ than the worst case scenario (in this case 
poorly differentiated) was recorded. „Moderately well differentiated‟ was 
classed as moderately differentiated. 
 
Tumour Grade 
Was recorded as it is reported in histology reports as a grade of 1 to 3 if the 
report stated two different grades e.g. „grade II or III‟ then the highest grade 
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quoted (in this case grade 3) was recorded. If conflicting grades were quoted 
on two separate histology reports then the grade from the definitive histology 
where the tumour was excised was used. 
 
Tumour Stage 
Tumour stage was categorised into an ordinal scale by using the Duke‟s 
classification system for the majority of the colorectal cancer patients so 
Duke‟s A =0 Duke‟s B = 1, Duke‟s C = 2 and Duke‟s D = 3. For the breast 
cancer patients and those with colorectal cancer whose tumours had been 
staged using the TNM system the following table (table 12) was used to 
convert the TNM stage into a single disease stage.  
 
TN (Tumour and Node) stage was often quoted without an M (metastasis) 
status. In this situation the M status was elucidated from the radiology reports 
and treatment type (i.e. adjuvant or palliative). If either the T (tumour) or the N 
(node) status was missing then the disease stage was considered unavailable 
and the information was omitted from the analysis. 
 
Table 12   Converting TNM stage to an ordinal scale 
 
 N0 N1 N2 N3 M1 
T1 I II III III IV 
T2 I II III III IV 
T3 II III III III IV 
T4 III III III III IV 
M1 IV IV IV IV IV 
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Nodal Status 
The total number of lymph nodes found to be involved in the malignant 
process was recorded and categorised into a four point ordinal scale using 
the following key:- 
0 Involved nodes = 0 
1-3 Involved nodes = 1 
4-9 Involved nodes = 2 
>9 Involved nodes = 3 
 
The involvement or not of the highest, apical or high tie node was also taken 
into account in the analysis with uninvolved = 0 and involved = 1. If for 
example it was stated in the histology report that 0 of 20 nodes were involved 
then it would be assumed for this analysis that the apical node was 
uninvolved, equally if 17 of 17 or all of the 17 nodes were said to be involved 
it was assumed for the purpose of this analysis that the apical node was 
involved. 
 
Tumour Location (colorectal cancer patients only) 
Was categorised as Colon = 0 and Rectum = 1, for the purpose of this study 
tumours of the caecum and sigmoid were placed in the colon tumour group 
and tumours of the recto-sigmoid were grouped with the rectal tumours.  
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Hormone Receptor Status (breast cancer patients only) 
Oestrogen receptor, progesterone receptor and HER2 status were all 
categorised in the same way – Negative = 0, Positive = 1. If any of these 
results were not recorded at the time of diagnosis but were later tested when 
advanced disease developed we accepted the results of this analysis to be 
true of the primary tumour. 
 
Involvement of Liver, Lungs, Bone or Brain 
Involvement of each Organ in the malignancy was recorded separately as 0 = 
not involved, 1 = involved. Only true parenchymal metastases were used for 
this analysis.  
 
If a patient developed metastatic disease in one of these organs but then 
went on to have a successful resection of the metastatic disease and no 
further metastatic disease was seen in that organ at the time of chemotherapy 
then the organ was recorded as not being involved in the malignant process. 
 
Radiological Response 
Was graded to be a response = 0, stable disease = 1 or progressive disease 
= 2. This grading was done by me based upon the information recorded from 
the radiology reports. If disease progression was seen in one area and 
disease response was seen in another then the disease status was recorded 
as stable, similarly if stable disease was seen in one area and response in 
another this was classed as responsive disease and likewise if stable disease 
in one area and was seen on a scan with progression in another area then 
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this was classed as progression. In cases where this classification was 
unclear I referred to the hospital notes and sought advice from a clinician.   
 
Radiological response could only be elucidated from a CT, Bone or MRI scan 
and this had to be within 120 days of the start of chemotherapy regimen being 
studied. 
 
Tumour Marker Response 
For the purposes of the regression analysis the Rustin categories described 
in Table 12 were arranged into an ordinal scale as follows:- 
 
Always Normal = 0 
Response = 1 
Stable = 2 
Progression from Within the Normal Range = 3 
Progression = 4 
 
If synchronous tumours were resected then the characteristics of the larger of 
the two tumours was recorded for the purpose of this analysis. 
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(3) Results 
 
(3.1) Breast Cancer Patients 
 
Of 540 patients who had been registered to the Oncology Patient 
Management Audit System (OPMAS) between June 1992 and June 2003, 
complete sets of hospital case-notes could be collected and examined for 
evidence of advanced breast cancer for 490 (91%) of the patients. Of the 50 
sets of case-notes which could not be examined, 45 sets (90%) could not be 
located in medical records (many of these had been destroyed in line with 
hospital policy, and in 4 cases some volumes of the case-notes could be 
found but not the complete set) and 5 sets (10%) had been microfilmed. 
 
Of the 490 patients whose notes were located, 7 (1.4%) were excluded from 
the study because of previous or coexisting malignancies however as long as 
it did not interfere with the treatment of their advanced breast cancer patients 
who had previously had other malignancies such as basal cell carcinoma, 
cervical cancer, endometrial adenocarcinoma, Hodgkin‟s disease, and 
Liposarcoma were included in the study. Evidence of the later development of 
advanced breast cancer or the presence of advanced disease at presentation 
was found in 180 or 36.7% of the women (37.3% of the remaining 483 women 
after exclusions). 
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(3.1.1) Tumour Marker Levels at the Time of, and Leading up to, 
Advanced Disease Diagnosis 
 
(3.1.1.1) At the time of Advanced Disease Diagnosis 
Of the 180 breast cancer patients with advanced disease 143 (79.4%) had 
one or more markers recorded within 60 days of the date of advanced 
disease diagnosis, 127 (88.8%) had CEA level recorded, 122 (85.3%) had 
CA15-3 recorded and 136 (95.1%) had CA19-9 recorded at this time, the 
proportions can be seen in Figure 6 and details of the marker levels can be 
seen in Table 13 including how many patients had tumour marker levels 
recorded with the new assay technique which was implemented in April 2004. 
 
Figure 6   Markers measured at the time of advanced disease diagnosis in 180 women with 
advanced breast cancer (within 60 days of this date). 
 
The data in Table 13 shows that the distribution of marker levels in all cases 
was positively skewed and many of the distributions could not be transformed 
logarithmically, reciprocally or by square rooting the data so the Mann-
Whitney U test was used to get a measure of the difference between values 
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obtained pre- and post-tumour marker assay change. Median marker levels 
and interquartile ranges at this time are shown in Figure 7. 
 
Table 13   Tumour marker levels at advanced disease diagnosis in 143 women with 
advanced breast cancer (within 60 days of this date). 
 MC = Marker assay change (April 2004) 
 
Tumour Marker 
Measured 
at ADD (% 
of 143 
women with 
one or more 
markers 
measured) 
Raised at 
ADD (% of 
those 
where 
marker 
was 
measured) 
Range Skew 
Mann-
Whitney U 
test result 
z (P) for 
markers 
measured 
CEA 
Pre-MC 115 (80.4%) 62 (53.9%) 1-45406 10.70 
2.46 (0.01) 
Post-MC 12 (8.4%) 7 (58.3%) 1-5326 2.63 
CA15-3 
Pre-MC 110 (76.9%) 75 (68.2%) 9-13083 5.17 
-0.15 (0.88) 
Post-MC 12 (8.4%) 8 (66.7%) 12-3676 2.64 
CA19-9 
Pre-MC 125 (87.4%) 35 (28.0%) 1-71940 7.78 
1.78 (0.07) 
Post-MC 11 (7.7%) 5 (45.5%) 8-123 1.45 
 
At the time of the diagnosis of advanced disease 143 women had one or 
more tumour marker levels recorded and 104 (72.7%) of these women had all 
3 tumour markers recorded. CEA was raised in 53.5% of all women where it 
was measured (69 of 127), CA15-3 was raised in 68.0% of women (83 of 
122) and CA19-9 was raised in 29.4% (40 of 136). 
 
Figure 8 shows the concordance between the raised marker levels in the 104 
women who had all three marker levels measured at this time. 
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Figure 7   Box and whisker plot showing markers measured at the time of advanced breast 
cancer diagnosis (within 60 days of this date). Change in marker assay was April 2004 
change. 
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Figure 8   Concordance of raised markers in the 104 women who had CEA, CA15-3 and CA19-9 
measured at advanced breast cancer diagnosis (within 60 days of this date). 
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Figure 15 and Table 16 show the sensitivities in more detail and compares 
them with sensitivities of each marker panel at the start of chemotherapy one 
and two. 
 
(3.1.1.2) Leading up to Advanced Disease Diagnosis 
Of the patients who had CEA, CA15-3 and CA19-9 level recorded at the 
time of advanced disease diagnosis (127, 122 and 136 patients 
respectively) 17 patients (7, 12, and 3 respectively) were eligible for analysis 
of tumour marker doubling times. Reasons for the exclusion of the other 
patients can be seen in Table 14 as can the calculated median marker 
doubling and lead times prior to the diagnosis of advanced disease. 
 
In two of the cases where CA15-3 lead time was measured (n=12) the 
increase in marker level did not appear to be exponential (increase in 
marker level both by 4U/ml in 23 weeks in one case and in the other case in 
211 weeks). Lead and doubling times were calculated to include these 
patients initially but amended results for CA15-3 lead and doubling times 
with these two individuals excluded can also be seen in Table 14. Individual 
tumour marker increases and median lead times can be seen in Figure 9. 
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Table 14   Results of marker doubling and lead time analysis in women with advanced 
breast cancer. 
 ADD = Advanced disease Diagnosis 
 ULN = Upper Limit of Normal 
* = With or without the category below 
 
 CEA 
n=127 (%) 
CA15-3 
n=122 (%) 
CA19-9 
n=136 (%) 
Excluded because:- 
Marker level at ADD not raised * 
No previous tumour marker measurement 
No previous normal value 
Previous level ≤ ULN 
Previous level unknown 
Marker kinetics do not show an increase in level  
Change of assay between 2 marker levels 
 
60 (47) 
35 (28) 
9 (7) 
12 (9) 
1 (1) 
1 (1) 
2 (2) 
 
39 (32) 
37 (30) 
7 (6) 
24 (20) 
0 
3 (2) 
0 
 
95 (70) 
25 (18) 
1 (1) 
12 (9) 
0 
0 
0 
Eligible for doubling time analysis 7 (6) 12 (10) 3 (2) 
Marker lead time in months – Mean / Median 
 Amended lead time 
6.1 / 3.9 
- 
8.1 / 4.8 
4.3 / 2.5 
4.5 / 1.7 
- 
Marker doubling time in months – Mean / Median 
Amended lead time 
1.4 / 0.8 
- 
29.7 / 3.3 
4.4 / 2.4 
1.2 / 0.7 
- 
 
 
Figure 9   Tumour marker lead times up to the diagnosis of advanced breast cancer (CA15-3 
median lead time quoted is the amended lead time n=10). 
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(3.1.2) Tumour Marker Levels at the Time of the First and Second 
Chemotherapy Regimens given in Advanced Disease 
36 (20.0%) of the 180 patients who had advanced breast cancer did not have 
evidence of palliative chemotherapy at all (4 of whom (2.2%) also had no 
tumour markers recorded) and 3 (1.7%) had palliative chemotherapy but not 
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at Airedale, all 39 (21.7%) were discounted from the analysis leaving 141 
women who received palliative chemotherapy at Airedale Hospital for 
advanced breast cancer. 
 
(3.1.2.1) At First Chemotherapy 
A further 3 women had some palliative chemotherapy at Airedale but not 
course one, and 12 of the remaining women had no markers recorded within 
30 days of the beginning of the first course of palliative chemotherapy (n=6) 
or no tumour markers recorded at all (n=6) in the hospital notes. This left 126 
(70.0% of the original 180) who had one or more tumour markers recorded at 
the beginning of the first palliative chemotherapy treatment. The distribution of 
markers measured can be seen in Figure 10. 
 
Figure 10   Tumour markers measured at the time of the beginning of the first palliative 
chemotherapy regimen in the 180 women with advanced breast cancer (within 30 days of this 
date).  
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measured, 83.3% (105) had CA15-3 measured and 95.2% (120) had CA19-9 
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measured, a breakdown of which can be seen in Table 15. Of the 126 women 
who had one or more markers measured at the start of the first chemotherapy 
regimen 68.3% (86) had all three markers measured at this point (8.1% (7) of 
these women had their markers measured after the change of assay).  
 
At the start of the first chemotherapy CEA was raised in 58.7% of all women 
where it was measured (64 of 109) similarly for CA15-3 was raised in 77.1% 
(81 of 105) of patients and CA19-9 was raised in 32.5% (39 of 120). Figure 11 
shows the concordance between the raised marker levels in the 86 women 
who had all three marker levels measured at this time. The distribution of 
marker levels at this time was skewed positively by varying degrees and 
several of the distribution curves could not be transformed logarithmically, 
reciprocally or by square rooting the data so the Mann-Whitney U test was 
used. Details can be seen in Table 15 and Figure 13. 
 
Figure 11   Concordance of raised markers in the 86 women who had CEA, CA15-3 and 
CA19-9 measured at the time of the first chemotherapy given in advanced breast cancer 
(within 30 days of this date). 
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Figure 15 and Table 16 show the sensitivities in more detail and compare 
them with the sensitivities of each marker panel at advanced disease 
diagnosis and the start of chemotherapy two. 
  
 
(3.1.2.2) At Second Chemotherapy 
Of the 141 women who had advanced breast cancer and received palliative 
chemotherapy at Airedale Hospital 51.8% (73) had only one course of 
palliative chemotherapy and so could not be included in this analysis (three of 
the 73 patients also had no tumour markers recorded, and one woman 
changed chemotherapy regimens after just one cycle and began a second 
regimen immediately so for the purposes of this study was classed as only 
having one course of chemotherapy). Of the remaining 68 women 2 had no 
tumour markers recorded in the hospital case-notes and 8 did not have 
tumour markers recorded sufficiently close to the start of the second 
chemotherapy course to be included in this study. The final lady had been 
previously treated elsewhere and the regimen number was not known, she 
was therefore also excluded from the analysis. 
 
The remaining 57 women (40.4% of the original 141) had one or more tumour 
markers recorded at the beginning of the second palliative chemotherapy 
treatment. The distribution of markers measured can be seen in Figure 12. Of 
all women who had a tumour marker measured at this time (n=57) 89.5% (51) 
had CEA measured and 94.7% (54) had CA15-3 measured with the same 
proportion also having CA19-9 measured. 
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Figure 12   Tumour markers measured at the time of the beginning of the second palliative 
chemotherapy regimen in 57 women with advanced breast cancer (within 30 days of this 
date).  
 
 
 
Further details of tumour marker levels at the start of the second 
chemotherapy given in advanced breast cancer can be seen in Table 15 and 
a comparison of marker levels at the start of the first and second 
chemotherapy regimens can be seen in Figure 13.  
 
Table 15   Tumour marker levels at the time of initiation of the first (n=126) and second 
(n=57) chemotherapy regimens given to patients with advanced breast cancer (within 30 
days of this date). 
 MC = Marker assay change (April 2004) 
 
 
C
h
e
m
o
th
e
ra
p
y
 
R
e
g
im
e
n
 
Tumour Marker 
Measured 
at Initiation 
of Therapy 
(% of 126 or 
57 women 
with one or 
more 
markers 
measured) 
Raised at 
Initiation of 
Therapy (% 
of those 
where 
marker was 
measured) 
Range 
S
k
e
w
 
Mann-
Whitney U 
test result 
z (P) for 
markers 
measured 
1 
CEA 
Pre-MC 100 (79.4%) 58 (58.0%) 1-38784 9.93 
2.65 (<0.01) 
Post-MC 9 (7.1%) 6 (66.7%) 3-6397 2.28 
CA15-3 
Pre-MC 95 (75.4%) 73 (76.8%)  9-11928 4.69 
1.46 (0.14) 
Post-MC 10 (7.9%) 8 (80.0%) 15-4353 2.07 
CA19-9 
Pre-MC 112 (88.9%) 34 (30.4%) 1-108777 8.38 
2.27 (0.02) 
Post-MC 8 (6.3%) 5 (62.5%) 22-649 2.61 
2 
CEA 
Pre-MC 43 (75.4%) 32 (74.4%) 1-3759 6.36 
0.56 (0.58) 
Post-MC 8 (14.0%) 3 (37.5%) 3-2516 1.29 
CA15-3 
Pre-MC 44 (77.2%) 32 (72.7%)  12-7750 4.16 
0.20 (0.84) 
Post-MC 10 (17.5%) 9 (90.0%) 18-955 1.89 
CA19-9 
Pre-MC 44 (77.2%) 15 (34.1%) 1-2008 3.61 
-0.02 (0.98) 
Post-MC 10 (17.5%) 2 (20.0%) 9-350 2.84 
(0) 
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Again as can be seen from Table 15, marker level distribution was skewed 
positively by varying degrees and several of the distribution curves could not 
be transformed logarithmically, reciprocally or by square rooting the data so 
the Mann-Whitney U test was used. 
 
There was no significant difference (P > 0.3 in all cases) between the CEA, 
CA15-3 or CA19-9 levels of patients who were beginning chemotherapy one 
and those beginning chemotherapy two either with or without the inclusion of 
post assay change marker levels. 
 
Of the 57 women who had one or more markers measured at the start of the 
second chemotherapy regimen 80.7% (46) had all three markers measured at 
this point (17.4% (8) of these women had their markers measured after the 
change of assay which occurred in 2004).  
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Figure 13   Box and whisker plot showing markers measured at the time of first and second 
chemotherapy regimens given in advanced breast cancer (within 30 days of start date). 
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At the start of the second chemotherapy regimen CEA was raised in 68.6% of all 
women where it was measured (35 of 51), CA15-3 was raised in 75.9% (41 of 54) 
of women and CA19-9 was raised in 31.5% (17 of 54). Figure 14 below shows the 
concordance between the raised marker levels in the 46 women who had all three 
marker levels measured at this time.  
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Figure 14   Concordance of raised markers in the 46 women who had CEA, CA15-3 and 
CA19-9 measured at the time of the second chemotherapy given in advanced breast cancer 
(within 30 days of this date). 
 
 
 
Figure 15 and Table 16 show the sensitivities in more detail and compares 
them with sensitivities of each marker panel at advanced disease diagnosis 
and the start of chemotherapy one. 
 
Figure 15   Tumour marker panel sensitivity at the time of the diagnosis of advanced disease 
and at the start of the first and second chemotherapy regimens given in advanced breast 
cancer (in patients who had all tumour markers recorded). 
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Table 16   Differences in between the sensitivity of each tumour marker panel at the time of the diagnosis of advanced disease, the start of the first, and the 
start of the second chemotherapy regimens given in advanced breast cancer (in patients who had all tumour markers recorded). 
 
   Note: Using Table 16 and Table 21. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
From Figure 15 we know that the sensitivity of the tumour marker panel CEA, CA15-3 and CA19-9 at the time of advanced disease diagnosis is 
84.6% and the sensitivity of CA15-3 alone at this time is 69.2%. The table can be used to compare the two sensitivities and see how different they 
are and whether this difference is statistically significant. 
 
1. The sensitivities of the tumour marker panel CEA, CA15-3 and CA19-9 is compared with the sensitivity of CA15-3 alone in the following 
square of the table. 
2. The results in the selected square of the table show that the 95% confidence interval for the difference in the sensitivities of the two 
tumour marker panels is 3.9 to 26.9 (a positive confidence interval which indicates that the sensitivity of the tumour marker panel on the 
left hand side of the table is greater than that on the top of the table) 
3. The p value in this case is 0.009 and is therefore significant. This indicates that there is a significant possibility that there is a difference 
between the sensitivity of the two tumour marker panels being compared. 
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4. The table can be used to compare the sensitivity of different tumour marker panels at the same time point or at different time points e.g at 
advanced disease diagnosis compared with at the start of chemotherapy one or two.  
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        p value is not significant 
 
        p value has borderline significance 
      
        p value is significant 
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Differences in between the sensitivity of each tumour marker panel at the time of the diagnosis of advanced disease, the start of the first, and the start of the 
second chemotherapy regimens given in advanced breast cancer (in patients who had all tumour markers recorded). 
 
Difference in Percentage of patients with raised markers - 95% Confidence Interval (p) 
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(<0.001) 
CA19-9                      
 
 116 
(3.1.3) Tumour Marker Response to Chemotherapy Given in Advanced 
Disease 
 
(3.1.3.1) At First Chemotherapy 
Of the 126 women who had advanced disease, the first course of palliative 
chemotherapy at Airedale and a tumour marker level recorded at the start of 
the first chemotherapy regimen a further 26 women (20.6%) were excluded at 
this stage as they did not have enough tumour marker levels recorded for 
analysis of any marker movement to take place (at least one marker level 
recorded within 30 days of the chemotherapy start date and a further 2 of the 
same marker levels recorded within the 100 days following this date). This left 
100 patients (55.6% of the original 180 women with advanced breast cancer) 
who could be analysed for Rustin response to chemotherapy one which is 
defined by Table 11 (Methods section).  
 
Of these patients, one had CA19-9 Rustin response ascertained at the time 
when the 1995 change in this marker occurred (Figure 16A, patient A) as the 
trajectory of this marker did not change dramatically following the marker 
assay change the change was discounted and the category of Rustin 
response was categorised in the normal way. Patients B, C, D and E shown in 
Figure 16A represent the marker movements of colorectal cancer patients 
who this change in marker assay also affected. As with the patient A, the 
trajectories of the marker responses for patients B, C and E were not thought 
to be affected by the marker assay change and Rustin category was 
established in the normal way. The trajectory of marker movement in patient 
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D did seem to be affected by the marker change but as this all occurred within 
the normal marker range this marker was categorised as Always Normal. 
 
One further patient had CA15-3 and CA19-9 Rustin response ascertained at 
the time of the 2004 change of assay (Figure 16B, patient F) as the trajectory 
of CA15-3 level did not change dramatically the marker assay change was 
discounted and Rustin response was again categorised in the normal way. 
For CA19-9 response in this patient the marker remained below the upper 
limit of normal throughout the marker change and so was categorised as 
Always Normal. 
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Figure 16   Marker levels following the initiation of the first chemotherapy regimen in patients 
where marker assay change occurred during the 100 days following chemotherapy start date. 
 
A. CA19-9 at the time of 1995 marker assay change. 
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B. CA15-3 at the time of 2004 marker assay change. 
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Figure 17 shows the distribution of the measurement of markers among these 
100 patients and illustrates the proportions of each which fell into each Rustin 
category of response. 
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Figure 17   Tumour markers measured and Rustin category of response in the 100 women 
whose tumour markers could be analysed following the initiation of chemotherapy one. 
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The following Kaplan-Meier graphs (Figure 18A, B and C) show overall 
survival from the start of the first chemotherapy given in advanced disease 
according to tumour marker and Rustin response category. 
 
Figure 18   Rustin response category and survival from the start of the first chemotherapy 
given in advanced breast cancer. 
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B. CA15-3 (n=86). 
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C. CA19-9 (n=88). 
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(3.1.3.2) At Second Chemotherapy 
Of the 57 women who had advanced disease, the second course of palliative 
chemotherapy at Airedale and a tumour marker level recorded at the start of 
the second chemotherapy regimen (within 30 days of this date) a further 7 
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women (12.3%) were excluded at this stage as they did not have enough 
tumour marker levels recorded for analysis of marker movement to take 
place. This left 50 patients (27.6% of the original 181 women with advanced 
breast cancer) who could be analysed for Rustin response to chemotherapy 
two.  
 
One patient had a transient rise in CEA level within 45 days of the initiation of 
the second chemotherapy regimen, as a result this rise was discounted and 
the CEA level was considered to remain stable, it was analysed as such for 
the purpose of this study. The Venn diagram below (Figure 19) shows the 
measurement of markers and marker responses among all 50 women whose 
markers could be analysed at this point in time. 
 
Figure 19   Tumour markers measured and Rustin category of response in the 50 women 
whose tumour markers could be analysed for Rustin response to chemotherapy two. 
 
 
0%
20%
40%
60%
80%
100%
1 2 3
Tumour Marker
P
e
r
c
e
n
ta
g
e
 (
n
=
5
0
)
Not Measured
Progression
Progression
from Within the
Normal Range
Stable
Response
Always Normal
 
 
2.0% 
(1) 
 
   (0) 
2.0% 
(1) 
 
    76.0% 
   (38) 4.0% 
(2) 
16.0% 
   (8) 
CA19-9 Measured 
CA15-3 Measured 
(0) 
CEA Measured 
   CEA  CA15-3    CA19-9 
    18 
      8 
      2 
    40 
   6 
    16 
    16 
 50 
 22 
 10 
      4 
      12 
                  8 
       30 
       12 
       42 
                  4 
 122 
The following four Kaplan-Meier graphs (Figure 20A, B, C and D) show 
overall survival from the start of the second chemotherapy given in advanced 
disease according to tumour marker and Rustin response category. 
 
Only one patient had a CEA level which showed progression from within the 
normal range, as this could not be used to generate a curve on the graph 
shown in Figure 20A, this patient was removed from this analysis. Two 
patients had CEA level which responded (i.e. fell by ≥ 50%) but from a level 
which was originally less that twice the upper limit of normal (ULN). In Figure 
20A these patients are categorised as having stable disease according to the 
modified Rustin criteria of response and the survival curve in Figure 20B 
shows the amended Kaplan-Meier graph which is generated if these two 
patients were categorised separately. 
 
Of the 47 patients analysed for CA15-3 Rustin response to the second 
chemotherapy regimen, one patient had a response from a level which was < 
twice the ULN, this was classed a stable in Figure 20C and because only one 
patient displayed this marker movement a separate curve could not be 
generated on the Kaplan-Meier graph in this case. No patients had such a 
response when CA19-9 kinetics were examined. 
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Figure 20   Rustin response category and survival from the start of the second chemotherapy 
given in advanced breast cancer. 
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B. CEA - Survival of the 2 patients who responded from < 2x ULN as a separate curve 
(n=41). 
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C. CA15-3 (n=47). 
 
0
0.5
1
0 200 400 600 800 1000 1200 1400 1600
Time (days) between start of chemotherapy and death or last 
contact
Probability
 
 
D. CA19-9 (n=48). 
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Median survivals could be calculated from the graphs in Figures 18 and 20; 
these are displayed in Table 22 and Figure 35. 
 
The sensitivity, specificity, positive predictive value (PPV) and negative 
predictive value (NPV) of the Rustin response criteria at identifying 
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radiological response to the first and second chemotherapy regimens are 
shown in Table 17 and survival according to radiological response can be 
seen in Figure 21A and 21B. Results of Spearman rank correlation and Cox‟s 
proportional hazards regression for both breast and colorectal cancer patients 
can bee seen in Table 24. The Cox‟s regression was also performed taking 
into account other possible confounding factors such as lymph node status. 
The results of this analysis can be seen in Table 25. 
 
All breast cancer patients who had a tumour stage quoted had this quoted 
using the TNM system, which was converted to a single stage using the 
conversion chart (Table 12, Patients and Methods section). 
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Table 17   Sensitivity, specificity, positive predictive value (PPV) and negative predictive  
value (NPV) of Rustin progression at identifying radiological progression and Rustin  
response at identifying radiological response from chemotherapy initiation in patients  
with advanced breast cancer. 
 P only = Only patients categorised as having Rustin progression considered to show tumour marker  
 progression 
 P and PN = Patients with both Rustin progression and progression from within the normal range  
 considered to show tumour marker progression. 
 
Breast 
First Chemotherapy  
(N
o
 of patients eligible for 
analysis) 
Sensitivity 
% (N
o
 of 
patients) 
Specificity 
% (N
o
 of 
patients) 
PPV  
% (N
o
 of 
patients) 
NPV  
% (N
o
 of 
patients) 
CEA (48) 
P only 8.3 (1/12) 100 (36/36) 100 (1/1) 76.6 (36/47) 
P and PN 8.3 (1/12) 97.2 (35/36) 50.0 (1/2) 76.1 (35/46) 
Response 35.7 (10/28) 80.0 (16/20) 71.4 (10/14) 47.1 (16/34) 
CA15-3 (51) 
P only 9.1 (1/11) 97.5 (39/40) 50.0 (1/2) 79.6 (39/49) 
P and PN As above As above As above As above 
Response 40.7 (11/27) 83.3 (20/24) 73.3 (11/15) 55.6 (20/36) 
CA19-9 (53) 
P only 25.0 (3/12) 97.6 (40/41) 75.0 (3/4) 81.6 (40/49) 
P and PN 25.0 (3/12) 90.2 (37/41) 42.9 (3/7) 80.4 (37/46) 
Response 6.9 (2/29) 91.7 (22/24) 50.0 (2/4) 44.9 (22/49) 
Second Chemotherapy  
(N
o
 of patients eligible for 
analysis) 
    
CEA (24) 
P only 33.3 (3/9) 100 (15/15) 100 (3/3) 71.4 (15/21) 
P and PN 33.3 (3/9) 93.3 (14/15) 75.0 (3/4) 70.0 (14/20) 
Response 33.3 (2/6) 77.8 (14/18) 33.3 (2/6) 77.8 (14/18) 
CA15-3 (28) 
P only 23.1 (3/13) 93.3 (14/15) 75.0 (3/4) 58.3 (14/24) 
P and PN As above As above As above As above 
Response 66.7 (4/6) 90.9 (20/22) 66.7 (4/6) 90.9 (20/22) 
CA19-9 (28) 
P only 7.7 (1/13) 100 (15/15) 100 (1/1) 55.6 (15/27) 
P and PN 15.4 (2/13) 100 (15/15) 100 (2/2) 57.7 (15/26) 
Response 50.0 (3/6) 86.4 (19/22) 50.0 (3/6) 86.4 (19/22) 
Figure 21   Radiological response category and survival in advanced breast cancer 
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(3.2) Colorectal Cancer Patients 
 
Complete sets of hospital case-notes could be located and examined for 86% 
(or 313) of the 366 patients who had been registered to OPMAS as receiving 
chemotherapy for colorectal cancer between June 1992 and February 2004. 
Of the 53 sets of case-notes which could not be examined, 48 sets (91%) 
could not be located in medical records (many of these had been destroyed in 
line with hospital policy, in 4 cases some of the case-notes could be found but 
not the complete set of volumes) and 5 sets (9%) had been microfilmed. 
 
Of the 313 patients whose notes were located 14 (4.5%) were excluded from 
the study because of previous or coexisting malignancies or because the site 
of the primary tumour was unclear (e.g. Lung or oesophageal cancer), or the 
possibility that the advanced disease present was not colorectal in origin. 
Evidence of advanced colorectal cancer was found in 199 or 63.6% of these 
patients (66.6% of the remaining 299 women after exclusions). Patients who 
had previously sarcoma, Squamous cell carcinoma, transitional cell 
carcinoma of the bladder, prostate cancer, basal cell carcinoma and others 
were included in the study if the advanced disease was treated as advanced 
colorectal cancer. 
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(3.2.1) Tumour Marker Levels at the time of, and Leading up to, 
Advanced Disease Diagnosis 
 
(3.2.1.1) At the time of Advanced Disease Diagnosis 
Of the 199 colorectal cancer patients with advanced disease, 22 further 
patients were discounted, 19 (9.5%) had no tumour markers recorded within 
60 days of the date of advanced disease diagnosis and 3 patients (1.5%) had 
an unknown date of diagnosis of advanced disease. The remaining 177 
patients (88.9%) had one or more markers recorded within 60 days of the 
date of advanced disease diagnosis, 176 (99.4%) of these patients had CEA 
level recorded and 175 (98.9%) had CA19-9 recorded at this time. 174 
patients (98.3%) had both CEA and CA19-9 measured within 60 days of 
advanced disease diagnosis, one patient had CA19-9 alone measured and 2 
patients had CEA alone measured.  
 
For 11 patients the tumour marker recorded at this time was measured 
following the change of assay which occurred in April 2004. The data for the 
marker levels at advanced disease diagnosis shows that the distributions 
were positively skewed and many of them could not be transformed 
logarithmically, reciprocally or by square rooting the data so the Mann-
Whitney U test was used to compare marker levels at the time of advanced 
disease diagnosis before and after the change in marker assay. Details of the 
marker levels can be seen in Table 18 and Figure 22.  
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Two patients had CEA and CA19-9 levels at advanced disease diagnosis 
which were taken before the assay change which occurred in 1993. The 
details in Table 18 and Figure 22 include these patients in the Pre-marker 
assay change group, however, if the data is excluded from this group the 
tumour marker details in Table 18 change very little (range does not change 
at all, skew is altered to 5.59 for CEA and 11.48 for CA19-9 and Mann-
Whitney results are altered to -1.12 (0.26) and -0.44 (0.66) respectively). If 
these patients were to be excluded the data from Figure 22 is also changed 
very slightly from a 25th Percentile of 15.3 to 14.8 (CA19-9) , a median of 29 
to 27 (CEA) and 60 to 58 (CA19-9) a 75th percentile of 182.5 to 181 (CEA) 
and 375 to 362 (CA19-9). 
 
Table 18   Tumour marker levels at advanced disease diagnosis in 177 patients with 
advanced colorectal cancer (within 60 days of this date). 
 MC = Marker assay change (April 2004) 
 
Tumour Marker 
Measured 
at ADD (% 
of 177 
women with 
one or more 
markers 
measured) 
Raised at 
ADD (% of 
those where 
marker was 
measured) 
Range Skew 
Mann-
Whitney U 
test result 
z (P) for 
markers 
measured 
CEA 
Pre-MC 165 (93.2%)  136 (82.4%) 1-6840 5.62 
-1.15 (0.25) 
Post-MC 11 (6.2%)  7 (63.6%) 2-284 2.92 
CA19-9 
Pre-MC 164 (92.7%) 97 (59.1%) 1-93000 11.2 
-0.50 (0.62) 
Post-MC 11 (6.2%) 8 (72.7%) 19-355 3.01 
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Figure 22   Box and whisker plot showing markers measured at the time of advanced 
colorectal cancer diagnosis (within 60 days of this date). Assay change was the 2004 assay 
change 
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At the time of the diagnosis of advanced disease CEA was raised in 81.8% of 
all patients (144 of 176) where it was measured and CA19-9 was raised in 
60.0% (105 of 175). Figure 23 shows the concordance between the raised 
marker levels in the 174 patients who had both marker levels measured at 
this time. 
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Figure 23   Concordance of raised markers in the 174 patients who had CEA and CA19-9 
measured at advanced colorectal cancer diagnosis (within 60 days of this date). 
 
 
 
Figure 28 and Table 21 show the sensitivities in more detail and compare 
them with sensitivities of each other marker panel at the start of 
chemotherapy one and two. 
 
(3.2.1.2) Leading up to Advanced Disease Diagnosis 
Of the patients who had CEA and CA19-9 level recorded at the time of 
advanced disease diagnosis (176 and 175 patients respectively) 36 patients 
(28 and 16 respectively) were eligible for analysis of tumour marker 
doubling times, reasons for the exclusion of the other patients can be seen 
in Table 19 as can the calculated median marker doubling and lead times 
prior to the diagnosis of advanced disease. Individual tumour marker 
increases and lead times can be seen in Figure 24. 
 
Table 19   Results of marker doubling and lead time analysis in patients with advanced 
colorectal cancer 
 ADD = Advanced disease Diagnosis 
 ULN = Upper Limit of Normal 
* = With or without the category below 
 
 
 
 
 
 
 
 
 
 
 
 CEA 
n=176 (%) 
CA19-9 
n=175 (%) 
Excluded because:- 
Marker level at ADD not raised * 
No previous tumour marker measurement 
No previous normal value 
Previous level ≤ ULN 
Previous level unknown 
Marker kinetics do not show an increase in level  
Change of assay between 2 marker levels 
33 (19) 
70 (40) 
22 (13) 
18 (10) 
0 
4 (2) 
1 (1) 
 
70 (40) 
57 (33) 
18 (10) 
12 (7) 
0 
1 (1) 
1(1) 
Eligible for doubling/lead time analysis 28 16 
Marker lead time in months - Mean / Median 7.0 / 4.5 3.5 / 3.0 
Marker doubling time in months - Mean / Median 4.1 / 2.0 4.9 / 2.3 
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Figure 24   Tumour marker lead times up to the diagnosis of advanced colorectal cancer.  
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(3.2.2) Tumour Marker Levels at the Time of the First and Second 
Chemotherapy Regimens given in Advanced Disease 
29 (14.6%) of the 199 patients who had advanced colorectal cancer did not 
have evidence of palliative chemotherapy at all (7 of whom also had no 
further evidence of advanced disease after re-resection and in some cases 
adjuvant chemotherapy). A further 4 (2.0%) patients had palliative 
chemotherapy but not at Airedale, all 33 (16.6%) were discounted from the 
analysis leaving 166 patients who received palliative chemotherapy at 
Airedale Hospital for advanced colorectal cancer. 
 
(3.2.2.1) At First Chemotherapy 
From the remaining 166 patients two patients had some palliative 
chemotherapy at Airedale but not course one, and 2 further patients had no 
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markers recorded in the hospital case-notes within 30 days of the beginning 
of the first course of palliative chemotherapy. This left 162 (81.4% of the 
original 199) patients with tumour markers recorded at the beginning of the 
first palliative chemotherapy treatment, all of these patients had both CEA and 
CA19-9 recorded at this time. CEA was raised in (138) 85.2% and CA19-9 
was raised in (106) 65.4% of these patients. Figure 25 below shows the 
concordance between the raised marker levels in the 162 patients. 
 
Figure 25   Concordance of raised markers in the 162 patients who had CEA and CA19-9 
measured at the time of the first chemotherapy given in advanced colorectal cancer (within 30 
days of this date). 
  
 
 
Figure 28 and Table 21 show the sensitivities in more detail and compare 
them with sensitivities of each other marker panel at advanced disease 
diagnosis and the start of chemotherapy two. 
 
 
As with marker levels at the time of the diagnosis of advanced disease marker 
level distribution was skewed positively by varying degrees. It was not 
possible to transform all of the distribution curves logarithmically, reciprocally 
or by square rooting the data so the Mann-Whitney U test was used to 
compare levels from patients measured before the change in marker assay 
with those taken after. Details of marker distribution at this time can be seen 
in Table 20 and Figure 26. 
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Two patients had CEA and CA19-9 levels at the start of the first 
chemotherapy regimen which were taken before the assay change which 
occurred in 1993. The details in Table 20 and Figure 26 include these patients 
in the Pre-marker assay change group, however, if the data is excluded from 
this group the tumour marker details in Table 20 change very little (range 
does not change at all, skew is altered to 4.15 for CEA and 9.06 for CA19-9 
and Mann-Whitney results are altered to -1.65 (0.10) and -1.03 (0.31) 
respectively). If these patients were excluded the data from Figure 26 would 
also changed very slightly from an unchanged 25th Percentile for both CEA 
and CA19-9, an unchanged median for CEA and a change from 103 to 89 for 
CA19-9 and a change in 75th percentile of 282 to 303 (CEA) and 837 to 818.5 
(CA19-9). 
 
(3.2.2.2) At Second Chemotherapy 
Of the 166 patients who received palliative chemotherapy at Airedale Hospital 
for advanced colorectal cancer 54.8% (91) had only one course of palliative 
chemotherapy and so could not be included in this analysis and two patients 
(1.2%) received their second chemotherapy elsewhere and so were excluded. 
Of the remaining 73 patients one patient had an unknown start date for 
chemotherapy two and so was excluded from the analysis. This left 72 
patients (43.4% of the original 166) who had one or more tumour markers 
recorded at the beginning of the second palliative chemotherapy treatment.  
 
All of the 72 patients had CA19-9 measured and 71 of them had CEA 
measured at this time. Table 20 shows the tumour marker levels at the 
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beginning of the first and second chemotherapy regimens and Figure 26 
enables comparison between these two time points in more detail. As can be 
seen from Table 20 marker distribution was, in all cases, skewed positively by 
varying degrees. Several of the distribution curves could not be transformed 
logarithmically, reciprocally or by square rooting the data so the Mann-
Whitney U test was used to test the difference between the pre- and post-
2004 marker assay change groups 
 
At the start of chemotherapy two only a single patient had CEA and CA19-9 
levels which were taken before the assay change which occurred in 1993. 
The details in Table 20 and Figure 26 include this patients in the Pre-marker 
assay change group, however, if the data from this patient is excluded from 
this group the tumour marker details in Table 20 again change very little 
(range does not change at all, skew is altered to 3.39 for CEA and 7.40 for 
CA19-9 and Mann-Whitney results are altered to -1.91 (0.06) and -0.99 (0.32) 
respectively). If these patients were excluded the data from Figure 26 would 
also changed very slightly from an unchanged 25th Percentile for CEA and a 
change from 36.8 to 36.5 for CA19-9, a change in median CEA from 169 to 
171 and a change from 184.5 to 176 for CA19-9 and a change in 75th 
percentile of 439.5 to 441.8 (CEA) and 546.3 to 472 (CA19-9). 
 
There was no significant difference (P > 0.4 in all cases) between the CA19-9 
tumour marker levels of patients who were beginning chemotherapy one and 
those beginning chemotherapy two, either with or without the inclusion of post 
assay change marker levels. CEA levels however were significantly different 
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between the two groups (z = 2.60 and 2.68 respectively and P < 0.01 both 
with and without the inclusion of post assay change marker levels). 
 
Table 20   Tumour marker levels at the time of initiation of the first (n=162) and second 
(n=72) chemotherapy regimens given to patients with advanced colorectal cancer (within 30 
days of these dates). 
 MC = Marker assay change (April 2004) 
 
 
C
h
e
m
o
th
e
ra
p
y
 
R
e
g
im
e
n
 
Tumour Marker 
Measured 
at initiation 
of therapy 
(% of 162 or 
72 patients 
with one or 
more 
markers 
measured) 
Raised at 
initiation of 
therapy (% 
of those 
where 
marker was 
measured) 
Range 
S
k
e
w
 
Mann-
Whitney U 
test result 
z (P) for 
markers 
measured 
1 
CEA 
Pre-MC 151 (93.2%)  130 (86.1%) 1-6686 4.18 
-1.67 (0.09) 
Post-MC 11 (6.8%) 8 (72.7%) 2-592 3.21 
CA19-9 
Pre-MC 151 (93.2%) 99 (65.6%) 1-93000 8.80 
-1.08 (0.28) 
Post-MC 11 (6.8%) 7 (63.6%) 14-4850 3.28 
2 
CEA 
Pre-MC 61 (84.7%) 59 (96.7%) 1-6204 3.42 
-1.93 (0.05) 
Post-MC 10 (13.9%) 9 (90.0%) 4-826 2.96 
CA19-9 
Pre-MC 62 (86.1%) 46 (74.2%) 1-127000 7.35 
-1.06 (0.29) 
Post-MC 10 (13.9%) 7 (70.0%) 23-1012 1.77 
 
Of the 72 patients who had one or more markers measured at the start of the 
second chemotherapy regimen 98.6% (71) had both CEA and CA19-9 
measured (10 of these patients had their markers measured after the change 
of assay).  
 
At the start of the second chemotherapy regimen CEA was raised in 95.8% 
(68 of 71) and CA19-9 was raised in 73.6% (53 of 72) of all patients where it 
was measured. Figure 27 shows the concordance between the raised marker 
levels in the 71 individuals who had both CEA and CA19-9 measured at this 
time. 
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Figure 26   Box and whisker plot showing markers measured at the time of first and second 
chemotherapy regimens given in advanced colorectal cancer (within 30 days of start date). 
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Figure 27   Concordance of markers in the 71 patients who had CEA and CA19-9 measured 
at the time of the second chemotherapy given in advanced colorectal cancer (within 30 days 
of this date). 
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Figure 28 and Table 21 show the sensitivities in more detail and compares 
them with sensitivities of each other marker panel at advanced disease 
diagnosis and the start of chemotherapy one. 
 
Figure 28   Tumour marker panel sensitivity at the time of the diagnosis of advanced disease 
and at the start of the first and second chemotherapy regimens given in advanced colorectal 
cancer (in patients who had all tumour markers recorded). 
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Table 21   Differences between the sensitivity of each tumour marker panel at the time of the 
diagnosis of advanced disease, the start of the first, and the start of the second 
chemotherapy regimens given in advanced colorectal cancer (in patients who had all tumour 
markers recorded).  Instructions for using this table can be found on page 114. 
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(3.2.3) Tumour Marker Response to Chemotherapy Given in Advanced 
Disease 
(3.2.3.1) At First Chemotherapy 
Of the 162 patients who had advanced disease, the first course of palliative 
chemotherapy at Airedale and a tumour marker level recorded at the start of 
the first chemotherapy regimen a further 12 patients (7.4%) were excluded at 
this stage as they did not have enough tumour marker levels recorded for 
analysis of marker movement to take place (at least one marker level 
recorded within 30 days of the chemotherapy start date and a further 2 
marker levels recorded within the 100 days following this date). This left 150 
patients (75.4% of the original 199 patients with advanced colorectal cancer) 
who could be analysed for Rustin response to chemotherapy one which is 
defined by Table 11 (Methods section).  
 
For one of the patients the change in assay of markers which occurred in 
1993 fell in the period of assessment of Rustin response following initiation of 
the first chemotherapy regimen. CEA and CA19-9 levels for this patient before 
and after the assay change can be seen in Figure 29. As the markers post-
assay change appear to be on a similar slope to those pre-assay change in 
this figure I have considered then to be continuous an therefore have 
considered patient A to show Stable CEA and CA19-9 levels. 
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Figure 29   CEA and CA19-9 marker levels following the initiation of the first chemotherapy 
regimen in the patient where marker assay changed during the 100 days following 
chemotherapy start date. 
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As could be seen in Figure 16A (breast section) several of the colorectal 
patients (Patients B. C, D and E) also had Rustin response analysed over the 
CA19-9 assay change which occurred in 1995 as was stated with this figure 
the assay change was not considered to affect the Rustin categories assigned 
in these cases. 
 
Figure 30 shows the distribution of the measurement of markers among the 
150 patients with colorectal cancer and illustrates the proportions of each 
which fell into each Rustin category of response. 
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Figure 30   Tumour markers measured and Rustin category of response in the 150 patients 
whose tumour markers could be analysed following initiation of chemotherapy one.  
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The four Kaplan-Meier graphs in Figure 31 show overall survival from the start 
of the first chemotherapy given in advanced disease according to tumour 
marker and Rustin response category. The log rank values for CEA and 
CA19-9 shown in Figures 31A and 31C were significant whether the patient 
shown in Figure 29 was included in the analysis or not (P < 0.001 in all 
cases). 
 
The data used to produce Figure 31A has one patient removed as the patient 
had a progression from within the normal range and this data cannot be 
analysed on its own. Four of the patients in Figure 31A and six of the patients 
in Figure 31C who are classified (according to the Rustin response criteria) as 
having stable tumour markers had a ≥ 50% fall in a tumour marker level but 
from a level that was not ≥ twice the ULN, these patients are analysed as a 
separate group in Figure 31B and 31D respectively.  
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Figure 31   Rustin response category and survival from the start of the first chemotherapy 
given in advanced colorectal cancer 
 
A. CEA (n=147). 
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B. CEA - Survival of the 4 patients who responded from < 2x ULN as a separate curve 
(n=147). 
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C. CA19-9 (n=146). 
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(3.2.3.2) At Second Chemotherapy 
Of the 72 patients who had advanced disease, the second course of palliative 
chemotherapy at Airedale and a tumour marker level recorded at the start of 
the second chemotherapy regimen (within 30 days of this date) a further 6 
Log-rank test P <0.001 
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(8.3%) were excluded at this stage as they did not have enough tumour 
marker levels recorded for analysis of marker movement to take place. This 
left 66 patients (33.2% of the original 199 patients with advanced colorectal 
cancer) who could be analysed for Rustin response to chemotherapy two. 
 
For three of the patients the change in assay of markers which occurred in 
1993 (Figure 32, Patient A) and April 2004 (Figure 32, Patients B and C) fell 
in the period of assessment of Rustin response following initiation of the 
second chemotherapy regimen. CEA and CA19-9 levels for these patients 
before and after the assay change can be seen in Figure 32. This made 
assessment of the Rustin Response to chemotherapy more difficult in these 
patients. As the post-assay change markers appear to be on a similar slope to 
the pre-change marker levels I have considered then to be continuous and 
therefore have considered patient A to show CEA progression and CA19-9 to 
show progression from within the normal range, patient B to progression for 
both CEA and CA19-9 and patient C to show stable CEA and response for 
CA19-9. 
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Figure 32   CEA and CA19-9 marker levels following the initiation of the second 
chemotherapy regimen in 3 patients where marker assay changed during the 100 days 
following chemotherapy start date. 
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A further patient had a doubling of CEA from 435 ng/ml to a level of >1000 
ng/ml at 48 days post chemotherapy start date, this level then fell to a stable 
level, for the purpose of the following analyses this was regarded as a case of 
prolonged tumour lysis and was categorised as stable in terms of Rustin 
response to chemotherapy two.  
 
Figure 33 shows the distribution of the measurement of markers among the 
66 patients and the proportions of each which fell into each Rustin category of 
response. 
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Figure 33   Tumour markers measured and Rustin category of response in the 66 patients 
whose markers could be analysed following initiation of chemotherapy two. 
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The Kaplan-Meier graphs in Figure 34 show survival from the start of the 
second chemotherapy given in advanced disease according to tumour marker 
Rustin response category. The log rank values for CEA and CA19-9 were not 
significant whether the three patients shown in Figure 32 were included in the 
analysis or not (P = 0.1 for CEA, and P = 0.4 for CA19-9 in both cases) and in 
the case of CEA regardless of the inclusion or exclusion of the patient with 
prolonged tumour lysis.  
 
Figure 34(A, B and C) shows graphs with all eligible patients included. There 
were 2 patients who had ≥ 50% a fall in CA19-9 but from a level which was 
originally less that twice the upper limit of normal (ULN), in Figure 34B these 
patients are categorised as having stable disease according to the modified 
Rustin criteria of response however the survival curve in Figure 34C shows 
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the amended Kaplan-Meier graph which is generated if these two patients 
were categorised as a separate group.  
 
Figure 34   Rustin response category and survival from the start of the second chemotherapy 
given in advanced colorectal cancer 
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C. CA19-9 - Survival of the 2 patients who responded from < 2x ULN as a separate curve 
(n=66). 
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Median survivals could be calculated from the graphs in Figures 31 and 34; 
these are displayed in Table 22 and Figure 35. 
 
The sensitivity, specificity, positive predictive value (PPV) and negative 
predictive value (NPV) of the Rustin response criteria at identifying 
radiological response to the first and second chemotherapy regimens are 
shown in Table 23 and survival according to radiological response can 
be seen in Figure 36A and B.  
 
Results of Spearman rank correlation and Cox‟s proportional hazards 
regression analysis for both breast and colorectal cancer patients can be 
seen in Table 24. In order to do these analyses the precise ordering of the 
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Rustin categories of response had to be specified. This order was unclear 
from the Kaplan-Meier graphs shown in Figures 18, 20, 31 and 34, because 
of this, and after discussion with a statistician, the categories were ordered as 
follows:- 
 1. Response (R) 
 2. Always Normal (AN) 
 3. Stable (S) 
 4. Progression from Within the Normal Range / Progression (PN / P) 
 
AN was placed between R and S on the basis that it was unclear which 
category it most closely resembled (i.e. which side of R it sat on) and so it 
was felt that the best guess would be to place it between the two. PN and P 
were grouped together because often there were very few individuals who 
had markers categorised as PN so very little could be said about this group 
alone. 
 
Tests for interaction were performed on the results of the breast and 
colorectal cancer patients again using the Cox‟s proportional hazards 
regression model, results of this analysis can be seen in Table 25. Because of 
time limitations not all possible confounding factors (which data was collected 
on originally) could be taken into account in this analysis. 
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Table 22   Median Survival in weeks according to tumour marker response to the first and 
second chemotherapy regimens given in advanced disease. 
 
A. Breast cancer 
 
 CEA CA15-3 CA19-9  
Chemotherapy 
Regimen (n
o
 of 
patients) 
1 (77) 2 (41) 1 (86) 2 (47) 1 (88) 2 (48) 
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Normal 
73.1 (33) 63.6 (8) 43.1 (17) 60.1 (6) 69.3 (52) 40.4 (21) 
Response 94.9 (17) 45.1 (8) 66.7 (23) 64.1 (11) 71.3 (6) 28.1 (6) 
Stable 41.9 (20) 26.3 (20) 51.6 (41) 35.0 (25) 35.7 (20) 49.3 (15) 
Progression 
from Within 
the Normal 
Range 
combined 
with 
Progression 
23.0 (7) 14.9 (5) 19.0 (5) 22.3 (5) 20.6 (10) 17.3 (6) 
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g
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e
s
t 
χ
2
 (Degrees 
of Freedom) 
24.0 (3) 11.5 (3) 17.1 (3) 9.3 (3) 24.0 (3) 15.0 (3) 
P < 0.001 0.009 < 0.001 0.026 < 0.001 0.002 
 
 
B. Colorectal cancer  
 
 CEA CA19-9  
Chemotherapy Regimen (N
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1 (147) 2 (64) 1 (146) 2 (66) 
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Always Normal 73.3 (13) 95.6 (2) 89.9 (45) 63.0 (13) 
Response 72.6 (46) 66.1 (15) 58.3 (44) 52.6 (13) 
Stable 50.6 (64) 30.4 (34) 44.3 (46) 30.4 (30) 
Progression from Within 
the Normal Range 
combined with  
Progression 
27.7 (24) 44.6 (13) 22.3 (11) 36.7 (10) 
Log-rank Test 
χ
2
 (Degrees of 
Freedom) 
18.1 (3) 6.4 (3) 18.2 (3) 2.6 (3) 
P < 0.001 0.09 <0.001 0.4 
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Figure 35   Median Survival in days according to tumour marker response, error bars indicate 
the 95% confidence interval and * indicates where the 95% confidence interval cannot be 
calculated 
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     B. First and second chemotherapy regimens given in advanced colorectal cancer. 
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Table 23 
Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) 
of Rustin progression at identifying radiological progression and Rustin response at  
identifying radiological response from chemotherapy initiation in patients with advanced  
colorectal cancer. 
 P only = Only patients categorised as having Rustin progression considered to show tumour marker  
 progression 
 P and PN = Patients with both Rustin progression and progression from within the normal range  
 considered to show tumour marker progression. 
 
Colorectal 
First Chemotherapy  
(N
o
 of patients eligible for 
analysis) 
Sensitivity 
% (N
o
 of 
patients) 
Specificity 
% (N
o
 of 
patients) 
PPV  
% (N
o
 of 
patients) 
NPV  
% (N
o
 of 
patients) 
CEA (113) 
P only 33.3 (9/27) 93.0 (80/86) 60.0 (9/15) 81.6 (80/98) 
P and PN As above As above As above As above 
Response 51.0 (25/49) 81.3 (52/64) 67.6 (25/37) 68.4 (52/76) 
CA19-9 (112) 
P only 20.0 (5/25) 96.6 (84/87) 62.5 (5/8) 80.8 (84/104) 
P and PN As above As above As above As above 
Response 36.7 (18/49) 73.0 (46/63) 51.4 (18/35) 59.7(46/77) 
Second Chemotherapy  
(N
o
 of patients eligible for 
analysis) 
    
CEA (50) 
P only 36.8 (7/19) 93.5 (29/31) 77.8 (7/9) 70.7 (29/41) 
P and PN As above As above As above As above 
Response 50.0 (7/14) 83.3 (30/36) 53.8 (7/13) 81.1 (30/37) 
CA19-9 (51) 
P only 15.0 (3/20) 93.5 (29/31) 60.0 (3/5) 63.0 (29/46) 
P and PN 25.0 (4/20) 93.5 (29/31) 66.7 (4/6) 64.4 (29/45) 
Response 28.6 (4/14) 86.5 (32/37) 44.4 (4/9) 76.2 (32/42) 
 
Figure 36   Radiological response category and survival in advanced colorectal 
cancer from 
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A. Breast cancer patients 
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R      = 1.00 
AN    = 1.30 (0.5) 
S       = 2.22 (0.1) 
P/PN = 5.75 (0.001) 
 
AIC = 585  
Without AN 
 
[n=36] 
 
R      = 1.00 
S       = 1.92 (0.2) 
P/PN = 4.10 (0.01) 
 
AIC = 184  
[n=28] 
 
0.3845 (0.04) 
 
(Fishers exact = 
0.394) 
With AN Included 
 
[n=48] 
 
R      = 1.00 
AN    = 1.37 (0.5) 
S       = 1.50 (0.5) 
P/PN = 9.00 (0.002) 
 
AIC = 267 
Without AN 
 
[n=27] 
 
R      = 1.00 
S       = 1.37 (0.6) 
P/PN = 7.94 (0.007) 
 
AIC = 118 
R
a
d
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g
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[n=61] 
 
                         R      = 1.00 
S       = 1.11 (0.8) 
P       = 3.18 (0.01) 
 
? S = P  (p = 0.01) 
 
AIC = 362 
 
[n=29] 
 
                        R      = 1.00 
S       = 1.69 (0.3) 
P       = 2.81 (0.06) 
 
? S = P  (p = 0.2) 
 
AIC = 140 
 
 
 
 
 
 
 
 
 
 
 
Table 24 
 
Table 24 A and B shows:  
                          1. Results of Spearman rank correlation analysis (of Rustin response categories which were ordered in    
the following way:- R (response) – AN (always normal) – S (stable) – P/PN (progression / progression from within the 
normal range), and radiological staging which were ordered:- R – S – P)  
 
                          2. Unadjusted Hazard Ratio calculated using Cox‟s Proportional Hazards regression model for survival 
of breast and colorectal cancer patients. Survival according to Rustin response category using Response as defined by 
these criteria as baseline (radiological response category used response as defined by radiological response criteria as 
baseline). 
The regression analysis was carried out both with and without the patients with Always Normal (AN) tumour markers 
included. 
Sometimes other groups were compared within the analysis e.g. The hazard ratio for survival of AN compared with that 
of S this is shown in the table in this way. The significance of the difference between the survivals of the two groups is 
also shown here.  
             
                           3. AIC = Akaike‟s information  criterion – A smaller value for this is indicative of a better model 
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B. Colorectal cancer patients 
 
T
u
m
o
u
r 
m
a
rk
e
r 
Chemotherapy one Chemotherapy two 
Spearman 
rank 
correlation 
(p) 
Unadjusted Hazard Ratio (p) 
Spearman 
rank 
correlation 
(p) 
Unadjusted Hazard Ratio (p) 
C
E
A
 [n=113] 
 
0.4453 (<0.001)  
 
With AN Included 
 
[n=147] 
 
R      = 1.00 
AN    = 0.61 (0.2) 
S       = 1.19 (0.4) 
P/PN = 2.51 (<0.001) 
 
? AN = S  (p = 0.07) 
 
AIC = 1124 
Without AN 
 
[n=134] 
 
R      = 1.00 
S       = 1.18 (0.4) 
P/PN = 2.49 (<0.001) 
 
AIC = 1026 
[n=50] 
 
0.4280 (0.002) 
With AN Included 
 
[n=64] 
 
R      = 1.00 
AN    = 0.58 (0.5) 
S       = 1.75 (0.08) 
P/PN = 1.43 (0.4) 
 
AIC = 411 
Without AN 
 
[n=62] 
 
R      = 1.00 
S       = 1.78 (0.07) 
P/PN = 1.41 (0.4) 
 
AIC = 394 
C
A
1
9
-9
 
[n=112] 
 
0.2601 (0.006) 
With AN Included 
 
[n=146] 
 
R      = 1.00 
AN    = 0.53 (0.006) 
S       = 1.20 (0.4) 
P/PN = 1.82 (0.09) 
 
? AN = S  (p <0.001)  
 
AIC = 1111 
Without AN 
 
[n=101] 
 
R      = 1.00 
S       = 1.19 (0.4) 
P/PN = 1.81 (0.1) 
 
AIC = 728 
[n=51] 
 
0.3465 (0.01) 
 
(Fishers exact = 
0.386) 
 
 
With AN Included   
 
[n=66] 
 
R      = 1.00 
AN    = 0.78 (0.5) 
S       = 1.14 (0.7) 
P/PN = 1.13 (0.8) 
 
AIC = 432 
Without AN 
 
[n=53] 
 
R      = 1.00 
S       = 1.23 (0.6) 
P/PN = 1.15 (0.7) 
 
AIC = 324 
R
a
d
io
lo
g
y
 
 
[n=114] 
 
                         R      = 1.00 
S       = 1.09 (0.7) 
P       = 2.58 (<0.001) 
 
? S = P  (p <0.001) 
 
AIC = 808 
 
[n=51] 
                         
                        R      = 1.00 
S       = 0.83 (0.6) 
P       = 2.16 (0.03) 
 
? S = P  (p = 0.008) 
 
AIC = 301 
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Table 25 
 
Results of Cox‟s Proportional Hazards regression model for survival of breast and colorectal 
cancer patients at chemotherapy one adjusted according to various factors. Rustin response 
categories were ordered in the following way:- R (response) – AN (always normal) – S (stable) 
– P/PN (progression / progression from within the normal range) and Response was used as 
the baseline for these calculations. 
 
 * Stage 0 (Dukes‟ A) and 1 (Dukes‟ B) combined as baseline with a HR of 1.00.  
All but two of the colorectal patients who had a tumour stage for their tumour had a Dukes‟ stage which was 
used. One of the 2 patients who just had a TNM stage had distant metastases at diagnosis so was categorised as 
Dukes‟ D the other patient had a TNM stage (T2 N2) which was converted to a single stage and classed as stage 
III (Dukes‟ C) using Table 12 (Patients and Methods Section). 
 
T
u
m
o
u
r 
  
  
  
  
S
it
e
 
T
u
m
o
u
r 
  
M
a
rk
e
r 
Adjusted Hazard Ratio+ (p) 
B
re
a
s
t 
C
E
A
 
For Lymph node status
 
[n=54] 
 
R      = 1.00 
AN    = 1.56 (0.3) 
S       = 2.54 (0.03) 
P/PN = 11.42 (<0.001) 
 
   0 involved    = 1.00 
   1-3 involved = 1.34 (0.5) 
   4-9 involved = 1.10 (0.8) 
   >9 involved  = 2.13 (0.1) 
 
? AN = S  (p = 0.2) 
For Lymph node status
 
and Liver Involvement [n=50] 
 
R      = 1.00 
AN    = 1.50 (0.3) 
S       = 2.38 (0.05) 
P/PN = 16.61 (<0.001) 
 
  0 involved    = 1.00 
  1-3 involved = 1.66 (0.3) 
  4-9 involved = 1.28 (0.6) 
  >9 involved  = 2.93 (0.04) 
 
    Liver Involved = 0.95 (0.9) 
C
A
1
5
-3
 
For Lymph node status
 
[n=62] 
 
R      = 1.00 
AN    = 1.24 (0.6) 
S       = 1.42 (0.3) 
P/PN = 8.30 (0.001) 
 
   0 involved    = 1.00 
   1-3 involved = 1.01 (1.0) 
   4-9 involved = 0.98 (1.0) 
   >9 involved  = 1.43 (0.3) 
For Lymph node status
 
and Liver Involvement [n=60] 
 
R      = 1.00 
AN    = 1.53 (0.4) 
S       = 1.69 (0.2) 
P/PN = 9.45 (0.001) 
   
  0 involved    = 1.00 
  1-3 involved = 0.94 (0.9) 
  4-9 involved = 0.88 (0.8) 
  >9 involved  = 1.29 (0.5) 
 
    Liver Involved = 1.24 (0.6) 
C
A
1
9
-9
 
For Lymph node status
 
[n=64] 
 
R      = 1.00 
AN    = 2.32 (0.1) 
S       = 3.71 (0.04) 
P/PN = 20.54 (<0.001) 
 
   0 involved    = 1.00 
   1-3 involved = 0.92 (0.8) 
   4-9 involved = 1.07 (0.9) 
   >9 involved  = 1.43 (0.4) 
 
? AN = S  (p = 0.2) 
For Liver Involvement [n=83] 
 
R      = 1.00 
AN    = 1.57 (0.3) 
S       = 3.07 (0.03) 
P/PN = 8.05 (<0.001) 
 
   Involved = 1.59 (0.07) 
For Lymph node status
 
and Liver Involvement [n=60] 
 
R      = 1.00 
AN    = 2.17 (0.2) 
S       = 3.87 (0.04) 
P/PN = 26.17 (<0.001) 
 
  0 involved    = 1.00 
  1-3 involved = 0.97 (0.9) 
  4-9 involved = 1.15 (0.8) 
  >9 involved  = 1.85 (0.2) 
 
    Liver Involved = 1.02 (1.0) 
C
o
lo
re
c
ta
l 
C
E
A
 
For Stage* [n=128] 
 
R      = 1.00 
AN    = 0.60 (0.2) 
S       = 1.19 (0.4) 
P/PN = 2.67 (0.001) 
 
   Dukes‟ C = 1.64 (0.05) 
   Dukes‟ D= 3.22 (0.001) 
 
? AN = S  (p = 0.06) 
 
For Stage* and Liver 
Involvement [n=123] 
 
R      = 1.00 
AN    = 0.57 (0.2) 
S       = 1.14 (0.5) 
P/PN = 2.64 (0.001) 
 
  Dukes‟ C = 1.59 (0.06) 
  Dukes‟ D = 3.19 (0.002) 
 
    Liver Involved  = 0.95  
                                 (0.8) 
For Lymph node status
 
and Liver Involvement [n=127] 
 
R      = 1.00 
AN    = 0.69 (0.4) 
S       = 1.43 (0.1) 
P/PN = 3.03 (<0.001) 
 
   0 involved    = 1.00 
  1-3 involved = 1.07 (0.8) 
  4-9 involved = 1.87 (0.02) 
  >9 involved  = 3.71 (>0.001) 
 
    Liver Involved   = 0.83 (0.4) 
C
A
1
9
-9
 
For Age [n=146] 
 
R      = 1.00 
AN    = 0.50 (0.004) 
S       = 1.19 (0.4) 
P/PN = 1.88 (0.08) 
 
   For one year = 0.99 (0.4) 
 
For Stage* [n=125] 
 
R      = 1.00 
AN    = 0.43 (0.001) 
S       = 0.96 (0.9) 
P/PN = 2.14 (0.06) 
 
   Dukes‟ C = 1.77 (0.03) 
   Dukes‟ D = 4.74 (<0.001) 
 
? AN = S  (p = 0.001) 
 
For Liver Involvement 
[n=140] 
 
R      = 1.00 
AN    = 0.48 (0.003) 
S       = 1.14 (0.5) 
P/PN = 1.66 (0.2) 
 
   Liver Involved = 0.95  
                                (0.8) 
 
For Stage* and Liver 
Involvement [n=120] 
 
R      = 1.00 
AN    = 0.37 (<0.001) 
S       = 0.90 (0.7) 
P/PN = 2.06 (0.08) 
 
  Dukes‟ C = 1.77 (0.03) 
  Dukes‟ D = 4.89 (<0.001) 
 
    Liver Involved = 0.91  
                                 (0.7) 
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(4) Discussion 
 
(4.1) Tumour Markers Leading up to Advanced Disease 
Diagnosis 
 
(4.1.1) Breast Cancer 
When looking at tumour marker lead times results are often limited by small 
sample sizes [105, 109] and our results are no exception. Lead times could be 
measured in relatively few ladies (17) in all cases the three main reasons for 
the exclusions were that marker level at ADD was not raised (Table 14), that 
there was no previous tumour marker measurement and finally that the 
previous marker level was ≤ the upper limit of normal (ULN). When we look at 
the results in Table 14 and Figure 9 we can see that CEA appears to have the 
longest lead time (if the patients where CA15-3 increase does not appear to be 
exponential are discounted) followed by CA15-3 and lastly CA19-9. If amended 
lead time was used then CA15-3 lead time was found to be the similar to that 
found by Molina et. al. in 1996 [108] (4.3 months compared with 4.8 months – 
Table 5) which are much more reliable results as they are derived from a 
sample of 89 individuals who developed advanced breast cancer rather than 
12. The results obtained for CEA also appear comparable to those quoted in 
Table 5 but I could find no previous results concerning CA19-9 lead times in 
breast cancer patients. As there are so few individuals in all 3 of our analyses 
these results cannot be relied upon with any degree of certainty. 
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(4.1.2) Colorectal Cancer 
Lead times could be measured in 36 individuals; the 3 main reasons for 
exclusion remained the same as in the breast cancer patients and are shown in 
Table 19. When we look at the results in Table 19 and Figure 24 we can see 
that CEA again appears to have a longer median lead time (4.5 months) than 
CA19-9 (3 months) a result which tallies with the lead times of other studies 
which are shown in Table 9 [136, 152-154, 156] however these are mean lead 
times and when we compare them with our mean lead times (again in Table 
19), these appear to be generally longer than those quoted in Table 9. Despite 
this CEA and CA19-9 appear to have similar doubling times (2 months) but 
again the numbers used in this study are relatively small compared to those in 
Table 9. 
 
Other studies have shown that CA19-9 is less effective than CEA at early 
identification of colorectal cancer recurrence [156] and our results support this, 
as can be seen from Table 19. Despite analysing almost the same number of 
patients, more patients were excluded from the CA19-9 analysis than from the 
CEA analysis as a result of having normal marker levels at the time of 
advanced disease diagnosis.  
 
 
 
 
 
 158 
(4.2) At the Time of Advanced Disease Diagnosis and First and 
Second Chemotherapy Regimens 
 
(4.2.1) Breast Cancer 
At advanced disease diagnosis only CEA was found to have significantly 
different marker levels measured before and after the marker assay change of 
2004 (Table 13). The same was seen for CEA and CA19-9 at chemotherapy 
one but none of the markers at chemotherapy two. This could be because the 
marker ranges shown in Figures 7 and 13 undergo the largest change for CEA, 
the results could also be affected by the relatively small numbers in the post-
marker change groups. Disregarding the post-marker change results the 
sensitivity of CEA and CA15-3 at advanced disease diagnosis was 54% and 
68% respectively (Table 13), these results were comparable, although towards 
the higher end of the figures quoted by other studies in Table 5 (Introduction). 
This could be because the time when sensitivity was measured in these studies 
was not uniform, Molina et. al. [97] recorded raised markers before advanced 
disease was diagnosed whereas the time of measurement was not stated by 
Luaro et. al. [99], however the sensitivity of CA15-3 correlates quite closely with 
estimates made by other reviews [35, 83]. The Sensitivity of CA19-9 was the 
lowest at 28% which again could not be compared with other results as none 
were found.  
 
As can be seen from Figure 15 and Table 16 a panel of all 3 tumour markers 
appeared to be the most sensitive in terms of proportion of patients with a 
tumour marker raised at advanced disease diagnosis (ADD) but the sensitivity 
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was not significantly different to that of CEA and CA15-3 without CA19-9 which 
was 80.8% (95% CI for the difference = - 6.5% to 14.1%, p=0.5). This 
sensitivity is higher than the 55.2% reported one study [112] and 75% quoted 
by two others [106, 110] despite the fact that one of these studies involves only 
patients with distant metastases [110] and so sensitivity here would be 
expected to be high.  
 
Both of these marker combinations (CEA - CA15-3 and all three markers) were 
significantly more sensitive than the best single tumour marker CA15-3 (p=0.05 
and 0.009 respectively) although for CEA-CA15-3 this significance was 
borderline. We found that the most sensitive single marker in those we looked 
at was CA15-3 (69.2% [95% CI = 60.4%-78.1%]) which was raised in 
significantly more people than had raised CEA at this time (95% CI for the 
difference -34.5% to -7.7%, p <0.005) and this fits with previous results 
displayed in Table 5 [112, 113]. CA19-9 alone was the least sensitive marker 
(27.9%) and this was found to be significant (95% CI for the difference between 
CA19-9 alone and CEA alone = 7.0% to 33.4%, p<0.005). 
 
Guadagni et. al. (2001) found that overall in a study of 2191 patients with breast 
disease (in 1453 cases this disease was malignant) adding CEA to CA15-3 
only increased the overall sensitivity of these two markers by 1.4% [204], in 
contrast to this Molina states that “most reports indicate that by using CEA as 
well as CA15-3 it is possible to increase sensitivity by 7% to 20% compared to 
that obtained with CA15-3 alone” [83]. We found that by adding CEA to CA15-3 
the sensitivity of CA15-3 increased by 11.5% from 69.2% to 80.8% (95% CI for 
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the difference = -0.2% to 23.4%, p=0.05), a borderline significant increase but 
one which was more compatible with the findings of Molina et. al. (2006) [83]. 
 
Tumour marker panels at the start of chemotherapy one and two share the 
same pattern of sensitivity as the tumour markers measured at the time of 
advanced disease diagnosis. As we would expect the sensitivity of the marker 
panels shown in Figures 8, 11, 14 and the summary graph in Figure 15 appears 
to rise between advanced disease diagnosis and the start of chemotherapy one 
and again between the start of chemotherapy one and the start of 
chemotherapy two and this is the case in all of the panels apart from CA19-9 
alone where the sensitivity is the same at chemotherapy one and two. Despite 
this apparent trend Table 16 shows that there was no significant difference 
between the proportion of patients with raised tumour markers at diagnosis of 
advanced disease and the proportion with raised markers in the same tumour 
marker panel at the start of chemotherapy regimen. The only exception was 
CEA alone where the difference was 21.5% (95% CI for the difference - 38.8% 
to - 4.2%, p=0.01), no significant difference in the sensitivity of this marker was 
found between the start of chemotherapy one and two.  
 
Again looking at Figure 15 but this time for chemotherapy one and two a panel 
of all 3 tumour markers appeared to be the most sensitive in terms of proportion 
of patients with a tumour marker raised at advanced disease diagnosis (ADD) 
but by looking at Table 16 we can see that in each case this sensitivity was not 
significantly affected by excluding CA19-9 from the marker panels (p=0.7 and 
1.0 respectively). At the time of chemotherapy one only the tumour marker 
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panel containing all 3 tumour markers was found to be significantly more 
sensitive that CA15-3 alone (which was again the most sensitive single tumour 
marker) and this was only borderline significance. The difference between the 
panel containing CEA and CA15-3 and that containing only CA15-3 did not 
reach significance. However at the time of chemotherapy two, as with 
advanced disease diagnosis, both of these tumour marker panels contained a 
raised marker significantly more often than CA15-3 alone (the significance of 
these results was borderline in both cases). At chemotherapy two it is also 
interesting to note that CA15-3 alone was no longer found to be significantly 
more sensitive than CEA (95% CI for the difference -24.7% to 11.7%, p =0.5) 
possibly as a result of the smaller sample size (n=46) meaning that a larger 
difference in proportion was needed before significance was reached. CA19-9 
alone was always the least sensitive marker and this was significant in all 
cases. 
 
(4.2.2) Colorectal Cancer 
Neither of the markers had significantly different marker levels pre- and post-
marker assay change at advanced disease diagnosis (Table 18). At the start of 
chemotherapy one and two the only marker where a borderline significant 
difference was found was CEA at the time of chemotherapy two (Table 20).  
 
The sensitivities of the markers at each time point can be seen in Figures 23, 
25, 27 and they are combined in Figure 28. At advanced disease diagnosis the 
sensitivity of CA19-9 which we calculated appeared to be a little higher than 
those quoted by other studies and shown in Table 9 (Introduction) however our 
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CEA results appear comparable with those quoted in this table [136, 151-158]. 
At all three time points (advanced disease, chemotherapy one and 
chemotherapy two) the sensitivity of CA19-9 was significantly lower than CEA 
alone and CEA and CA19-9 combined (Table 21, Figure 28). At all time points 
the addition of CA19-9 to CEA appeared to increase its sensitivity only 
marginally however this increase never reached a significant level. This finding 
is similar to that of Fiella et. al. (1994) [156].  
 
Tumour marker panels at the start of chemotherapy one and two share the 
same pattern of sensitivity as the tumour markers measured at the time of 
advanced disease diagnosis in that there is a gradual increase in sensitivity 
between a marker panel at advanced disease diagnosis and the same panel at 
the start of chemotherapy one and a further increase in sensitivity from this time 
point to the start of chemotherapy two (Figure 28). Significant differences in the 
proportion of patients with raised tumour markers at any of these time points 
were seen with CEA alone and CA19-9 alone where the proportion with a 
raised marker level at advanced disease diagnosis was not significantly 
different to the proportion at chemotherapy one but for CEA alone both of these 
were significantly less than the proportion of patients with a raised marker at 
chemotherapy two (95% CI for the difference between chemotherapy one and 
two = -19.5% to -1.7%, p=0.02). For CA19-9 alone the sensitivity was 
significantly greater at chemotherapy two than at advanced disease diagnosis 
but no difference was found between chemotherapy one and two. This 
progressive increase of the proportion of patients with raised markers as the 
disease progresses from identification, to chemotherapy one, and then 
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chemotherapy two is expected in patients with both breast and colorectal 
cancer if tumour marker levels relate to tumour burden, because tumour burden 
would also be expected to increase between these time points. More patients 
are needed in all cases to see if these differences do reach significance. 
 
(4.3) Response to Chemotherapy Given in Advanced Disease 
 
(4.3.1) Breast Cancer 
CA15-3 had the fewest, and CA19-9 had the most patients, whose tumour 
markers were categorised as Always Normal (AN) and this was the case at 
chemotherapy one and chemotherapy two (Figure 17 and 19). This indicates 
that CA15-3 has more potential to provide useful information about response to 
treatment than CA19-9 as AN markers do not provide any indication of disease 
state over time. 
 
We found that survival varied significantly across Rustin categories of tumour 
marker response for all three tumour markers following the first chemotherapy, 
as the Kaplan-Meier graphs in Figure 18 and the results of the log-rank tests in 
Table 22A demonstrate, this finding is similar to those of Rubach et. al. (1997) 
who found significant differences in survival between patients whose CEA and 
CA15-3 marker movements were categorised as normal, decreasing, 
fluctuating or increasing [9] (Table 7, Introduction). The results of the Cox‟s 
proportional hazards regression model are shown in Table 24, this model picks 
apart the difference in survivals according to tumour marker response category 
or radiological staging producing a hazard ratio (HR) for survival for each 
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category. Following chemotherapy one, hazard ratios (HRs) for individuals with 
stable (S) CEA and those with progressive (P) CEA (either progression or 
progression from within the normal range) were 2.8 times and 10.0 times 
respectively that of individuals with responsive (R) markers. Individuals with 
markers always within the normal range (AN) did not have a significantly 
different hazard ratio to responders however it was significantly (p= 0.04) 
different to those with stable (S) markers. Unlike CEA the difference in the 
hazard ratios (HRs) of CA15-3 and CA19-9 only reached significance when 
comparing R and P (HR=8.89 and 5.75 respectively and p ≤0.001 in both 
cases). This was also the case for radiological response where P had a 
significantly worse HR than S or R. In all tumour markers AN appears, although 
not significant, to have a greater HR than R indicating that this may be a worse 
prognostic indicator in patients with breast cancer. This finding is echoed by the 
median survivals shown in Table 22A and Figure 35A but it is impossible to 
confirm from our results as the wide confidence intervals of Figure 35A show. 
 
Following chemotherapy two, Cox‟s analysis for CEA and CA19-9 (Table 24) 
showed that in both cases only P now showed a significantly different HR from 
R (HR=7.95, p =0.001 and HR=9.00, p =0.002 respectively). This was no 
change for CA19-9 but a change for CEA as at chemotherapy one S was also 
significantly different from R, this may reflect a real change in the significance 
of having stable markers at this point but the HRs at the two time points are 
similar so it may or may have arisen as a result of the fewer patients available 
for analysis at chemotherapy two. CA15-3 marker response now showed that S 
alone had a significantly greater HR than the patients whose CA15-3 showed R 
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(HR=2.88). I would have expected patients whose markers showed progression 
to also have a significantly increased HR over the responders however this 
anomaly may be due to the anomalous length of survival of one of the patients 
who had progressive CA15-3 (Figure 20C). The HRs for radiological response 
at chemotherapy two did not reach statistical significance (P had a borderline 
significant HR at 2.81) but were similar to HRs at the time of chemotherapy 
one. The lack of statistical significance at this time is not surprising as the result 
of the log-rank test shown in Figure 21B was also not significant possibly as a 
result of the small numbers of people (n=29) where survival and radiological 
response could be measured at this time.  
 
By looking at the results of Akaike‟s information criterion (AIC) (a test of how 
well a statistical model fits the data) shown in green in Table 24 we can see 
that at chemotherapy one the radiological response model has the best fit when 
we include AN in the tumour marker models. However when this group is 
removed CEA and CA19-9 response become better models than the radiology. 
The same pattern is seen at chemotherapy two with radiological response 
fitting the data better than tumour marker response until AN is excluded 
resulting in the CA19-9 response model alone becoming a slightly better model. 
In all cases CA19-9 goes form being the worst model to the best, possibly 
because as previously stated so many patients in this group have AN markers 
and when these are excluded the markers which respond one way or another 
reflect the disease state well. The removal of the AN from CA15-3 had little 
effect on this model. This is an unexpected finding as in most other studies 
CA15-3 appears to correlate with clinical course better than CEA [65, 99, 112] 
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(although the opposite was found by Blijlevens et. al. In 1995 [105]), however 
this correlation with the course of the disease does not appear to translate into 
better correlation with the survival model as shown by the AIC scores of CA15-
3 compared with CEA (Table 24). 
 
Following adjustment according to possible confounding factors (Table 25) 
lymph node status had no significant effect on the results of the Cox‟s analysis 
in Table 24 for CEA or CA15-3 but it did for CA19-9 where, following 
adjustment, patients with stable (S) as well as P marker changes for CA19-9 
now had significant HRs compared with P alone in the unadjusted analysis (S 
was not found to be statistically different from AN, p =.0.2). None of the HRs for 
lymph node status reached statistical significance so we cannot say that the 
original nodal status of the tumour had any detectable influence upon the 
survival according to the Rustin category of response of any of the markers. 
These results could have occurred because lymph node status has little 
bearing on the reaction of tumour markers to chemotherapy or could reflect the 
change in nodal testing over time, the variation in nodes tested varies greatly 
between individuals possibly making this a less accurate measure of disease 
extent, there is also the possibility that by grouping nodal status into an ordinal 
scale as we did some small effects have not become apparent. Adjusting for 
Liver involvement alone and liver involvement and lymph node status together 
we concluded that liver involvement also had no significant effect upon any of 
the marker responses however had the same effect upon the CA19-9 S 
patients as lymph node status alone. 
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As has been shown by previous studies Marker changes can reflect the clinical 
course of advanced breast cancer (Table 6) some of those use a 20 or 25% 
definition of response and progression [65, 105, 112] some less than this [122] 
(Robertson et. al. Used both 10 and 20% changes as the basis for a scoring 
system which they related to response [110]), some use more complex 
measures such as “the inter-assay coefficient of variation” [123] and in other 
studies the measures of response evaluation are not clear [99]. When we 
compared how Rustin response corresponded with radiological response 
(Table 17) CA19-9 had the lowest sensitivity at chemotherapy one and CEA 
had the lowest at chemotherapy two, CA15-3 had the greatest sensitivity at 
both chemotherapy one and two (40.7% and 66.7% respectively) but this did 
not reach the sensitivity of the original Rustin response criteria in ovarian 
cancer which is quoted as having a sensitivity of 92%, the same paper also 
quotes a specificity of 72% [40] and we found CEA, CA15-3 and CA19-9 to 
have a greater specificity than this at chemotherapy one and two in patients 
with breast cancer. CA15-3 also had the greatest PPV and NPV at these time 
points. 
 
Table 17 also shows the concordance of tumour marker progression and 
radiological progression, Rustin progression reflects radiological progression 
with a specificity of >90% for all three tumour markers following chemotherapy 
one and >93% following chemotherapy two which is comparable to the Rustin 
response categories in ovarian cancer which have been shown to have 
specificities of ≥ 98% [3]. The sensitivities however, are not as comparable and 
the highest reached is 33.3% by CEA at chemotherapy two compared with 82% 
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[3] or 85.9% [5] for the original Rustin response criteria in epithelial ovarian 
cancer. These sensitivities are also lower than those quoted by Robertson et. 
al. (1991) however they combined markers in a panel with ESR and, unlike our 
results they also found no significant difference in survival between progressors 
and non-progressors [122]. Our sensitivities are also lower than those reported 
by Dixon et. al. (1993) who used the same marker panel but who also used a 
complex method scoring and of categorisation that would be difficult to use 
clinically [123]. Some other papers are difficult to compare as they divide 
patients into those with normal and abnormal baseline levels [65]. 
 
In order to get a better feel for the correlation between Rustin response and 
radiological staging results of the Spearman rank correlation can be seen in 
Table 24. The only marker where Rustin response showed a significant 
correlation with radiological stage following chemotherapy one was CA15-3 
which compares favourably with the findings of Guadagni et. al. (2001) who 
(unlike us) found that both CEA and CA15-3 paralleled response to treatment 
but this was significantly more powerful in CA15-3 [204]. We found that the 
correlation for CA15-3 was not strong (rs = 0.28) and the significance was 
borderline p=0.048, however a stronger correlation between these two factors 
was seen following the second chemotherapy regimen (rs = 0.44, p=0.02) and 
at this point in time a moderate correlation was also seen between CA19-9 
response and radiological staging (rs = 0.38, p=0.04), a correlation was also 
seen between CEA category and radiological stage (rs = 0.34) but this did not 
reach significance. Radiological stage was assessed as described in the 
Materials and methods section and as such may have been subject to error of 
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interpretation. It is also worth noting that there appears to be some difference in 
survival according to radiological response at chemotherapy one but no 
significant difference following chemotherapy two (log-rank test p=0.003 and 
0.2 respectively) as can be seen Figure 21 possibly as a result of the reduced 
number of patients eligible for analysis at this point (n=29 compared with 61). 
 
It is worth noting that like other studies we found one breast cancer (and one 
colorectal cancer) patient where there was a marker surge followed by a 
decline [118, 124] (other discrete kinetic patterns of tumour markers were also 
seen by Sonoo et al (1996)) this phenomenon is though to be attributable to 
tumour lysis and was discounted.  
 
(4.3.2) Colorectal Cancer 
As Table 10 shows (Introduction) there is already a body of evidence which 
indicates that CEA progression correlates with disease progression [157, 166, 
173] and that CEA kinetics relate to differences in survival [180, 181, 185] but 
fewer papers include CA19-9 [157, 161, 166]. As is the case with breast cancer 
studies there appears to be little consistency in the measures of response and 
progression within these articles, some studies simply look at a rise [173] or fall 
[180] in the marker level whilst others used a 10% [161], 25% [158], 35% [166] 
or 36% [182] increase or decrease. Most papers are very guarded in their 
recommendation of the use of tumour markers to monitor response to 
treatment, for example Trillet-Lenoir et. al. (2004) state that to assess the 
response of metastatic CRC to chemotherapy, CEA alone or in combination 
with CA19-9 (in adition to CT) “should be used with caution in common 
 170 
practice“ [161] and Hanke et. al. (2001) who state that “a CEA or CA19-9 rise is 
only conditionaly apropreate for recording progressions“ [157].  
 
Our results show that, as was the case in patients with breast cancer, for both 
chemotherapy one and two CA19-9 was the marker where the greatest number 
of patients were classified as having Always Normal (AN) tumour markers 
(Figure 30 and 33). For both CEA and CA19-9 survival was found to vary 
significantly across Rustin categories of tumour marker response following the 
first chemotherapy as the Kaplan-Meier graphs and results of the log-rank tests 
demonstrate in Figure 31 and Table 22B. This was not the case at the time of 
chemotherapy two where no significant difference in survival was detected 
(Figure 34 and Table 22B). 
 
Results of the Cox‟s regression analysis (Table 24) for CEA suggested that an 
AN response may be better in terms of survival than R but this did not reach 
statistical significance (HR=0.61, p=0.2). The only HR which was significantly 
different from R was that for P (HR=2.51, p<0.001). The difference between AN 
and S was not found to be significant (p=0.07).  
 
It was found that for CA19-9 AN markers appear to be better in terms of 
survival than R and this time results did reach significance (HR=0.53, p=0.006). 
This finding in patients with colorectal cancer is reinforced by Table 22B which 
appears to show that median survival in colorectal cancer patients was longer 
in those whose markers are AN as opposed to the breast cancer patients 
(Table 22A) which appear to have longer mean survival if there is tumour 
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marker response (R) following chemotherapy one. Despite this as Figure 35 A 
and B show because of the relatively small numbers and large variation within 
the samples these findings cannot be confirmed. 
 
Cox‟s regression analysis for CA19-9 was the only instance following 
chemotherapy one where P was not found to have a significantly different HR 
from R (Table 24), this could be due to the long survival of a patient who had 
progression according to CA19-9 (this outlier can be seen in Figure 31C). This, 
combined with the fact that the Cox‟s proportional hazards model assumes 
constant ratio of hazard to outcome over time and this may not be strictly true 
for the Kaplan-Meier graph in Figure 31C, may have affected the results in this 
case. Radiological response follows the usual trend where the HR for survival 
for P was significantly different from the HR for both S and R (which were not 
significantly different from each other). 
 
Following chemotherapy two no significantly different hazard ratios could be 
found for any of the responses in either of the tumour markers, P did however 
have a significantly worse HR for survival than S or R when radiological 
response was analysed )and this analysis was based on the data from fewer 
patients). As was seen with the results for chemotherapy one, and although 
significance was not reached, in both cases the HRs for AN were less than 
those of R. This indicates that in patients with colorectal cancer, unlike those 
with breast cancer, having a CEA or CA19-9 level which remains AN may 
confer a survival advantage, even over patients who have responsive tumour 
markers. This is an interesting finding particularly as it correlates with the 
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findings of Rubach et. al. (1997) whose results indicated (but did not confirm) 
that there may be a survival advantage in having marker levels within the 
normal range compared to markers which decrease [9] (Table 7, Introduction). 
It is also important to note that in our results although at chemotherapy one AN 
breast cancer patients had greater HRs than the HRs in responsive patents 
(non of these reached significance), following chemotherapy two median 
survivals were longer for AN patients than they were for responders in the case 
of CEA and CA19-9.  
 
By looking at the results of Akaike‟s information criterion (AIC) in Table 24 we 
can see that at chemotherapy one the radiological response model has the best 
fit when we include AN in the tumour marker models (as with the breast cancer 
patients) and the markers are similar to each other in their level of fit. However 
when the AN group is removed CA19-9 response becomes a slightly better 
model than the radiology. At Chemotherapy two radiological response is the 
best fitting model both before and after removal if the AN groups. Although 
removal of the AN group in all cases (breast and colorectal cancer) improves 
the AIC score and therefore the „fit‟ of the model it is not possible yet to predict 
which patients will fall into this category of response and so it can only be 
applied following the tumour marker response, this may be a useful tool 
retrospectively rather than clinically. 
 
In both breast and colorectal cancer patients the „goodness of fit‟ of the models 
(both radiological and tumour marker) as assessed by AIC is better following 
the second chemotherapy than following the first possibly because the 
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individuals included at chemotherapy two go on to have fewer further 
chemotherapy regimens, compared to those included at chemotherapy one, 
which can influence their survival, therefore the difference in survival which is 
seen could reflect the changes in disease state which occur at the time of this 
chemotherapy regimen more accurately. 
 
When the results of the Cox‟s analysis of CA19-9 Rustin response following 
chemotherapy one was adjusted (Table 25) for age this was found to have no 
significant effect on the results, however when tumour stage was taken into 
account a significant result was seen for both CEA and CA19-9, this is not a 
total surprise as raised levels of both CEA [133, 135, 144, 145] and CA19-9 
[135] have been shown to correlate with tumour stage in localised disease. A 
greater original tumour stage was associated with an increased HR from 
Dukes‟ A/B to Dukes‟ C - HR=1.64, p=0.05 and from Dukes‟ A/B to Dukes‟ D 
HR=3.22, p=0.001 for CEA, and Dukes‟ A/B to Dukes‟ C - HR=1.77, p=0.03 
and from Dukes‟ A/B to Dukes‟ D HR=4.74, p<0.001 for CA19-9. Despite this 
the significance of the findings did not greatly affect the results of the Cox‟s 
analysis (the HR of AN remained significantly below R for CA19-9 and the HR 
of P remained significantly above R for CEA).  
 
In the past studies have found that raised CEA levels correlate with the 
presence [145, 153, 166, 172, 173], or size [174], of liver metastases and some 
studies have also found a link between them and raised CA19-9 [155]. It is also 
known that CA19-9 can become raised in benign liver disorders such as 
cirrhosis and benign obstructive jaundice [35] as can CEA [43] as clearance of 
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this tumour marker occurs in the liver [49] (CA15-3 may also become raised in 
liver cirrhosis [68]), and we wanted to ensure that any significant correlation 
between tumour marker response and survival was not being influenced by the 
presence of liver metastases so our results were tested to see if liver 
involvement could have any effect upon the results. As was the case with the 
breast cancer patients, liver involvement had no significant effect on the results.  
 
In contrast to liver involvement, increased Lymph node status did appear to be 
associated with significantly larger HRs in patients with 4-9 or >9 involved 
nodes, this test was only done in CEA at this time. This is an interesting finding 
as CEA and CA15-3 levels have been shown to correlate with lymph node 
status in patients with breast cancer [98] and yet as can be seen from Table 25 
they had no bearing upon CEA or CA15-3 response in breast cancer patients 
but a link was seen in CEA marker response in colorectal cancer patients. 
 
When comparing Rustin category and radiological staging, tumour marker 
response reflected radiological response as can be seen in Table 23 we found 
that our CEA response criteria had a lower sensitivity than that of Wang et. al. 
(2001) who also used a 50% reduction criteria and found that this had a 
sensitivity of 72% when detecting true imaging responses and a PPV of 53%  
[184] compared to 51% and 67.6% respectively in our results following 
chemotherapy one, this may have been because Wang et. al. required that the 
fall in CEA to be maintained for at least 4 weeks whereas we did not. We found 
CEA to be more sensitive at identifying radiological response than CA19-9 at 
both chemotherapy one and two but sensitivities for both were considerably 
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lower than the sensitivity of the original Rustin response criteria (92% [40]). The 
lowest specificity was 73.0% (CA19-9 at chemotherapy one) which was 
comparable to the 72% quoted for the original response criteria in ovarian 
cancer [40]. 
 
Progression as defined by our modified Rustin criteria correspond with 
radiological progression with a specificity of ≥93% for both tumour markers 
following chemotherapy one and chemotherapy two which is comparable to the 
original Rustin criteria (specificities ≥ 98% [3]). As with the breast cancer 
patients, the sensitivities however, are not as comparable. The highest reached 
is 36.8% by CEA at chemotherapy two compared with 82% [3] or 85.9% [5] for 
the original Rustin criteria in epithelial ovarian cancer. 
 
At chemotherapy one and two survival varied significantly according to 
radiological response (Figure 36A and B) unlike marker response in breast 
cancer, CEA and CA19-9 Rustin response also showed a significant correlation 
with radiological staging as can be seen by the results of the Spearman rank 
correlation in Table 24. At both points in time this correlation was stronger for 
CEA (rs = 0.45 and 0.43 respectively) than for CA19-9 (rs = 0.26 and 0.35 
respectively). This leaves a paradox within our results at the time of 
chemotherapy two because Figure 36B shows that survival differs significantly 
according to radiological staging but Figures 34A and B and Table 24 show that 
these differences do not reach significance according to Rustin categories and 
yet there is a significant correlation between radiological response and Rustin 
response categories at this time (Table 24). It is possible that with the inclusion 
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of more individuals a significant association between tumour marker response 
and survival may have been found because the HRs following chemotherapy 
one are similar to those following chemotherapy two but these calculation are 
based upon more than twice the number of individuals. 
 
(4.4) Limitations of the Analysis 
 
Many reviews point out flaws in the existing literature implicating poor study 
design leading to confounders and reliance on P values [205] in the lack of 
consistency in the evidence for the efficacy of tumour markers. In the updated 
ASCO guidelines published in 2006 looking at markers in gastrointestinal 
malignancies the authors state that “the literature is characterised by studies 
that included small patient numbers, studies that were retrospective, and 
studies that commonly performed multiple analyses until one revealed a 
statistically significant result” [188]. Some parts of our analysis were 
underpowered and all were retrospective, which can lead to best fit results, 
both of which could have lead to errors. Human error in copying figures (e.g. to 
and from data collection sheets) and in performing calculations could also have 
lead to some inaccuracies although checking aimed to minimise this wherever 
possible. In some areas such as Tables 16 and 21 there has also been multiple 
testing. 
 
The analysis of tumour marker response and survival was vulnerable to 
inconsistencies from four main areas: firstly it was based heavily upon the first 
marker level, if this marker level happened to be an anomalous result then this 
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could have a profound effect upon the perceived tumour marker response. 
Secondly, marker levels were not measured at uniform intervals so could have 
all been clustered together in the first 3 weeks of analysis. This could result in 
the recorded tumour marker response differing from the true nature of the 
tumour marker change. Thirdly, according to our criteria of response and 
progression definition of progression does not require a confirmatory marker 
level if patient dies before a further marker level is taken whereas definition of 
response does require a confirmatory marker level. Fourthly, the change of 
marker assays may have introduced a further source of error, however by 
graphing and looking at each marker change individually (in Figures 16, 29 and 
32) this has hopefully been minimised. 
 
The definition and categorisation of radiological stage within this study was 
subjective and not comparable to the way radiological response is categorised 
in clinical practice. In this study if radiological disease progression was seen in 
one area and disease response was seen in another I categorised the disease 
status as stable. However, clinically the lesion which sowed the worst response 
to treatment would be used and this case would be classed as progressive 
disease. The information regarding radiological response was purely included 
in this study to give an indication of the correlation between both radiological 
changes and tumour marker movement in response to chemotherapy 
treatment. 
 
Within our methods there were slight deviations from the true Rustin response 
criteria which state that the for Rustin response to be confirmed the 50% fall in 
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tumour markers “must be confirmed and maintained for at least 28 days” [41] 
and of course the inclusion of the “progression from within the normal range” 
patients with truly Progressive patients  
 
Although Data about factors such as involvement of the apical/highest node, 
lung, brain or bone involvement, ER/PR/Her2 status in breast cancer patients 
and position of the original tumour in colorectal cancer patients were collected 
they were not included in the Cox‟s proportional hazards regression model 
analysis due to time pressures. Data on other factors such as performance 
status and disease free interval was not collected and so it is possible that 
there are confounding factors which have not been identified by this analysis. 
These potential confounding factors could also be a further source of error 
because the properties of the primary tumour were usually taken from the 
original histology and in some cases there had been neo-adjuvant therapy 
given prior to this which may have down staged the tumour. 
 
(4.5) Further Work 
 
It would be valuable to conduct a study prospectively to see if tumour marker 
kinetics still correspond with survival, the true extent of this correspondence 
and how tumour marker kinetics relate to clinical course as defined by RECIST 
criteria.  
 
It is important to establish how soon after initiation of chemotherapy tumour 
marker kinetics can be shown to be indicative of response to treatment. 
Depending upon the results of this analysis treatment could be modified 
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according to tumour marker kinetics to investigate if this can affect tumour 
marker movement in the first instance, and because it has been shown that 
kinetics do relate to survival [157], if this can affect survival as has been 
indicated by other studies using small samples e.g. Dixon et al (1993) who 
found that directing chemotherapy according to tumour marker response was 
“associated with a significant lengthening of remission duration and an 
improved quality of life and survival” [123]. Treatment in a tumour marker 
directed way such as this is currently being investigated in the OVO5 phase III 
clinical trial in recurrent ovarian cancer which aims to investigate if there is a 
difference in patient survival in patients whose chemotherapy treatment is 
initiated when clinically indicated compared to patients where chemotherapy is 
initiated in a tumour marker dependant manner CA125. This trial is currently 
closed to recruitment but still in the follow up phase, preliminary results have 
not yet been published [206]. 
 
Adding other possible confounding factors to the Cox‟s proportional hazards 
regression model to see which factors do appear to be linked with survival 
would also provide valuable information however there may need to be more 
patients included in this analysis before it produces accurate results. 
 
Crawford, Peace et al (2005) have already investigated the significance of 
CA125 nadir levels in ovarian cancer and found that patients whose CA125 
reaches a lower nadir level survive longer on average than those patients 
whose CA125 does not drop as low [39]. It would be interesting to how the 
nadir of each of the markers studied here relate to survival. 
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(5) Conclusion 
 
Many studies have small sample sizes [207] and the literature contains 
differences and inconsistencies in methodology which make it difficult to 
compare findings between studies and in some cases, makes their conclusions 
misleading. During this study I have further improved my analytical skills and 
have realised the importance of approaching the existing literature critically and 
thoroughly. Despite these issues there is an increasing body of evidence which 
suggests that although looking at “single and dichotomised” [111] tumour 
marker values in metastatic breast and colorectal cancer can provide some 
prognostic information, tumour marker kinetics may provide valuable 
information about disease response to therapy [118] which has also been 
associated with significant differences in survival [9]. Some work has been 
done in other disease sites, for example the work of Yamao et. al. (1999) in 
gastric cancer [208] and of course the work of Rustin and colleagues in ovarian 
cancer [1-5] and some criteria have been laid down by the EGTM who in their 
recent report into tumour markers in colorectal cancer conclude that “ the 
clinical use of existing markers should be optimised” [189] citing the use of CEA 
in monitoring treatment for advanced disease as an illustration of this [189]. 
Because tumour markers provide a relatively low cost way of providing clinical 
information this is particularly important in the current financial situation within 
the NHS. 
 
By using modified Rustin response criteria in patients with advanced breast and 
colorectal cancer this study has identified a subset of patients, those with 
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progressive markers, where survival is significantly reduced compared with 
those with responsive markers. This is true for CEA, CA15-3 and CA19-9 at 
chemotherapy one and CEA, CA19-9 at chemotherapy two in breast cancer 
patients, and CEA at chemotherapy one in colorectal cancer patients. Using the 
same modified response criteria CEA and CA19-9 kinetics in colorectal cancer 
and CA15-3 kinetics in breast cancer have been found to correlate significantly 
with radiological response at chemotherapy one and two (CA19-9 response 
also correlates with radiological staging at chemotherapy two but not one in 
breast cancer). This may be particularly valuable clinically as it has been found 
that using RECIST criteria to interpret radiology results can delay the 
identification of disease progression when compared with WHO criteria [6, 7] 
and also with the advent of new therapies which may stabilise tumour growth 
initially rather than reduce it [8]. Despite this, radiological staging does appear 
to fit the statistical model better than any of the markers when patients with 
markers which are always normal are included. 
 182 
Appendices 
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Appendix A – Breast Cancer Data Collection Sheet 
 
Patient Tumour 
Patient 
Number 
 Tumour Differentiation  
Previous 
malignancy/ies and 
date/s of diagnosis/es 
 
Age at First 
Diagnosis 
 Tumour Grade (0 – IV)  
Trial  Tumour Stage (T N M)  
Death due 
to Breast 
Ca? 
 No of lymph nodes involved  
  Apical Node (free / Involved)  
  Oestrogen receptor status  
  Progesterone receptor status  
  Her 2 status  
      
Date 
Tumour marker levels Dates and types of 
Chemotherapy/Radiot
herapy/Hormone 
therapy Regimen (first 
and last dates, 
number of cycles, and 
if adjuvant or 
palliative) and dates 
and types of surgical 
procedure 
Test - 
Radiology/Histology  
Histology 
Number 
Results 
CEA CEA* CA15-3 CA15-3* CA19-9 CA19-9* CA125 
            
            
            
            
Continued            
* = Tumour marker levels following change of assay 
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Appendix B – Colorectal Cancer Data Collection Sheet 
 
 
 
Patient Tumour 
Patient Number  Tumour Differentiation  
Previous 
malignancy/ies and 
date/s of diagnosis/es 
 
Age at First 
Diagnosis 
 
Tumour Stage 
0 - IV  
Trial  T N M  
Death due to 
Colorectal Ca? 
 No of lymph nodes involved  
  Highest Node (free / Involved)  
      
      
Date 
Tumour marker levels Dates and types of 
Chemotherapy/Radiotherapy/Hormone 
therapy Regimen (first and last dates, 
number of cycles, and if adjuvant or 
palliative) and dates and types of 
surgical procedure 
Test - 
Radiology/Histology  
Histology 
No 
Results 
CEA CEA* CA19-9 CA19-9* CA125 
          
          
          
          
          
          
          
Continued          
          
* = Tumour marker levels following change of assay 
 185 
References 
 
1. Rustin, G.J., et al., Use of tumour markers in monitoring the course of 
ovarian cancer. Annals of Oncology, 1999. 10(Suppl 1): p. 21-27. 
2. Rustin, G.J., et al., Use of CA-125 to define progression of ovarian cancer 
in patients with persistently elevated levels. Journal of Clinical Oncology, 
2001. 19(20): p. 4054-4057. 
3. Guppy, A.E. and G.J.S. Rustin, CA125 Response: can it replace the 
traditional response criteria in ovarian cancer? The Oncologist, 2002. 7(5): 
p. 437-443. 
4. Rustin, G.J.S., et al., Defining response of ovarian carcinoma to initial 
chemotherapy according to serum CA 125. Journal of Clinical Oncology, 
1996. 14(5): p. 1545-1551. 
5. Rustin, G.J., et al., Defining progression of ovarian carcinoma during 
follow-up according to CA 125: a North Thames Ovary Group Study. 
Annals of Oncology, 1996. 7(4): p. 361-364. 
6. Therasse, P., E.A. Eisenhauer, and J. Verweij, RECIST revisited: A review 
of validation studies on tumour assessment. European Journal of Cancer, 
2006. 42: p. 1031-1039. 
7. Mazumdar, M., A. Smith, and L.H. Schwartz, A statistical simulation study 
finds discordance between WHO criteria and RECIST guideline. Journal of 
Clinical Epidemiology, 2004. 57(4): p. 358-365. 
8. Sohaib, A. A Brave New World - The opportunity and practicality of 
targeted therapy in renal cell cancer and future directions (How should we 
measure efficacy of tyrosine kinase inhibitors - is RECIST enough?). in 
National Cancer Research Institute Cancer Conference. 2006. 
Birmingham. 
9. Rubach, M., et al., Serum CA 15.3. CEA and ESR patterns in breast 
cancer. The International Journal of Biological Markers, 1997. 12(4): p. 
168-173. 
10. http://info.cancerresearchuk.org/cancerstats, Cancer Research UK. 2007. 
11. King, R.J.B., Cancer Biology. 2 ed. 2000: Pearson Education, Prentice 
Hall. 
12. Parsonnet, J., et al., Helicobacter pylori infection and the risk of gastric 
carcinoma. New England Journal of Medicine, 1991. 325(16): p. 1127-
1131. 
13. Baird, P.J., Serological evidence for the association of papillomavirus and 
cervical neoplasia. Lancet, 1983. 2(8340): p. 17-18. 
14. Kumpulainen, E.J., R.J. Keskikuru, and R.T. Johansson, Serum tumour 
marker CA 15.3 and stage are the two most powerful predictors of survival 
in primary breast cancer. Breast Cancer Research and Treatment, 2002. 
76: p. 95-102. 
15. Lindmark, G., et al., The association of preoperative serum tumour 
markers with Dukes' stage and survival in colorectal cancer. British 
Journal of Cancer, 1995. 71: p. 1090-1094. 
16. Gold, P. and S.O. Freedman, Demonstration of tumour-specific antigens 
in human colonic carcinomata by immunological tolerance and absorption 
techniques. The Journal of Experimental Medicine, 1965. 121: p. 439-462. 
 186 
17. Nicolini, A., et al., Prolonged survival by 'early' salvage treatment of breast 
cancer patients: A retrospective 6-year study. British Journal of Cancer, 
1997. 76(8): p. 1106-1111. 
18. Schneider, J., N. Bitterlich, and G. Schulze, Improved sensitivity in the 
diagnosis of gastro-intestinal tumours by fuzzy logic-based tumour marker 
profiles including the tumor M2-PK. Anticancer Research, 2005. 25(3A): p. 
1507-1515. 
19. Schneider, J., Tumour markers in detection of lung cancer. Advances in 
Clinical Chemistry, 2006. 42: p. 1-41. 
20. Bill-Axelson, A., et al., Radical prostatectomy versus watchful waiting in 
early prostate cancer. New England Journal of Medicine, 2005. 352: p. 
1977-1984. 
21. Tannock, I.F., et al., Docetaxel plus prednisone or mitoxantrone plus 
prednisone for advanced prostate cancer. New England Journal of 
Medicine, 2004. 351(15): p. 1502-1512. 
22. Jain, S., A.G. Bhojwani, and J.K. Mellon, Improving the utility of prostate 
specific antigen (PSA) in the diagnosis of prostate cancer: the use of PSA 
derivatives and novel markers. Postgraduate Medical Journal, 2002. 78: p. 
646-650. 
23. Antoniou, A., et al., Assessment of serum prostate specific antigen in 
childhood. BJU international, 2004. 93(6): p. 838-840. 
24. Thompson, I.M., et al., Prevalence of prostate cancer amond men with a 
prostate-specific antigen level < or = 4.0ng per millilitre. New England 
Journal of Medicine, 2004. 350: p. 2239-2246. 
25. Kehinde, E.O., et al., High serum prostate specific antigen levels in the 
absence of prostate cancer in Middle-Eastern men: the clinician's 
dilemma. BJU International, 2003. 91(7): p. 618-622. 
26. Stenman, U., et al., The clinical importance of free prostate-specific 
antigen (PSA). Current Oppinion in Urology, 1998. 8(5): p. 393-399. 
27. Stamey, T.A., et al., Prostate -specific antigen as a serum marker for 
adenocarcinoma of the prostate. New England Journal of Medicine, 1987. 
317(15): p. 909-916. 
28. Zyskowski, A., et al., Strontium-89 treatment for prostate cancer bone 
metastases : Does a prostate-specific antigen response predict for 
improved survival? Australasian Radiology, 2001. 45(1): p. 39-42. 
29. Brown, D.A., et al., Measurement of serum levels of macrophage inhibitory 
cytokine 1 combined with prostate-specific antigen improves prostate 
cancer diagnosis. Clinical Cancer Research, 2006. 12(1): p. 89-96. 
30. Colombo, N., et al., International Collaborative Ovarian Neoplasm trial 1:a 
randomised trial of adjuvant chemotherapy in women with early-stage 
ovarian cancer. Journal of the National Cancer Institute, 2003. 95(2): p. 
125-32. 
31. Winter-Roach, B., L. Hooper, and H. Kitchener, Systematic review of 
adjuvant therapy for early stage (epithelial) ovarian cancer. International 
Journal of Gynecological Cancer, 2003. 13(4): p. 395-404. 
32. Group, I.C.O.N., Paclitaxel plus carboplatin versus standard 
chemotherapy with either single-agent carboplatin or cyclophosphamide, 
doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 
randomised trial. Lancet, 2003. 360(9332): p. 505-515. 
 187 
33. McGuire, W.P., et al., Cyclophosphamide and cisplatin compared with 
paclitaxel and cisplatin in patients with stage III and stage IV ovarian 
cancer. New England Journal of Medicine, 1996. 334(1): p. 1-6. 
34. Bast, R.C., et al., A radioimmunoassay using a monoclonal antibody to 
monitor the course of epithelial ovarian cancer. New England Journal of 
Medicine, 1983. 309(15): p. 883-887. 
35. Duffy, M.J., New Cancer Markers. Annals of Clinical Biochemistry, 1989. 
26: p. 379-387. 
36. Moss, E.L., J. Hollingworth, and T.M. Reynolds, The role of CA125 in 
clinical practice. Journal of Clinical Pathology, 2005. 58(3): p. 308-312. 
37. Rossi, A.C., et al., A retrospective study of preoperative CA 125 levels in 
82 patients with ovarian cancer. Archives of Gynaecology and Obstetrics, 
2004. 269(4): p. 263-265. 
38. Crawford, S.M., et al. The prognostic significance of the CA125 nadir in 
patients that achieve a CA125 response. in American Society of Clinical 
Oncology Annual Meeting Proceedings. 2004: Journal of Clinical 
Oncology. 
39. Crawford, S.M. and J. Peace, Does the nadir CA125 concentration predict 
a long-term outcome after chemotherapy for carcinoma of the ovary? 
Annals of Oncology, 2005. 16: p. 47-50. 
40. Guastalla, J.P., et al., CA-125 evaluation of chemotherapy (Cx) response 
in patients with recurrent ovarian cancer (ROC): Rustin criteria revisited, in 
American Society of Clinical Oncology. 2002. 
41. Rustin, G.J.S., et al., Re: new guidelines to evaluate the response to 
treatment in solid tumours (ovarian cancer). Journal of the National 
Cancer Institute, 2004. 96(6). 
42. Hörig, H., et al., Strategies for cancer therapy using carcinoembryonic 
antigen vaccines. Expert Reviews in Molecular Medicine, 2000: p. 1-24. 
43. Goldstein, M.J. and E. Petterson Mitchell, Carcinoembryonic antigen in the 
staging and follow-up of patients with colorectal cancer. Cancer 
Investigation, 2005. 23: p. 338-351. 
44. Koprowski, H., et al., Colorectal carcinoma antibodies detected by 
hybridoma antibodies. Somatic Cell Genetocs, 1979. 5(6): p. 957-971. 
45. Bates, P.A., J. Luo, and M.J.E. Sternberg, A predicted three dimensional 
structure for the carcinoembryonic antigen (CEA). FEBS Letters, 1992. 
301(2): p. 207-214. 
46. Tynan, K., et al., Assembly and analysis of cosmid contigs in the CEA-
gene family region of human chromosome 19. Nucleic Acid Research, 
1992. 20(7): p. 1629-1636. 
47. Zimmerman, W., et al., Chromosomal localization of the carcinoembryonic 
antigen gene family and differential expression in various tumors. Cancer 
Research, 1988 48(9): p. 2550-2554. 
48. Blumenthal, R.D., H.J. Hansen, and D.M. Goldenberg, Inhibition of 
adhesion, invasion,and metastasis by antibodies targeting CEACAM6 
(NCA-90) and CEACAM5 (carcinoembryonic antigen). Cancer Research, 
2005. 65(19): p. 8809-8817. 
49. Bendardaf, R., H. Lamlum, and S. Pyrhönen, Prognostic and predictive 
molecular markers in colorectal carcinoma. Anticancer Research, 2004. 
24: p. 2519-2530. 
 188 
50. Shitrit, D., et al., Diagnostic value of CYFRA 21-1, CEA, CA19-9, CA15-3 
and CA 125 assays in pleural effusions: analysis of 116 cases and review 
of the literature. The Oncologist, 2005. 10(7): p. 501-507. 
51. King, J., et al., High serum carcinoembryonic antigen concentration in 
patients with colorectal liver metastases is associated with poor cell-
mediated immunity, which is predictive of survival. British Journal of 
Surgery, 1997. 84(10): p. 1382-1385. 
52. Reddish, M.A., et al., Epitope mapping of Mab B27.29 within the peptide 
core of the malignant breast carcinoma-associated mucin antigen coded 
for by the human MUC 1 gene. Journal of Tumour Marker Oncology, 
1992. 7(1): p. 19-27. 
53. Duffy, M.J., et al., CA 15-3: a prognostic marker in breast cancer. The 
International Journal of Biological Markers, 2000. 15(4): p. 330-333. 
54. McAuley, J.L., et al., MUC1 cell surface mucin is a critical element of the 
mucosal barrier to infection. Journal of Clinical Investigation, 2007. [Epub 
ahead of print]. 
55. Bon, G.G., et al., Clinical and technical evaluation of ACS™BR serum 
assays of MUC1 gene-derived glycoprotei in breast cancer, and 
comparison with CA 15-3 assays. Clinical Chemistry, 1997. 43(4): p. 585-
593. 
56. Duffy, M.J., CA 15-3 and related mucins as circulating markers in breast 
cancer. Annals of Clinical Biochemistry, 1999. 36: p. 579-586. 
57. Kufe, D., et al., Differential reactivity of a novel monoclonal antibody (DF3) 
with human malignant versus benign breast tumours. Hybridoma, 1984. 
3(3): p. 223-232. 
58. Hilkens, J., et al., Monoclonal antibodies against human milk-fat globule 
membranes detecting differentiation antigens of the mammary gland and 
its tumors. International Journal of Cancer, 1984. 34: p. 197-206. 
59. Grinstead, J.S., et al., Effect of glycosylation on MUC1 humoral immune 
recognition:NMR studies of MUC1 glycopeptide-antibody interactions. 
Biochemistry, 2002. 41: p. 9946-9961. 
60. Gion, M., et al., CA27.29: a valuable marker for breast cancer 
management. A confirmatory multicentric study on 603 cases. European 
Journal of Cancer, 2001. 37(3): p. 355-363. 
61. Exploding the myths about CA analyte determination, in CanAg Journal. 
2003. p. 2-5. 
62. Ren, J., et al., Human MUC1 carcinoma-associated protein confers 
resistance to genotoxic anticancer agents. Cancer Cell, 2004. 5(2): p. 163-
175. 
63. Reddish, M.A., et al., Pre-immunotherapy serum CA27.29 (MUC-1) mucin 
level and CD69+ lumphocytes correlate with effects of Theratope® sialyl-
Tn-KLH cancer vaccine in active specific immunotherapy. Cancer 
Immunology, Immunotherapy, 1996. 42: p. 303-309. 
64. Kontani, K., et al., Modulation of MUC1 mucin as an escape mechanism of 
breast cancer cells from autologous cytotoxic T-lymphocytes. British 
Journal of Cancer, 2001. 84(9): p. 1258-1264. 
65. Martoni, A., et al., CEA, MCA, CA15.3 and CA549 and their combinations 
in expressing and monitoring metastatic breast cancer: a prospective 
comparative study. European Journal of Cancer, 1995. 31A(10): p. 1615-
1621                             
 189 
66. Simms, M.S., et al., MUC1 as a tumour marker in bladder cancer. British 
Journal of Urology International, 1999. 84(3): p. 350-352. 
67. D'Alessandro, R., et al., Serum tissue polypeptide specific antigen (TPS): 
A complimentary tumour marker to CA15-3 in the management of breast 
cancer. Breast Cancer Research and Treatment, 2001. 68(1): p. 9. 
68. Colomer, R., et al., Circulating CA 15-3 levels in the postsurgical follow-up 
of breast cancer patients and in non-malignant diseases. Breast Cancer 
Research and Treatment, 1989. 13: p. 123-133. 
69. Duffy, M.J., Serum tumour markers in breast cancer: Are they of clinical 
value? Clinical Chemistry, 2006. 52(3): p. 345-351. 
70. Nakayama, T., et al., CA19-9 as a predictor of recurrence in patients with 
colorectal carcinoma. Journal of Surgical Oncology, 1997. 66: p. 238-243. 
71. Duffy, M.J., CA 19-9 as a marker for gastrointestinal cancers: a review. 
Annals of Clinical Biochemistry, 1998. 35: p. 364-370. 
72. Vestergaard, E.M., et al., Reference values and biological variation for 
tumour marker CA 19-9 in serum for different Lewis and secretor 
genotypes and evaluation of secretor and Lewis genotyping in a 
caucasian population. Clinical Chemistry, 1999. 45(1): p. 54-61. 
73. Terracciano, D., et al., Analysis of glycoproteins in human colon cancers, 
normal tissues and in human colon carcinoma cells reactive with 
monoclonal antibody NCL-19-9. Oncology Reports, 2005. 14: p. 719-722. 
74. Duffy, M.J., et al., Increased concentrations of the antigen CA19-9 in 
serum of cystic fibrosis patients. Clinical Chemistry, 1985. 31(7): p. 1245-
1246. 
75. Del Villano, B.C., et al., Radioimmunometric assay for a monoclonal 
antibody-defined tumor marker, CA 19-9. Clinical Chemistry, 1983. 29(3): 
p. 549-552. 
76. Maisey, N.R., et al., CA19-9 as a prognostic factor in inoperable 
pancreatic cancer: The implication for clinical trials. British Journal of 
Cancer, 2005. 93(7): p. 740-743. 
77. Berger, A.C., et al., Undetectable preoperative levels of serum CA 19-9 
correlate with improved survival for patients with resectable pancreatic 
adenocarcinoma. Annals of Surgical Oncology, 2004. 11(7): p. 644-649. 
78. Schlieman, M.G., H.S. Ho, and R.J. Bold, Utility of tumor markers in 
determining resectability of pancreatic cancer. Archives of Surgery, 2003. 
138(9): p. 951-955. 
79. Beretta, E., et al., Serum CA19-9 in the postsurgical follow up of patients 
with pancreatic cancer. Cancer, 1987. 60(10): p. 2428-2431. 
80. Ziske, C., et al., Prognostic value of CA 19-9 levels in patients with 
inoperable adenocarcinoma of the pancreas treated with gemcitabine. 
British Journal of Cancer, 2003. 89: p. 1413-1417. 
81. Pectasides, D., et al., CEA, CA 19-9, and CA-50 in monitoring gastric 
carcinoma. American Journal of Clinical Oncology, 1997. 20(4): p. 348-
353. 
82. Cook, A.M., et al., The Utility of tumour markers in assessing the response 
to chemotherapy in advanced bladder cancer. British Journal of Cancer, 
2000. 82(12): p. 1952-1957. 
83. Molina, R., et al., Serum biomarkers in breast cancer. Clinical Laboratory 
International, 2006. 30(2): p. 8-9. 
 190 
84. Arriagada, R., et al., Late local recurrences in a randomised trial 
comparing conservative treatment with total mastectomy in early breast 
cancer patients. Annals of Oncology, 2003. 14(11): p. 1617-1622. 
85. Veronesi, U., et al., Sentinel-lymph-node biopsy as a staging procedure in 
breast cancer: update of a randomised controlled study. Lancet Oncology, 
2006. 7(12): p. 983-990. 
86. Meiog, J.S.D., J.A. van der Hage, and C.J.H. van de Velde, Preoperative 
chemotherapy for women with operable breast cancer. Cochrane 
Database of systematic Reviews, 2007. Issue 2(Art. No.:CD005002. DOI: 
10.1002/14651858.CD005002.pub2). 
87. Poole, C.J., et al., Epirubicin and cyclophosphamide, methotrexate, and 
fluorouracil as adjuvant therapy for early breast cancer. New England 
Journal of Medicine, 2006. 355(18): p. 1851-1862. 
88. listed], E.B.C.T.C.G.N.a., Tamoxifen for early breast cancer: an overview 
of the randomised trials. Lancet, 1998. 351(9114): p. 1451-1467. 
89. Baum, M., et al., Anastrozole alone or in combination with tamoxifen 
versus tamoxifen alone for adjuvant treatment of postmenopausal women 
with early breast cancer: first results of the ATAC randomised trial. Lancet, 
2002. 359(9324): p. 2131-2139. 
90. Beslija, S., et al., Second consensus on medical treatment of metastatic 
breast cancer. Annals of Oncology, 2007. 18: p. 215-225. 
91. Beslija, S., et al., Second consensus on medical treatment of metastatic 
breast cancer. Annals of Oncology, 2007. 18(2): p. 215-225. 
92. Slamon, D.J., et al., Use of chemotherapy plus a monoclonal antibody 
against HER2 for metastatic breast cancer that overexpresses HER2. 
New England Journal of Medicine, 2001. 344(11): p. 783-792. 
93. Piccart-Gebhart, M.J., et al., Trastuzumab after adjuvant chemotherapy in 
HER2-positive breast cancer. The New England Journal of Medicine, 
2005. 353(16): p. 1659-1672. 
94. Smith, I., et al., 2-year follow-up of trastuzumab after adjuvant 
chemotherapy in HER2-positive breast cancer: a randomised controlled 
trial. The Lancet, 2007. 369(9555): p. 29-36. 
95. Dinesh, K., ed. British National Formulary 51. 51 ed. British National 
Formulary. 2006, British Medical Journal Publishing Group, Royal 
Pharmaceutical Society Publishing. 918. 
96. Pavlakis, N., R.L. Schmidt, and M. Stockler, Bisphosphonates for breast 
cancer (Review). 2005, The Cochrane Library. 
97. Molina, R., et al., C-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with 
breast cancer: prognostic value. Breast Cancer Research and Treatment, 
1998. 51: p. 109-119. 
98. Molina, R., et al., Prospective evaluation of CEA and CA 15.3 in patients 
with locoregional breast cancer. Anticancer Research, 2003. 23: p. 1035-
1042. 
99. Lauro, S., et al., Comparison of CEA, MCA, CA 15-3 and CA 27-29 in 
follow-up and monitoring therapeutic response in breast cancer patients. 
Anticancer Research, 1999. 19: p. 3511-3516. 
100. Ebeling, F.G., et al., Serum CEA and CA 15-3 as prognostic factors in 
primary breast cancer. British Journal of Cancer, 2002. 86: p. 1217-1222. 
 191 
101. Shering, S.G., et al., Preoperative CA 15-3 concentrations predict 
outcome of patients with breast carcinoma. Cancer, 1998. 83: p. 2521-
2527. 
102. Cañizares, F., et al., Preoperative values of CA 15-3 and CEA as 
prognostic factors in breast cancer: A multivariate analysis. Tumour 
Biology, 2000. 22: p. 273-281. 
103. Duffy, M.J., et al., High preoperative CA 15-3 concentrations predict 
adverse outcome in node-negative and node-positive breast cancer: study 
of 600 patients with histologically confirmed breast cancer. Clinical 
Chemistry, 2004. 50(3): p. 559-563. 
104. Ebeling, F.C., et al., Tumour markers CEA and CA15-3 as prognostic 
factors in breast cancer - univariate and multivariate analysis. Anticancer 
Research, 1999. 19: p. 2545-2550. 
105. Blijlevens, N.M.A., et al., Clinical value of TPS, CEA and CA 15-3 in breast 
cancer patients. Anticancer Research, 1995. 15: p. 2711-2716. 
106. Nicolini, A., et al., Evaluation of serum CA15-3 determination with CEA 
and TPA in the post-operative follow-up of breast cancer patients. British 
Journal of Cancer, 1991. 64: p. 154-158. 
107. Sölétormos, G., et al., A novel method for monitoring high-risk breast 
cancer with tumour markers: CA 15.3 compared to CEA and TPA. Annals 
of Oncology, 1993. 4: p. 861-869. 
108. Molina, R., et al., Utility of C-erbB-2 in tissue and in serum in the early 
diagnosis of recurrence in breast cancer patients: comparison with 
carcinoembryonic antigen and CA 15.3. British Journal of Cancer, 1996. 
74(7): p. 1126-1131. 
109. Pectasides, D., et al., Clinical value of CA 15-3, mucin-like carcinoma-
associated antigen, tumour polypeptide antigen, and carcinoembryonic 
antigen in monitoring early breast cancer patients. American Journal of 
Clinical Oncology, 1996. 19(5): p. 459-464. 
110. Robertson, J.F., et al., The objective measurement of remission and 
progression in metastatic breast cancer by use of serum tumour markers. 
European Journal of Cancer, 1999. 35(1): p. 47-53. 
111. De La Lande, B., et al., Prognostic value of CA 15-3 kinetics for metastatic 
breast cancer. The International Journal of Biological Markers, 2002. 
17(4): p. 231-238. 
112. Kurebayashi, J., et al., Significance of serum carcinoembryonic antigen 
and CA 15-3 in monitoring advanced breast cancer patients treated with 
systemic therapy: A large-scale retrospective study. Breast Cancer, 2003. 
10(1): p. 38-44. 
113. Nishimura, R., et al., Elevated serum CA15-3 levels correlate with positive 
oestrogen receptor and initial favourable outcome in patients who died 
from recurrent breast cancer. Breast Cancer, 2003. 10(3): p. 220-227. 
114. Loprinzi, C.L., et al., Prospective evaluation of carcinoembryonic antigen 
levels and alternating chemotherapeutic regimens in metastatic breast 
cancer. Journal of Clinical Oncology, 1986. 4: p. 46-56. 
115. Tampellini, M., et al., Relationship between CA 15-3 serum levels and 
disease extent in predicting overall survival of breast cancer patients with 
newly diagnosed metastatic disease. British Journal of Cancer, 1997. 
75(5): p. 698-702. 
 192 
116. Chan, D.W., et al., Use of Truquant BR radioimmunoassay for early 
detection of breast cancer recurrence in patients with stage II and stage III 
disease. Journal of Clinical Oncology, 1997. 15(6): p. 2322-2328. 
117. Giai, M., et al., TPS and CA 15-3 serum values as a guide for treating and 
mmonitoring breast cancer patients. Anticancer Research, 1996. 16(2): p. 
875-881. 
118. Sonoo, H. and J. Kurebayashi, Serum tumour marker kinetics and the 
clinical course of patients with advanced breast cancer. Japanese Journal 
of Surgery, 1996. 26: p. 250-257. 
119. Nicolini, A. and A. Carpi, Postoperative follow-up of breast cancer 
patients: overview and progress in the use of tumour markers. Tumour 
Biology, 2000. 21(4): p. 235-248. 
120. Nicolini, A., et al., "Tumour marker guided" salvage treatment prolongs 
survival of breast cancer patients: Final report of a 7-year study. 
Biomedicine and Pharmacotherapy, 2003. 57: p. 452-459. 
121. Berruti, A., et al., Prognostic value in predicting overall survival of two 
mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first 
relapse of disease. European Journal of Cancer, 1994. 30A(14): p. 2082-
2084. 
122. Robertson, J.F.R., et al., Objective measurement of therapeutic response 
in breast cancer using tumour markers. British Journal of Cancer, 1991. 
64: p. 757-763. 
123. Dixon, A.R., et al., Continuous chemotherapy in responsive metastatic 
breast cancer: A role for tumour markers? British Journal of cancer, 1993. 
68(1): p. 181-185. 
124. Kiang, D.T., L.J. Greenberg, and B.J. Kennedy, Tumor marker kinetics in 
the monitoring of breast cancer. Cancer, 1990. 65: p. 193-199. 
125. Staib, L., et al., Surgery of colorectal cancer: Surgical morbididty and five- 
and ten-year results in 2400 patients - monoinstitutional experience. World 
Journal of Surgery, 2002. 26(1): p. 59-66. 
126. (NICE), N.I.C.E., TA100 Colon cancer (adjuvant) - capecitabine & 
oxaliplatin: Guidance, 2006. 
127. Midgley, R.S.J. and D.J. Kerr, ABC of colorectal cancer: Adjuvant therapy. 
British Medical Journal, 2000. 321: p. 1208-1211. 
128. Wolmark, N., et al., Randomized trial of postoperative adjuvant 
chemotherapy with or without radiotherapy for carcinoma of the rectum: 
National Surgical Adjuvant Breast and Bowel Project Protocol R-02. 
Journal of the National Cancer Institute, 2000. 92(5): p. 388-396. 
129. Lee, J.H., et al., Randomized trial of postoperative adjuvant therapy in 
stage II and III rectal cancer to define the optimal sequence of 
chemotherapy and radiotherapy: a preliminary report. Journal of Clinical 
Oncology, 2002. 20(7): p. 1751-1758. 
130. Best, L., et al., Palliative chemotherapy for advanced or metastatic 
colorectal cancer. Cochrane Database of Systematic Reviews, 2000. 
Issue 1(Art. No.: CD001545. DOI: 10.1002/14651858.CD001545. ). 
131. (NICE), N.I.C.E., TA93 Colorectal cancer (advanced) - irinotecan, 
oxaliplatin and raltitrexed (review): Guidance, 2005. 
132. Zhao, X.W., et al., [Detection and clinical study of serum tumor markers in 
patients with colorectal cancer][Article in Chinese]. Zhonghua Zhong Liu 
Za Zhi, 2005. 27(5): p. 286-288. 
 193 
133. Andicoechea, A., et al., Preoperative carbohydrate antigen 195 (CA195) 
and CEA serum levels as prognostic factors in patients with colorectal 
cancer. The International Journal of Biological Markers, 1998. 13(3): p. 
158-164. 
134. Díez, M., et al., Time-dependency of the prognostic effect of 
carcinoembryonic antigen and p53 protein in colorectal adenocarcinoma. 
Cancer, 2000. 88: p. 35-41. 
135. Zheng, C.X., et al., The prognostic value of preoperaitve serum levels of 
CEA, CA19-9 and CA72-4 in patients with colorectal cancer. World 
Journal of Gastroenterology, 2001. 7(3): p. 431-434. 
136. Morita, S., et al., Does serum CA19-9 play a practical role in the 
management of patients with colorectal cancer? Diseases of the Colon 
and Rectum, 2004. 47: p. 227-232. 
137. Chen, C., et al., Is it reasonable to add preoperative serum level of CEA 
and CA19-9 to staging for colorectal cancer? Journal of Surgical 
Research, 2005. 124: p. 169-174. 
138. Wiratkapun, S., et al., High preoperative serum carcinoembryonic antigen 
predicts metastatic recurrence in potentially curative colonic cancer: 
Results of a five-year study. Diseases of the Colon and Rectum, 2001. 44: 
p. 231-235. 
139. Gebauer, G. and W. Müller-Ruchholtz, Carcinoembryonic antigen and 
CA19-9: Implications of quantitative marker measurement in tissues for 
prognosis of colorectal cancer. Cancer Detection and Prevention, 2001. 
25(4): p. 344-351. 
140. Carpelan-Holmström, M., et al., Pre-operative  serum levels of CA242 and 
CEA predict outcome in colorectal cancer. European Journal of Cancer, 
1995. 32A(7): p. 1156-1161. 
141. Carriquiry, L.A. and A. Piñeyro, Should carcinoembryonic antigen be used 
in the management of patients with colorectal cancer. Diseases of the 
Colon and Rectum, 1999. 42: p. 921-929. 
142. Reiter, W., et al., Multivariate analysis of the prognostic value of CEA and 
CA19-9 serum levels in colorectal cancer. Anticancer Research, 2000. 
20(6D): p. 5195-5198. 
143. Weissenberger, C., et al., Adjuvant radiochemotherapy of stage II and III 
rectal adenocarcinoma: Role of CEA and CA19-9. Anticancer Research, 
2005. 25: p. 1787-1794. 
144. Nakagoe, T., et al., Prognostic value of carcinoembryonic antigen (CEA) in 
tumour tissue of patients with colorectal cancer. Anticancer Research, 
2001. 21: p. 3031-3036. 
145. Li Destri, G., et al., Monitoring carcinoembryonic antigen in colorectal 
cancer: is it still useful? Surgery Today, 1998. 28: p. 1233-1236. 
146. Chapman, M.A.S., et al., Preoperative carcinoembryonic antigen is related 
to tumour stage and long-term survival in colorectal cancer. British Journal 
of Cancer 1998. 78(10): p. 1346-1349. 
147. Ishida, H., et al., Ki-67 and CEA expression as prognostic markers in 
Dukes' C colorectal cancer Cancer Letters, 2004. 207: p. 109-115. 
148. Hilska, M., et al., The significance of tumour markers for proliferation and 
apoptosis in predicting survival in colorectal cancer. Diseases of the colon 
and rectum, 2005. 48: p. 2197-2208. 
 194 
149. Matsui, T., et al., Sialyl Lewisa expression as a predictor of the prognosis 
of colon carcinoma patients in a prospective randomised clinical trial. 
Japanese Journal of Clinical oncology, 2004. 34(10): p. 588-593. 
150. Nakayama, T., et al., Expression of Sialyl Lewisa as a new prognostic 
factor for patients with advanced colorectal carcinoma. Cancer, 1995. 75: 
p. 2051-2056. 
151. Chu, D.Z.J., et al., Prognostic significance of carcinoembryonic antigen in 
colorectal carcinoma. Archives of Surgery, 1991. 126: p. 314-316. 
152. Nicolini, A., et al., Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in 
the diagnosis of primary colorectal cancer and its relapse. Cancer 
Detection and Prevention, 1995. 19(2): p. 183-195. 
153. McCall, J.L., et al., The value of serum carcinoembryonic antigen in 
predicting recurrent disease following curative resection of colorectal 
cancer. Diseases of the Colon and Rectum, 1994. 37: p. 875-881. 
154. Quentmeier, A., et al., Re-operation for recurrent colorectal cancer: The 
importance of early diagnosis for resectability and survival. European 
Journal of Surgical Oncology, 1990. 16: p. 319-325. 
155. Kouri, M., et al., Poor prognosis associated with elevated serum CA 19-9 
level in advanced colorectal carcinoma, independent of DNA ploidy of 
SPF. European Journal of Cancer, 1993. 29A(12): p. 1691-1696. 
156. Filella, X., et al., Use of CA19-9 in the early detection of recurrences in 
colorectal cancer: Comparison with CEA. Tumour Biology, 1994. 15: p. 1-
6. 
157. Hanke, B., et al., CEa and CA19-9 measurement as a monitoring 
parameter in metastatic colorectal cancer (CRC) under palliative first line 
chemotherapy with weekly 24-hour infusion of high-dose 5-flourouracil (5-
FU) and folinic acid (FA). Annals of Oncology, 2001. 12: p. 221-226. 
158. Berglund, Å., et al., Tumour markers as early predictors of response to 
chemotherapy in advanced colorectal carcinoma. Annals of Oncology, 
2002. 13: p. 1430-1437. 
159. Chau, I., et al., The value of routine serum carcino-embryonic antigen 
measurement and computed tomography in the surveillance of patients 
after adjuvant chemotherapy for colorectal cancer. Journal of Clinical 
Oncology, 2004. 22(8): p. 1420-1429. 
160. Wolf, R.F. and A.M. Cohen, The miniscule benefit of serial 
carcinoembryonic antigen monitoring after effective curative treatment for 
primary colorectal cancer. Journal of the American College of Surgeons, 
1997. 185(1): p. 65-70. 
161. Trillet-Lenoir, V., et al., Any clinical benefit from the use of oncofoetal 
markers in the management of chemotherapy for patients with metastatic 
colorectal carcinomas? Clinical Oncology, 2004. 16(3): p. 196-203. 
162. Bakalakos, E.A., et al., Is carcino-embryonic antigen useful in the follow-
up management of patients with colorectal liver metastases? The 
American Journal of Surgery, 1999. 177: p. 2-6. 
163. Barone, C., et al., Advanced colon cancer: Staging and prognosis by CEA 
test. Oncology 1990. 47: p. 128-132. 
164. Massacesi, C., et al., Predictors of short-term survival and progression to 
chemotherapy in patients with advanced colorectal cancer treated with 5-
flourouracil-based regimens. American Journal of Clinical Oncology, 2002. 
25(2): p. 140-148. 
 195 
165. Stelzner, S., et al., Factors predicting survival in stage IV colorectal 
carcinoma patients after palliative treatment: A multivariate analysis. 
Journal of Surgical Oncology, 2005. 89: p. 211-217. 
166. Kouri, M., S. Pyrhönen, and P. Kuusela, Elevated CA19-9 as the most 
significant prognostic factor in advanced colorectal cancer. Journal of 
Surgical Oncology, 1992. 49: p. 78-85. 
167. Mitry, E., et al., Predictive factors of survival in patients with advanced 
colorectal cancer: an individual data analysis of 602 patients included in 
irinotecan phase III trials. Annals of Oncology, 2004. 15: p. 1013-1017. 
168. Tomasevic, Z., et al., Negative CEA values in metastatic colorectal  
carcinoma and the likelihood of complete chemotherapy response. The 
International Journal of Biological Markers, 2003. 18(1): p. 28-32. 
169. Park, I.J., et al., Cutoff values of preoperative s-CEA levels for predicting 
survivals after curative resection of colorectal cancer. Journal of Korean 
Medical Science, 2005. 20: p. 624-627. 
170. Webb, A., et al., The prognostic value of CEA, βHCG, AFP, CA125, CA19-
9 and C-erb B-2, βHCG immunohistochemistry in advanced colorectal 
cancer. Annals of Oncology, 1995. 6(581-587). 
171. Wang, W., et al., CA19-9 as the most significant prognostic indicator of 
metastatic colorectal cancer. Hepato-Gastroenterology, 2002. 49: p. 160-
164. 
172. Wanebo, H.J., et al., Prospective monitoring trial for carcinoma of colon 
and rectum after surgical resection. Surgery, Gynaecology & Obstetrics, 
1989. 169(6): p. 479-487. 
173. Aabo, K., H. Pedersen, and M. Kjaer, Carcinoembryonic antigen (CEA) 
and alkaline phosphatase in progressive colorectal cancer with special 
reference to patient survival. European Journal of Cancer and Clinical 
Oncology, 1986. 22(2): p. 211-217. 
174. Ishizuka, D., et al., Colorectal carcinoma liver metastases: clinical 
significance of preoperative measurement of serum carcinoembryonic 
antigen and carbohydrate antigen 19-9 levels. International Journal of 
Colorectal Disease, 2001. 16: p. 32-37. 
175. Sasaki, A., et al., Value of serum carbohydrate antigen 19-9 for predicting 
extrahepatic metastasis in patients with liver metastasis from colorectal 
carcinoma. Hepato-Gastroenterology, 2005. 52: p. 1814-1819. 
176. Aldrighetti, L., et al., [Prognostic factors for long-term outcome of hepatic 
resection for colorectal liver metastases]. Chirurgia Italiana, 2005. 57(5): 
p. 555-570. 
177. Hohenberger, P., et al., Pre-and postoperative carcinoembryonic antigen 
determinations in hepatic resection for colorectal metastases. Annals of 
Surgery, 1994. 219(2): p. 135-143. 
178. Korenaga, D., et al., Serum carcinoembryonic antigen concentration 
doubling time correlates with tumour biology and life expectancy in 
patients with recurrent gastrointestinal carcinoma. Archives of Surgery, 
1997. 132(2): p. 188-194. 
179. Lawton, J.O., G.R. Giles, and E.H. Cooper, Evaluation of CEA in patients 
with known residual disease after resection of colonic cancer. Journal of 
the Royal Society of Medicine, 1980. 73: p. 23-28. 
 196 
180. Allen-Mersh, T.G., et al., Significance of a fall in serum CEA concentration 
in patients treated with cytotoxic chemotherapy for disseminated colorectal 
cancer. Gut, 1987. 28: p. 1625-1629. 
181. Quentmeier, A., et al., Assessment of serial carcinoembryonic antigen: 
Determinations to monitor the therapeutic progress and prognosis of 
metastatic liver disease treated by regional chemotherapy. Journal of 
Clinical Oncology, 1989. 40: p. 112-118. 
182. Hamm, C. and C. Cripps, Carcinoembryonic antigen in metastatic 
colorectal cancer. Clinical and Investigative Medicine, 1998. 21(4/5): p. 
186-191. 
183. Ito, K., et al., Usefulness of analytical CEA doubling time and half-life time 
for overlooked synchronous metastases in colorectal carcinoma. 
Japanese Journal of Clinical oncology, 2002. 32(2): p. 54-58. 
184. Wang, W.S., et al., Carcinoembryonic antigen in monitoring of response to 
systemic chemotherapy in patients with metastatic colorectal cancer. 
International Journal of Colorectal Disease, 2001. 16(2): p. 96-101. 
185. Preketes, A.P., et al., CEA reduction after cryotherapy for liver metastases 
from colon cancer predicts survival. Australia and New Zealand Journal of 
Surgery, 1994. 64(9): p. 612-614. 
186. listed], N.a., Clinical practice guidelines for the use of tumor markers in 
breast and colorectal cancer. Adopted on May 17, 1996 by the American 
Society of Clinical Oncology. Journal of Clinical Oncology, 1996. 14(10): p. 
2843-2877. 
187. Bast, R.C., et al., 2000 update of recommendations for the use of tumor 
markers in breast and colorectal cancer: clinical practice guidelines of the 
American Society of Clinical Oncology. Journal of Clinical Oncology, 2001. 
19(6): p. 1865-1878. 
188. Locker, G.Y., et al., ASCO 2006 update and recommendations for the use 
of tumour markers in gastrointestinal cancer. Journal of Clinical Oncology, 
2006. 24(33): p. 5313-5327. 
189. Duffy, M.J., et al., Tumour markers in colorectal cancer: European Group 
on Tumour Markers (EGTM) guidelines for clinical use. European Journal 
of Cancer, 2007. 43: p. 1348-1360. 
190. Renehan, A.G., et al., Impact on survival if intensive follow up after 
curative resection for colorectal cancer: Systematic review and meta-
analysis of randomised trials. British Medical Journal, 2002. 324: p. 813-
820. 
191. Rosen, M., et al., Follow-up of colorectal cancer: a meta-analysis. 
Diseases of the Colon and Rectum, 1998. 41(9): p. 1116-1126. 
192. Ohlsson, B. and B. Pålsson, Follow-up after colorectal cancer surgery. 
Acta Oncologica, 2003. 42(8): p. 816-826. 
193. Ohlsson, B., et al., Follow-up after curative surgery for colorectal 
carcinoma. Diseases of the Colon and Rectum, 1995. 38: p. 619-626. 
194. Secco, G.B., et al., Is intensive follow-up really able to improve prognosis 
of patients with local recurrence after curative surgery for rectal cancer? 
Annals of Surgical Oncology, 2000. 7(1): p. 32-37. 
195. Bonthuis, D.C., et al., Small but significant survival benefit in patients who 
undergo routine follow-up after colorectal cancer surgery. European 
Journal of Surgical Oncology, 2004. 30: p. 1093-1097. 
 197 
196. Rodríguez-Moranta, F., et al., Postoperative surveillance in patients with 
colorectal cancer who have undergone curative resection: A prospective, 
multicenter, randomised, controlled trial. Journal of Clinical Oncology, 
2006. 24(3): p. 386-393. 
197. Rojas, M.P., et al., Follow-up strategies for women treated for early breast 
cancer. Cochrane Database of Systematic Reviews, 2000. Issue 4(Art. 
No.: CD001768. DOI: 10.1002/14651858.CD001768.pub2). 
198. Therasse, P., Evaluation of response: new and standard criteria. Annals of 
Oncology, 2002. 13(Suppl. 4): p. 127-129. 
199. Hayward, J.L., et al., Assessment of response to therapy in advanced 
breast cancer. British Journal of Cancer, 1977. 35(3): p. 292-298. 
200. Miller, A.B., et al., Reporting results of cancer treatment. Cancer, 1981. 
47(1): p. 207-214. 
201. Therasse, P., et al., New guidelines to evaluate the response to treatment 
in solid tumours. Journal of the National Cancer Institute, 2000. 92(3): p. 
205-216. 
202. Park, J.O., et al., Measuring response in solid tumours: Comparison of 
RECIST and WHO response criteria. Japanese Journal of Clinical 
Oncology, 2003. 33(10): p. 533-537. 
203. Eisen, T. A Brave New World - The opportunity and practicality of targeted 
therapy in renal cell cancer and future directions (New agents for renal 
cancer state of play in October 2006). in National Cancer Research 
Institute Cancer Conference. 2006. Birmingham. 
204. Guadagni, F., et al., A re-evaluation of carcinoembryonic antigen (CEA) as 
a serum marker for breast cancer: a prospective longitudinal study. 
Clinical Cancer Research, 2001. 7(8): p. 2357-2362. 
205. Henry, N.L. and D.F. Hayes, Uses and abuses of tumor markers in the 
diagnosis, monitoring, and treatment of primary and metastatic breast 
cancer. The Oncologist, 2006. 11: p. 541-552. 
206. Guthrie, D., et al., OVO5 Protocol - A Randomised Trial in Relapsed 
Ovarian Cancer. Early Treatment Based on CA 125 Levels Alone. 2000, 
MRC Gynaecological Cancer Working Party. 
207. Hine, K.R. and P.W. Dykes, Prospective randomised trial of early cytotoxic 
therapy for recurrent colorectal carcinoma detected by serum CEA. Gut, 
1984. 25: p. 682-688. 
208. Yamao, T., et al., Tumour markers CEA, CA19-9 and CA125 in monitoring 
of response to systemic chemotherapy in patients with advanced gastric 
cancer. Japanese Journal of Clinical Oncology, 1999. 29(11): p. 550-555. 
 
 
